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DNA contains the genetic information of all living organisms. Therefore, its integrity 
and stability are essential for the long-term viability of the organism. However, DNA is a 
chemical entity, which gets constantly damaged by both endogenous and exogenous DNA 
damaging agents. These DNA damages may lead to mutations and eventually cause diseases 
like cancer. Multiple DNA repair mechanisms have evolved in living organisms to repair 
DNA damages. Even so, not all DNA damages can be repaired before the replication 
apparatus encounters the DNA damage. As such, cells developed a damage tolerance 
pathway known as translesion synthesis (TLS) that allows cells to overcome replication 
blockage and facilitate bypass of the DNA lesions. This process is carried out by TLS 
polymerases, of which most belong to the Y family of DNA polymerases. These specialized 
enzymes are capable of bypassing the damaged DNA, but they also are low fidelity enzymes, 
frequently associated with mutagenesis and carcinogenesis.  
In this dissertation, I have investigated the replication bypass of different DNA 
lesions, including abasic site, 8,5’-cyclopurines and tobacco-specific nitrosamine-derived O2-
alkylthimidines in Escherichia coli and in human embryonic kidney (HEK293T) cells. The 
comparative replicative assays in bacterial and human cells revealed that bypass of these 
DNA lesions are significantly different in the two systems and that the mammalian 




the cytotoxic and mutagenic properties of these lesions, it is evident that replicative bypass 
efficiency varies with the complexity of the lesion. Moreover, multiple TLS polymerases are 
involved in the mutagenesis of different DNA lesions. These studies provide important 





Mutagenesis and Genetic Control of Translesion Synthesis Across an Abasic Site,             
8,5’-Cyclopurines and O2-Alkylthymidine DNA Lesions  
 
 
Savithri Anurada Kumari Weerasooriya 




A Dissertation  
Submitted in Partial Fulfillment of the 
Requirements for the Degree of 
Doctor of Philosophy 
at the 
































Doctor of Philosophy Dissertation 
Mutagenesis and Genetic Control of Translesion Synthesis Across an Abasic Site, 8,5’-
Cyclopurines and O2-Alkylthymidine DNA Lesions  
Presented by 
Savithri A. K. Weerasooriya 
 
Major Advisor 
Dr. Ashis K. Basu 
 
Associate Advisor 
Dr. Steven Suib 
 
Associate Advisor 
Dr. Mark Peczuh 







I dedicate this dissertation to my loving father, Mr. Ranjith Weerasooriya, my loving mother 
Mrs. Hema Kumari, my loving brothers, and to my amazing husband Saminda whose 






Foremost, I would like to express my sincere gratitude to my major advisor, Dr. Ashis 
Basu, for his tremendous support and constant encouragement throughout my time as his 
student. I have been extremely fortunate to have a supervisor who cared so much not only for 
his research, but also for his students. As a young researcher, his patience and compassion 
towards me has been remarkable. His motivation, enthusiasm and immense knowledge are 
truly inspiring and have helped me to grow as a researcher. I would further extend my 
gratitude to my advisory committee, Dr. Steven Suib, Dr. Mark Peczuh, Dr. Fatma 
Selampinar and Dr. Alfredo Angeles-Boza for their generous support, guidance, and 
motivation. 
Lab would not have been a fun place to work without all of my lab mates. I am 
grateful to all seniors Drs. Paromita, Vijay, Paritosh, and Rajat, who were great mentors. I 
would like to thank Vijay for all invaluable suggestions and support given to all my projects. 
Special thanks to Dr. Varsha, for being a wonderful friend, a source of great intellectual and 
emotional support, and for all the great things we did together. Also, I would like to thank 
current group members Arindam, Kimberly, Arindom, and Brent for their friendship and 
support throughout these years. I also thank Nadeeshani, Vidya, and all the undergraduates, 
Savas, Ashley, Anonya, Vruksha and Hamsa for their help in my projects. 
I express my heartfelt gratitude to my husband Saminda for his unconditional love, 
unwavering support, and patience throughout these years. This journey would not have been 
possible without you in my life. I am highly indebted to my parents for believing in me and 
for constant encouragement throughout my life. I would also like to thank my two brothers 




A final thank you to all of my family and friends, both here and back home, for all of 





Table of Content 
1	   Literature Survey ............................................................................................................... 1	  
	   Cancer ........................................................................................................................... 1	  1.1
	   DNA Damage ............................................................................................................... 4	  1.2
1.2.1	   Reactive Oxygen Species (ROS) ....................................................................................... 7	  
1.2.2	   Sources of ROS .................................................................................................................. 7	  
1.2.3	   Oxidative stress .................................................................................................................. 9	  
	   Abasic site ................................................................................................................... 11	  1.3
1.3.1	   Structural Aspects ............................................................................................................ 12	  
1.3.2	   Repair ............................................................................................................................... 12	  
	   8,5’-Cyclopurines ....................................................................................................... 13	  1.4
1.4.1	   Chemistry of Cyclopurines Formation ............................................................................. 14	  
1.4.2	   Biological Significance of Cyclopurines ......................................................................... 16	  
1.4.3	   Cyclopurines and Human Diseases .................................................................................. 18	  
	   Tobacco Induced Carcinogenesis ............................................................................... 20	  1.5
1.5.1	   Tobacco Smoke ................................................................................................................ 22	  
1.5.2	   NNK Carcinogenicity ...................................................................................................... 23	  
1.5.3	   Methylation Pathway: ...................................................................................................... 24	  
1.5.4	   POB Pathway: .................................................................................................................. 26	  
	   DNA Repair ................................................................................................................ 28	  1.6
1.6.1	   DNA Damage Signaling and Cell-cycle Checkpoints ..................................................... 29	  
1.6.2	   DNA Repair Pathways ..................................................................................................... 30	  
1.6.3	   Reversion Repair .............................................................................................................. 31	  
1.6.4	   Base Excision Repair ....................................................................................................... 31	  
1.6.5	   Nucleotide Excision Repair ............................................................................................. 32	  




1.6.7	   DNA Double-strand Break Repair ................................................................................... 33	  
	   Translesion Synthesis (TLS) ....................................................................................... 36	  1.7
1.7.1	   Y-family DNA Polymerase .............................................................................................. 38	  
1.7.2	   Mammalian Y-family DNA Polymerase ......................................................................... 39	  
1.7.2.1	   Polymerase eta (pol η) ................................................................................................ 39	  
1.7.2.2	   Polymerase iota (pol ι) ................................................................................................ 40	  
1.7.2.3	   Polymerase kappa (pol κ) ........................................................................................... 41	  
1.7.2.4	   REV1........................................................................................................................... 41	  
1.7.3	   Polymerase zeta (pol ζ) .................................................................................................... 42	  
1.7.4	   Bacterial (Escherichia coli) Y-family Polymerase .......................................................... 42	  
1.7.5	   Polymerase IV (pol IV) .................................................................................................... 42	  
1.7.6	   Polymerase V (pol V) ...................................................................................................... 43	  
1.7.7	   Escherichia coli Polymerase II (pol II) ............................................................................ 44	  
	   Bacterial SOS Response ............................................................................................. 44	  1.8
2	   Scope of the Dissertation ................................................................................................. 46	  
3	   Materials and Methods .................................................................................................... 49	  
	   Materials ..................................................................................................................... 49	  3.1
3.1.1	   Chemicals, enzymes, plasmid DNA, cells, siRNA and instruments ................................ 49	  
3.1.2	   Synthesis and characterization of oligonucleotides ......................................................... 51	  
3.1.3	   Abasic site (Z) lesion containing oligonucleotides .......................................................... 51	  
3.1.4	   S-cdA and S-cdG lesion containing oligonucleotides ...................................................... 52	  
3.1.5	   O2-Me-dT and O2-POB-dT containing oligonucleotides ................................................. 52	  
	   Methods ...................................................................................................................... 53	  3.2
3.2.1	   Purification and analysis of oligomers with polyacrylamide gel electrophoresis ............ 53	  




3.2.3	   Bacterial electro-competent cell preparation and SOS induction .................................... 54	  
3.2.4	   M13mp7L2 vector containing site specifically incorporate abasic site (Z) ..................... 55	  
3.2.5	   Large scale M13mp7L2 vector preparation ..................................................................... 55	  
3.2.6	   Construction of ss-M13mp7L2 genome containing a single abasic site .......................... 56	  
3.2.7	   Transformation of ss-M13mp7L2 vector containing a site specifically incorporated 
abasic site in E. coli  ........................................................................................................ 58	  
3.2.8	   Plaque lift hybridization for mutational screening ........................................................... 60	  
3.2.9	   Single-stranded pMS2 vector containing site specifically incorporated abasic site/S-
cdA/S-cdG/O2-Me-dT or O2-POB-dT lesion ................................................................... 62	  
3.2.10	   Large scale preparation of single-stranded pMS2 (ss-pMS2) vector .............................. 62	  
3.2.11	   ss-pMS2 construct preparation ........................................................................................ 64	  
3.2.12	   Transformation of site specifically incorporated lesion (S-cdA) containing ss-pMS2 
vector in E. coli and progeny analysis: ............................................................................ 65	  
3.2.13	   Mutant screening by dot-blot hybridization .................................................................... 67	  
3.2.14	   Replication and analysis of site specifically incorporated abasic site/ S-cdA/ S-cdG/ O2-
Me-dT or O2-POB-dT containing ss-pMS2 in human embryonic kidney 293T cells and 
siRNA induced TLS knockdown cells ............................................................................ 70	  
3.2.15	   Replication and analysis of site specifically incorporated lesion containing ss-pMS2 in 
HEK293T cells ................................................................................................................ 70	  
3.2.16	   Isolation of progeny pMS2 from HEK293T and its amplification ................................. 70	  
3.2.17	   siRNA induced knockdown of TLS polymerases in HEK293T cells and mutational 
analysis of TLS products ................................................................................................. 71	  
3.2.18	   TLS assay in HEK293T cells and siRNA induces TLS knockdown cells ...................... 72	  
3.2.19	   Total RNA isolation with RNeasy Plus Mini Kit: ........................................................... 72	  
3.2.20	   Quantification of RNA .................................................................................................... 73	  
3.2.21	   Reverse Transcription Polymerase Chain Reaction (RT- PCR) Analysis. ..................... 73	  




4	   Chapter 1† : Replicative Bypass of Abasic Site in Escherichia coli and Human Cells: 
Similarities and Differences ...................................................................................... 76	  
	   Abstract ....................................................................................................................... 77	  4.1
	   Introduction ................................................................................................................. 78	  4.2
	   Results ......................................................................................................................... 81	  4.3
4.3.1	   PAGE analysis of the purified lesion containing oligonucleotide ................................... 81	  
4.3.2	   Construction of the AP-site containing vector and its replication ................................... 82	  
4.3.3	   TLS of Z in E. coli ........................................................................................................... 83	  
4.3.4	   Mutations resulting from bypass of Z in E. coli .............................................................. 85	  
4.3.5	   TLS of AP-site in human cells. ........................................................................................ 95	  
4.3.6	   AP-site mutagenesis in HEK293T cells ........................................................................... 98	  
4.3.7	   Contribution of pol ζ and Rev1 in TLS of AP-site .......................................................... 98	  
	   Discussion and Conclusions ..................................................................................... 104	  4.4
5	   Chapter 2†: Mutagenicity and Genotoxicity of (5’S)-8,5’-Cyclo-2’- Deoxynucleosides 
in Escherichia coli and Human Embryonic Kidney (HEK293T) cells ................ 107	  
	   Abstract ..................................................................................................................... 108	  5.1
	   Introduction ............................................................................................................... 109	  5.2
	   Results ....................................................................................................................... 112	  5.3
5.3.1	   Viability of S-cdA in E. coli ........................................................................................... 112	  
5.3.2	   Mutagenicity of S-cdA in E. coli ................................................................................... 115	  
5.3.3	   Mutagenicity of S-cdA and S-cdG in HEK293T cells ................................................... 119	  
5.3.4	   Mutational specificity of S-cdG and S-cdA in TLS polymerase knockdown HEK293T 
cells ................................................................................................................................ 121	  
	   Discussion and Conclusions ..................................................................................... 129	  5.4




5.4.2	   Mutagenicity in HEK293T cells .................................................................................... 130	  
6	   Chapter 3: Mutagenicity and Cytotoxicity of Tobacco-Specific Nitrosamine, 4-
(methylnitrosamino)-1-(3-pyridyl)-1-butanone (NNK) -Induced O2-
Alkylthymidine DNA lesions ................................................................................... 134	  
	   Abstract ..................................................................................................................... 135	  6.1
	   Introduction ............................................................................................................... 136	  6.2
	   Results ....................................................................................................................... 139	  6.3
6.3.1	   Inhibition of replication by O2-Me-dT and O2-POB-dT adducts and contribution of pols 
η, ζ and REV1 for lesion bypass. .................................................................................. 139	  
6.3.2	   Mutational specificity of O2-Me-dT and O2-POB-dT in HEK293T cells ...................... 141	  
6.3.3	   Contribution of pols η, ζ and REV1 in mutagenesis of O2-Me-dT and O2-POB-dT ..... 142	  
	   Discussion and Conclusions ..................................................................................... 150	  6.4
6.4.1	   Involvement of pol η, ζ and REV1 for bypass of O2-Me-dT and O2-POB-dT .............. 150	  
6.4.2	   Mutagenicity of O2-Me-dT and O2-POB-dT and error prone bypass by pol η, ζ and 
REV1 ............................................................................................................................. 152	  
7	   Summary and Future Work ......................................................................................... 155	  





List of Figures 
Figure 1: Different types of DNA damage cause different types of lesions, and these, in turn, 
are handled by the cell in different ways, Adapted from ref15 ....................................... 6	  
Figure 2: Formation of abasic site ........................................................................................... 11	  
Figure 3: Formation of 8,5’-Cyclopurines ............................................................................... 15	  
Figure 4: Metabolic activation of NNK . Adapted from ref95 .................................................. 24	  
Figure 5: DNA adducts formed from the NNK methylating pathway ..................................... 25	  
Figure 6:  DNA adducts formed from the NNK pyridyloxobutylating pathway ..................... 27	  
Figure 8: Evolutionary conserved role of DNA polymerase in translesion synthesis (TLS). 
Adapted from ref135 ...................................................................................................... 37	  
Figure 9: SOS response mechanism in bacteria. Adapted form ref 169 .................................... 45	  
Figure 13: Structure of pMS2. MCS represent a multiple cloning site where hairpin structure 
is included .................................................................................................................... 62	  
Figure 14: General protocol for making pMS2 construct followed by replication and analysis 
in E. coli ....................................................................................................................... 66	  
Figure 16: Oligonucleotides and tetrahydrofuran analoge of abasic site used in the study ..... 80	  
Figure 18: A representative agarose gel analysis of the M13 constructs. Lane 1 shows ss-M13 
DNA where as lane 2 show same after digestion with EcoRI. Lanes 3 and 4 represent 
circular constructs. Lanes 5 and 6 represent the construct after and before scaffold 
removal, respectively, of a mock ligation mixture ...................................................... 88	  
Figure 19:TLS frequencies for GZGTC and GTGZC constructs in wild type and pol II-, pol 
IV-, pol V-, and triple-knockout E. coli strains without and with SOS ....................... 84	  
Figure 20: Mutations induced by Z in GZGTC and GTGZC sequence contexts in E. coli with 
or without SOS ............................................................................................................. 87	  
Figure 21: A comparison of the frequency of Z→T versus targeted Z deletion (i.e., Z→Δ) 
multiplied with % TLS for GZGTC and GTGZC constructs in wild type and pol II-, 
pol IV-, pol V-, and triple-knockout E. coli strains without and with SOS ................. 89	  
Figure 22: A comparison of the frequency of Z→T versus targeted Z deletion (i.e., Z→Δ) 
for GZGTC and GTGZC constructs in wild type and pol II-, pol IV-, pol V-, and 
triple-knockout E. coli strains without and with SOS .................................................. 90	  
Figure 23: Effects of siRNA knockdowns of pol ζ and Rev1 on the extent of replicative 
bypass of Z for GZGTC and GTGZC constructs. Percent TLS in the pol knockdowns 
was measured using an internal control of unmodified plasmid containing a different 
sequence near the lesion site.  When control siRNA was used, the % bypass remained 




Figure 24: Percent mutations induced by Z in GZGTC and GTGZC sequence contexts 
multiplied with % TLS for GZGTC and GTGZC constructs in HEK293T cells 
without or with siRNA knockdowns of pol ζ and Rev1 ............................................ 100	  
Figure 25: Percent mutations induced by Z in GZGTC and GTGZC sequence contexts in 
HEK293T cells without or with siRNA knockdowns of pol ζ and Rev1 .................. 101	  
Figure 26: Oligonucleotides and lesions used in the study .................................................... 111	  
Figure 27: Viability of S-cdA in E. coli. Viability was determined by comparing 
transformation efficiency of the S-cdA plasmid with that of the control construct.  The 
data represent  average of four independent experiments. SOS was induced with 20 
J/m2 UV irradiation. ................................................................................................... 113	  
Figure 29: Progeny analysis of the replication of S-cdA construct in different E. coli strains 
with out and with SOS. Data from several transformations have been combined 
(shown in table 13). SOS was induced with 20 J/m2 UV radiaton ............................. 123	  
Figure 31: Effect of siRNA knockdowns of TLS pols on mutational frequency of S-cdG and 
S-cdA in HEK293T cells. The 293T represents HEK293T cells treated with NC 
siRNA. Data from several independent transformations have been combined (shown 
in table 14 and 15). ..................................................................................................... 123	  
Figure 32: Mutational frequency of S-cdG and S-cdA in HEK293T cells treated with NC 
siRNA (293T) and siRNA against TLS polymerase. The data represent combined 
mutational frequency from several independent experiments (Shown in table 14 and 
15). ............................................................................................................................. 124	  
Figure 34: Effect of siRNA-induced knockdowns of TLS pols on the replicative bypass of 
O2-Me-dT and O2-POB-dT in HEK293T cells. The TLS % in various pol knockdown 
s was estimated using an internal control of an unmodified plasmid containing a 
mutation two nucleotides 5’ to the lesion site. The data represent the mean and the 
standard deviation of results from at least 3 independent experiments ± S.D. 
HEK293T cells were treated with negative control (NC-si) siRNA whereas the other 
single knockdowns are as indicated. The statistical significance between NC-siRNA 
treated HEK293T and TLS pols knockdowns were calculated using a two-tailed, 
unpaired Student’s t test (*p < 0.05: **p < 0.01) ...................................................... 143	  
Figure 35: Total mutational frequency (MF) of O2-Me-dT and O2-POB-dT in HEK293T cells 
treated with negative control siRNA (NC-si) or siRNA for TLS pols. The data 
represent the average of at least three independent experiments (except for pol ι, as 
shown in Table 20 and 21) ±S.D. The p values were calculated by using two-tailed, 






List of Tables 
 
Table 1: Sequences of siRNA used for TLS knockdown ........................................................ 52	  
Table 2: Primer sequences used for RT-PCR for quantification of the siRNA induced TLS 
knockdown ................................................................................................................... 74	  
Table 3: Viability of abasic site in E. coli cells ....................................................................... 85	  
Table 4: Mutational frequency in wild type E. coli cells† ........................................................ 88	  
Table 5: Mutational frequency in pol II- deficient E. coli strain ............................................. 91	  
Table 6: Mutational frequency in pol IV- deficient E. coli strain ............................................ 92	  
Table 7: Mutational frequency in pol V- deficient E. coli strain ............................................. 93	  
Table 8: Mutational frequency in triple knockout E. coli strain .............................................. 94	  
Table 9: TLS % in different polymerase knockdown HEK293T cells .................................... 97	  
Table 10: Mutation frequency of GZGTC in TLS polymerase knockdown HEK293T cells†
.................................................................................................................................... 102	  
Table 11: Mutation frequency of GTGZC in TLS polymerase knockdown HEK293T cells†
.................................................................................................................................... 103	  
Table 12: Viability of  S-cdA in E. colia ................................................................................ 114	  
Table 13: Mutations induced by S-cdA ................................................................................. 118	  
Table 14: Mutational frequency of S-cdG in HEK293T cells treated with siRNA against TLS 
polymerase† ................................................................................................................ 125	  
Table 15: Mutational frequency of S-cdA in HEK293T cells treated with siRNA against TLS 
polymerase knockdown cells† .................................................................................... 126	  
Table 16: Semi-targeted and other mutations induced by S-cdG in TLS polymerase 
knockdown HEK293T cells ....................................................................................... 127	  
Table 17: Semi-targeted and other mutations induced by S-cdA in TLS polymerase 
knockdown HEK293T cells ....................................................................................... 128	  
Table 20: DNA sequence analysis of TLS across a O2-Me-dT in HEK293T cells, in which the 
expression of defined TLS DNA polymerases was knocked-down using siRNA† ... 148	  
Table 21: DNA sequence analysis of TLS across a O2-POB-dT in HEK293T cells, in which 
the expression of defined TLS DNA polymerases was knocked-down using siRNA†
.................................................................................................................................... 149	  
1 Literature Survey 
 Cancer 1.1
Cancer is one of the leading causes of death worldwide. Statistics from World Health 
Organization (WHO) revealed that 8.2 million deaths related to cancer occurred in the year 
2012. WHO also predicted that the death toll will increase to 9 million in 2015.1  
According to the American Cancer Society, cancer is the second leading cause of 
death in the United States. Approximately 1,658,370 new cancer cases are expected to be 
diagnosed in 2015 and estimated deaths from cancer will be 589,430, that is, nearly 1,620 
deaths per day.2 Although this statistics show a decrease in mortality rate from its peak in 
1991, there is a continuous effort to create awareness and ultimately combat cancer. Hence, 
researchers worldwide are motivated to explore avenues such as cancer prevention, early 
detection, and effective therapeutic intervention to increase the quality of life and cancer 
survival.  
Cancer is the uncontrolled growth of abnormal cells in the body. If not controlled, it 
can ultimately lead to death. Development of cancer is a complex multistep process, which 
involves an alteration in the DNA of a normal cell that leads to proliferation, survival, 
invasion, and metastasis of an abnormal cell mass. This process is known as the 
carcinogenesis. Nearly all cancers/tumors occur due to a failure of the genes involved in the 
cell growth and division. Some tumors can be benign while others may exhibit malignancy, 
and almost all the malignant tumors are cancerous.  Distinctive types of cancers exhibit 
unique characteristics; therefore, prognosis and treatment in each case may be different. 
Nonetheless, occasionally there are marked resemblances amongst the various cancer types.3  
 It is believed that all cancers share a common pathogenesis. Development of a cancer 




populations within the microenvironments of the tissues of an organism. In this regard, 
carcinogenesis is centered on two constituent processes, the continuous acquirement of 
heritable genetic variation in individual cells by random mutations and the natural selection 
of resultant phenotypic diversity. During the selection process, cells that have acquired 
deleterious mutations and are incapable of proliferating may be eliminated, while a single cell 
acquired a set of adequately advantageous mutations that allow autonomous proliferation can 
survive and become malignant.4 
DNA in normal cells is subjected to damage by various agents, both internal and 
external of origin, which may lead to mutations. Somatic mutations that arise in the cancer 
genome may comprise of several types of DNA sequence changes, such as, base 
substitutions, insertions or deletions of small DNA segments, DNA rearrangements, and gene 
copy number increase or decrease. Cancerous DNA may also have acquired completely new 
DNA sequences form exogenous sources like viruses.5 Moreover, mutation rates increase 
substantially due to exposure to exogenous mutagenic agents, such as, tobacco carcinogens, 
chemicals and radiation. Rates of somatic mutations are also increased in several inherited 
diseases like Fanconi anaemia and Xeroderma Pigmentosum (XP), which have increased 
potential for development of cancer.4 
It is generally accepted that accumulation of mutations in oncogenes, tumor 
suppressor genes, and stability genes are responsible for tumorigenesis. All these genes are 
critically important in maintaining regular cell cycle. Proto-oncogenes are genes that code for 
proteins to help regulate cell growth and differentiation. Any mutations that result in 
activation of the proto-oncogene to become an oncogene, which produce onco-proteins, can 




When cells encounter stress stimuli such as oncogene activation or DNA damage, 
tumor suppressor genes are activated to prevent cell cycle progression, to promote DNA 
repair or apoptosis. p53 is one of the most important tumor suppressor genes and its activity 
is tightly regulated in normal cells. Therefore, mutations in such tumor suppressor genes 
could cause inhibition of cell-cycle arrest or apoptosis, eventually leading to uncontrolled cell 
growth, resulting in tumorigenesis.7 Stability genes are genes that are involved in DNA repair 
processes, mitotic division, and chromosomal segregation. These genes are involved in 
keeping genetic alterations to a minimum, and thus when mutated, it accelerate the 
progression of accumulated mutations. Mutations that occur in the germline of these genes 
will result in hereditary cancer predispositions, while mutations in single somatic cells will 
lead to sporadic tumors.8  
The prime objective of every life form is to transfer its genetic material intact and 
unchanged to the next generation. Therefore, maintaining genome integrity is essential for 
normal cellular functions. However, endogenous and exogenous damaging agents constantly 
insult genome stability. To counteract this threat, cells have evolved several systems to detect 
DNA damage, signal its presence and trigger its repair. Despite the presence of finely tuned 
DNA repair mechanisms, some of the DNA damages escape repair and interfere replication 
fork progression. Specialized polymerases known as translesion synthesis polymerases are 
able to synthesize DNA past such damaged bases with low fidelity leading to mutations. It is 
now widely accepted that this process of translesion synthesis (TLS) is responsible for 
increased point mutations in the genome leading to carcinogenesis. Hence it is important to 
improve our knowledge in the area of translesion synthesis for better understanding of DNA 




 DNA Damage 1.2
DNA contains the genetic information of all living organisms. Therefore, its integrity 
and stability are essential for survival of the species. In both normal and cancer cells, DNA 
constantly undergoes a myriad of damages either spontaneously, or through exposure to 
endogenous and exogenous agents, leading to a plethora of damages in DNA.9 
Spontaneous DNA lesions are introduced every day during normal cellular processes 
like DNA replication, DNA repair, or DNA rearrangement, and also as a result of chemical 
modifications of DNA molecule by hydrolysis, methylation, oxidation, and deamination of 
nitrogen bases. Abasic site, one of the most common lesions arises as a result of hydrolysis of 
nucleotides under normal physiological conditions. Deamination, either spontaneous or 
induced by a reactive species, of cytosine, adenine, guanine, or 5-methylcytosine, converts 
these bases to miscoding uracil, hypoxanthine, xanthine and thymine, respectively.9, 10 
All organisms are exposed to ionizing radiation and ultraviolet (UV) radiation from 
sun, whereas humans are frequently exposed to radiation during medical procedures. These 
exposures result in DNA damage. In addition to radiation, environmental factors such as 
exposure to chemical toxins and infections by pathogenic bacteria and viruses have also been 
shown to induce DNA damage. For humans, chemicals produced by tobacco products are 
probably the most prevalent environmental carcinogens found in the nineteenth and twentieth 
centuries, which cause a variety of DNA lesions and ultimately result in tobacco-induced 
carcinogenesis.11-13 
Certain cellular metabolites and byproducts generated during metabolism also cause 
DNA damages. Reactive oxygen species (ROS), produced endogenously during respiration 




However, living cells have developed a natural defense system during evolution to fight 
against ROS-induced DNA damages.14 
If these DNA lesions are not repaired rapidly, they can either block or stall genome 
replication and transcription. Furthermore, if incorrectly repaired or bypassed during 
replication, they might result in mutations or wider-scale genome aberrations that threaten 







Figure 1: Different types of DNA damage cause different types of lesions, and these, in 
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1.2.1 Reactive Oxygen Species (ROS) 
Free radials are initially known in chemistry as intermediates in organic and inorganic 
reactions. In 1954, Gilbert and Rebecca Gersham were the pioneers to publish suggesting that 
these radicals are important players in biological environments and responsible for 
deleterious processes in the cell.16, 17 Soon afterwards in 1956, Herman Denham suggested 
that these species might play a role in physiological events and particularly in the aging 
process. Thereafter, numerous studies were conducted in the field of biochemistry to 
understand the role of free radicals.16, 18   
Normal cellular processes generate reactive species capable of reacting aggressively 
with biological macromolecules, including DNA, proteins and lipids.  Reactive oxygen 
species (ROS) are one such important group of reactive species found in cells during normal 
physiological conditions as well as in abnormal conditions. These are species of oxygen, in 
which oxygen is reduced to varying degree; therefore, they are in a more reactive state than 
molecular oxygen. These ROS include superoxide ion radical (O2−), hydroxyl radical (OH), 
peroxyl radical (ROO) alkoxyl radicals (RO), and one form of singlet oxygen (1O2).16 
 ROS originate from both endogenous and exogenous sources. Cellular metabolism and 
byproducts of metabolism are examples for endogenous sources. In healthy cells, ROS are 
produced specifically to serve essential biological functions such as cell signaling and 
cellular defense. However, they also are formed as byproducts, particularly during aerobic 
respiration, by oxidoreductase enzymes and metal catalyzed oxidations. Exogenous sources 
for ROS production include xenobiotics and ionizing and UV radiation.19   
1.2.2 Sources of ROS 
During oxidative phosphorylation, about 1-2% of molecular oxygen is converted to 




to “leakage” of electrons form the electron transport chain in mitochondrial membrane. These 
leaking electrons react with surrounding oxygen to form superoxide radical, which in turn are 
converted to hydrogen peroxide (H2O2) by superoxide dismutase. Unlike superoxide ion, 
H2O2 is able to cross the cellular membrane and generates highly reactive hydroxyl radicals 
by reacting with metal cations, e.g., iron or copper via Fenton reaction.20 
O2+ e- ⟶ O2-. (Superoxide anion) 
O2
-.+ H2O ⟶HO2. ( Hydroperoxyl radical) 
HO2
.
  +  e- + H ⟶ H2O2 (Hydrogen peroxide) 
H2O2 + e-  ⟶ OH- + O.. H (Hydroxyl radical) 
Fenton reaction; 
H2O2+ Fe2+ ⟶OH-+ OH.. + Fe3+ 
 
Cytochrome P450 (CPY), a family of hemo-thiolated enzymes, is the terminal 
oxidase of the monoxygensae system found in mammalian endoplasmic reticulum (ER). 
These enzymes catalyze the oxidative metabolism of a variety of endogenous and exogenous 
lipophilic compounds. Poor coupling of CPY catalytic cycle significantly increases 
endogenous ROS production. In particular, induction of P450 2E1 and 2B during metabolism 
of ethanol and phenobarbital, respectively, have been proposed to contribute considerably to 
ROS production.20 
Other important endogenous sources of ROS include host inflammatory cells like 




known to stimulate a rapid but transient increase in oxygen uptake called “respiratory burst”, 
which gives rise to a wide variety of ROS, including superoxide anion, hydrogen peroxide, 
and nitric oxide. For instance, activation of Kupffer cells, specialized macrophages, has been 
found to be associated with tumor induction due to ROS release.21 Microsomes are 
responsible for ROS formation in hyperoxia sites. In other organs, liver in particular, 
peroxisomes also contribute to H2O2 generation.22 
Furthermore, ROS production can be initiated by exogenous sources including 
radiations and xenobiotics, including chlorinated compounds. Ionizing radiation such as γ- 
radiation and non-ionizing UV radiation can produce an array of ROS from ionizing of 
intercellular water and hydrolytic cleavage of H2O2, respectively.16 The relationship between 
ionizing radiation and DNA damage via generation of hydroxyl radicals is now well 
established. Hydroxyl radicals subsequently react with water in two possible pathways:  
In the first pathway, ionization of the water molecule results in the formation of a 
hydrated electron (e-aq) and H2O●+ that rapidly loses a proton to generate the hydroxyl radical. 
This hydrated electron slowly decays into H● and hydroxide anion. It is now known that 
generation of reactive ●OH through such processes results in persistent attack on the 
nucleophilic intracellular DNA.23  
The second process involves excitation of the water molecule followed by homolysis 
into H and the hydroxyl radical (OH). Amongst many intracellular radicals produced under 
physiological and pathophysiological conditions, the OH radical is one of the most reactive 
species and one that plays a significant role in a wide variety of DNA damages.23  
1.2.3 Oxidative stress 
Under normal physiological conditions in healthy cells, the balance between the 




enzymatically by antioxidants like vitamin C, vitamin E, vitamin A, carotene, glutathione or 
enzymatically by superoxide dismutase, catalase and glutathione peroxidase. However, under 
certain conditions (such as aging, diseases, or due to exposure to radiation), an imbalance 
between these two process could occur leading to a condition called  “oxidative stress,” a 
state characterized by excessive production of ROS. Oxidative stress can significantly alter 
critical cellular macromolecules such as DNA, protein and lipids. Although modifications to 
lipids and proteins can be removed via regular turnover of the molecules, modifications to 
DNA needs to be repaired.24 Therefore, the primary deleterious consequence of oxidative 
stress stems from damage to DNA, as it has been implicated in mutagenesis, carcinogenesis, 
aging and many neurological diseases.  
As elaborated above, hydroxyl radical is considered to be the major culprit for 
oxidative DNA damage. Damage to DNA by OH includes, base modification, sugar damage, 
strand breaks, abasic sites and protein-DNA cross-links. Hydrogen abstractions from 
deoxyribose sugar moiety, a principal reaction between OH and DNA, can leads to base loss 
and single strand breaks in DNA. Moreover, addition of OH to the π bonds of DNA 
nucleobases may result in distinct DNA lesions (adducts). In spite of the existence of DNA 
repair enzymes to repair these lesions efficiently, low levels of adducts may persist in DNA, 
resulting in mutagenesis and carcinogenesis. Therefore, assessment of mutational properties 
of such lesions provide better understanding of their biological consequences in a more 
comprehensive way.25 Abasic site and 8,5’-cyclo-2’-deoxynucleoside lesions are important 






 Abasic site 1.3
Abasic sites, also called apurinic or apyrimidinic sites (AP-sites), are one of the most 
common lesions in DNA. 26  AP-sites can be generated via spontaneous hydrolysis of N-
glycosidic bond. DNA damaging agents such as free radicals and alkylating agents can also 
form AP sites. Alkylating DNA damaging agents destabilize the N-glycosidic bond due to 
modification of bases generating a better leaving group.10, 27-32 It has been estimated that a 
mammalian cell looses at least 104 purines per day under normal physiological conditions.33 
In addition, AP sites are also formed as intermediates during base excision repair (BER) 
mechanism.34 Interestingly it has been determined that depyrimidination occurs at least 100 
times lower than depurination, for reasons that are not well characterized.35 
 






















1.3.1 Structural aspects  
Several groups have studied the structural aspects of abasic site using a stable 
tetrahydrofuran or open analogue form in different types of duplex DNA. Based on NMR and 
restrained molecular dynamics data, it has been observed that AP-site containing DNA 
assumes more or less regular B-form.36, 37 However, depending on the adjacent pairs and 
opposite bases, sequence-specific conformational differences have been observed in DNA 
duplexes.36 Most studies on purines opposite abasic sites showed that they remained stacked 
within the DNA helix. In contrast, pyrimidine opposite abasic site may either remain stacked 
within the helix or exists as extra-helical depending on the nature of the abasic site and the 
flanking bases.38-40 Although there is only a modest affect on helix distortion, thermodynamic 
and calorimetric data suggest that the abasic sites cause a significant instability of DNA 
duplex.41   
1.3.2 Repair  
Most of the abasic sites formed are primarily repaired by the base excision repair 
(BER) mechanism. During BER, AP site is cleaved by AP endonuclease forming a 3’-OH 
group and a 5’-deoxyribose phosphate residue (5’dRP).42, 43 Further repair is carried out by at 
least two distinct BER sub pathways, the short patch repair or long patch repair. AP sites can 
be incised by AP layase/DNA glycosylases and initiate short patch BER of AP site. AP 
layase cleaves DNA at 3’ side of AP site generating a 5’ phosphate and a 3’ α-β unsaturated 
terminus, which are further processed by DNA repair mechanisms.43, 44  
Though AP sites can be repaired by BER, AP sites formed within the single-stranded 
DNA (ssDNA) likely would not be repaired as it lacks information on the complementary 
strand. Further, if BER is attempted in ssDNA of the replication fork, it is more likely to 




AP sites that escape from DNA repair is highly detrimental to cells and a strong block to 
DNA replication. However, translesion synthesis polymerases are able to bypass AP sites 
frequently generating mutations. 
 8,5’-Cyclopurines 1.4
Ionizing radiation and other processes that give rise to reactive oxygen species generate 
many lesions in DNA, including tandem DNA lesions. This type of DNA damage is found to 
play an important role in mutagenesis, carcinogenesis and ageing. 8,5’-Cylopurine 2’-
deoxynucleosides (cPDNS), which are formed due to ionization radiation, have been detected 
in DNA derived from many different cells and organisms.46 They are also considered one of 
the major oxidative stress response markers. These cyclopurines exists as 5’R and 5’S 
diastereomers and are considered unique tandem lesions due to the presence of an additional 
C8-C5’ covalent bond between the purine base and the sugar moiety of the same nucleoside. 
This additional N-glycosidic bond gives extra stability to the damaged nucleoside.47 NMR 
studies have shown that the 2-deoxyribose sugar moiety of 5’S cdG has an O4’ exo 
conformation and able to maintain Watson-Crick base pairing interaction with 
complementary cytosine base. However, this O4’- exo pseudorotation causes a perturbation 
in the helical twist and base-pair stacking of DNA, causing thermodynamic destabilization of 
the DNA double helix.48 Furthermore, due to the additional covalent bonding and the extra 
stability, they are resistant to acid-induced hydrolysis, therefore preventing their repair by 
base excision repair (BER) and can only be repaired by nucleotide excision repair (NER) 
mechanism.49 Hence it is proposed that these lesions may be responsible, at least in part, for 
neurodegenerative diseases like Xeroderma pigmentosum (XP) and Cockayne syndrome 




1.4.1 Chemistry of Cyclopurines Formation 
8,5’-Cyclo-2’-deoxyadenosine (cdA) and 8,5’-cyclo-2’-deoxyguanosnie (cdG) are  a 
class of major DNA lesions formed by ionizing radiation and the Fenton reaction induced 
hydroxyl radical attack on 2’-deoxyadenosine and 2’-deoxyguanosine, respectively. It is 
evident that these lesions are not formed by singlet oxygen or other types of ROS. 
Cyclopurines represent concomitant damage to both the base and the sugar moiety of the 
same nucleotide and are considered tandem DNA lesions.51  
The formation of cyclopurines involves two steps illustrated in Figure 3. In the first 
step, hydroxyl radical attack at the C5’ of the sugar moiety to abstract an H atom generates 
the C5’ radical. This radical formed at C5’ then attack double bond between N7 and C8 of 
the purine ring of the same nucleoside in the absence of oxygen to form an 8,5’ bond. 
Subsequent oxidation of the N7-centered radical leads to the formation of the 8,5’-
cyclopurined. Evidence for this reaction was first presented when 8,5’-cyclo-AMP was 
formed after adenosine-5’-monophospahte (AMP) was exposed to ionizing radiation in the 
absence of oxygen. The experimental rate constant for H abstraction was determined as 
2.8×109 M-1s-1 and the rate constant for cyclization reaction is 1.6×105 s-1. Since the second 
reaction is relatively slow, it can be interfered by cellular molecular oxygen to produce a 
peroxyl radical. However, the inhibitory reaction may not be prominent in the eukaryotic 
nucleus, where there is substantially low O2 concentration. This may be the reason that there 
were no evidences for presence of cyclopurines in the mitochondria, where there is a higher 
O2 concentration.52, 53 
 Furthermore, research on cyclopurines have identified two diastereomers (S, R), in 




the nucleoside. Biochemical and structural studies showed that both R isomers of cdA and 
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1.4.2 Biological Significance of Cyclopurines 
The genomes all organisms are constantly under attack by various DNA damaging 
agents. Every cell in the body gives rise to thousands of lesions per day. However, DNA is 
protected by a variety of repair systems, including nucleotide excision repair (NER) and base 
excision repair (BER). These two systems remove the majority of DNA lesions.  
Earlier studies have shown that cyclopurines can only be repaired by NER and may not be 
repaired by BER due to the presence of an extra covalent bond between C8 and C5’ of the 
same nucleoside.49, 54-56 Most of the initial investigations on repair were performed with S or 
R isomer of cdA and less attention was given to cdG. Kuraoka et al. have searched for 
glycosylase and nuclease activity of HeLa extract on a plasmid containing either 5’R or 5’S 
isomers of cdA. This study showed that glycosylase activity was unsuccessful in the cleavage 
of 8,5’bond and postulated that BER may be inefficient in repairing these lesions. However, 
both isomers were removed in the cell-free extract, suggesting that these are repaired by 
NER. It was also noted that 5’R isomer was repaired more efficiently than the 5’S isomer of 
cdA. Moreover, both cyclopyrimidine dimer (CPD) and 5’S-cdA had a comparable NER 
efficiency.49.  
 Gene expression was impaired by a single (5′S)-cdA on the transcribed strand of a 
gene in Chinese hamster ovary and human cells, with efficiency comparable to CPD. This 
kind of effect on gene expression blockage can be related to those patients with XP whose 
NER is defective. Therefore it was hypothesized that the accumulation of cyclopurines in an 
active gene would prevent transcription, which in turn may lead to neurodegeneration related 
to XP disease. This hypothesis was further tested in human cells transfected with the vector 




modified luciferase response as well as through direct monitoring of the transcriptional 
activity of cells from a XP patient with neurodegeneration.54  
In vitro kinetic study using T7 DNA polymerase and mammalian DNA polymerase δ 
showed that presence of any diastereomers of cdA hindered primer extension. In the case of 
T7 DNA polymerase, it was able to incorporate a base opposite the 5’ R isomer, while pol δ 
was blocked before the lesion and no extension was observed. This indicates that bypass 
polymerases can bypass bulky helix distorting lesions.49 Indeed, purified pol η was able to 
efficiently bypass 5’R-cdA, while 5’S-cdG was strongly blocked after incorporation of one 
base opposite the lesion. This suggested that difference in stereoisomers can influence not 
only the nuclease activity, but also the translesion synthesis across a specific adduct.57 
Experimental evidences show that single 5’S-cdA in TATA box sequence was able to 
block binding of transcription binding factors (TATA box binding proteins) and significantly 
block gene expression.58 This observation also supports the notion that accumulation of 
cyclopurines may be responsible for neuronal death in XP. Apart from transcriptional 
blockage, 5’S-cdA has shown to trigger transcriptional mutagenesis, a situation where RNA 
polymerase bypasses non-bulky DNA lesions. Characterization of mutant transcripts 
resulting from bypass of S-cdA by RNA polymerase II (Pol II) showed misincorporation of 
an adenosine opposite to the next nucleotide 5’- to S-cdA and to cause multiple nucleotide 
deletions. This mutational event is also suspected to contribute to neuropathology in XP 
patients as a result of lesion bypass by RNA polymerase II.59  Another study found out that 
levels of 5’S-cdA and 5’R-cdA were higher in neil1-/- mice suggesting that NEIL1 plays an 
important role in their repair.60 
Recent studies published from our group evaluated the solution structure of site-




strand.  These studies established that O4’-exo (west) pseudorotation was maintained in each 
pair.  S-cdG.dC pair was able to maintain Watson-Crick base pair, but S-cdG.dT pair adopted 
a wobble-pair. In contrast, there was no hydrogen bonding observed between S-cdG.dA 
pair.48  
1.4.3 Cyclopurines and Human Diseases 
Xeroderma pigmentosum (XP) is a neurological disease characterized by loss of large 
neurons in brain, spinal cord, and peripheral nervous system. It is also a cancer-prone disease, 
and XP patients exhibit increased skin cancer incidences due to UV sensitivity. Based on 
several scientific reports, it is now established that NER is defective in XP patients. 
Therefore, one can conclude that oxidatively induced DNA lesions including cyclopurines, 
which are specifically substrates for NER, might play a role in XP neurologic diseases.50  
Scientific rationales for cyclopurins being responsible for XP include, (i) cyclopurines 
are substrates for NER, which is defective in XP patient, (ii) cyclopurines are not repaired by 
BER, (iii) gene expression in XP cells are strongly blocked by cyclopurines, an effect likely 
to cause neurodegeneration, (iv) cyclopurines are inherently stable and could accumulate in a 
cell in the absence of repair.50, 61   
Cockayne syndrome (CS) is a genetic neurological condition with severe growth 
failure, premature aging, hypersensitivity to sunlight, microcephaly, and other neurologic 
abnormalities. CS complementation group A (CS-A), is associated with mutations in CSA 
gene. Evidence shows that CSA is required for repair of 5’S-cdA by NER. Therefore, it was 
hypothesized that accumulation of 5’S-cdA may be implicated in clinical features of CS-A 
patients.62, 63 Furthermore, elevated levels of 5’S-cdA was observed in csb-/- mice indicating 




In women with BRCA1 mutation, accumulation of cdA and cdG was observed, 
supporting the notion that BRCA1 may be involved in cyclopurins repair during NER, and if 
unrepaired may contribute to breast cancer.65-67 Furthermore, it has been observed that 




 Tobacco Induced Carcinogenesis 1.5
Cancer is one of the leading causes of deaths in the United States. According to the 
United States Public Health Services, “cigarette smoking is the major single cause of cancer 
in the United States.” Although the tobacco usage is declining in most industrial countries, 
overall consumption is increasing with approximately 5.5 trillion cigarettes smoked each 
year.69 World Health Organization (WHO) predicts that, due to current smoking trends and 
unhealthy lifestyles, the estimated annual death toll will exceed to 12 million, and about 15 
million new cancer cases will be detected annually by 2020.70 Based on International Agency 
for Research on Cancer (IARC) statistics, numerous cancers are associated with tobacco 
including lung, oral cavity, nasal cavity, esophagus, stomach, liver, pancreas, bladder, ureter, 
and kidney.71 Approximately, 90% of male and 75-80% of female lung cancer deaths 
reported in US are due to cigarette smoking.72 Furthermore, tobacco smoke accounts for 30% 
of all cancer motility in developed countries. Human risks associated with tobacco smoke are 
not just limited to smokers, but also to non-smokers, including children and infants, as a 
result of indirect exposure through second hand smoke (SHS).71 
The link between cigarette smoking and cancer was initially documented in the 1964 in 
the US Surgeon General’s report, which had enormous positive effect on public health in the 
United States. Since then, smoking prevalence of men has decreased from 51.1% to the 
current 21.6%, while for women it has decreased from 33.3% to 16.5%. These facts indicate 
the critical importance of awareness and tobacco control in disease prevention.73, 74  
Tobacco products contain a variety of chemicals such as nicotine and carcinogens, 
which are responsible for many preventable and premature deaths worldwide. The impact on 
human health due to tobacco depends on the type of the tobacco product and also the duration 




manufactured and/or hand rolled cigarettes, whilst second hand smokers are expose to 
tobacco smoke from the environment, where cigarette smoking occurs. Smoke-less tobacco 
or chewing tobacco is another way people get expose to tobacco toxicity.75  
Nicotine, the major component of all types of tobacco products, is an addictive 
chemical.76 It is responsible for activating signaling pathways related to tumor initiation. In 
addition to nicotine, tobacco products consist of a variety of chemical carcinogens, including 
polyaromatic hydrocarbons (PAH), tobacco specific nitrosamines, volatile nitrosamines, 
aromatic amines, aldehydes, volatile hydrocarbons, metals, and many more organic and 
inorganic compounds. Most of these carcinogens are linked to multiple cancers in humans 
occurring in various systems like reparatory, digestive and urinary systems of tobacco users. 
Furthermore, binding of these tobacco smoke constitutes directly (without metabolic 
activation) to cellular receptors are responsible for activation metabolic pathways such as Akt 
and PKA, which in turn contribute to tobacco carcinogenicity.77 
It is inevitable that prevention tobacco usage and smoking cessation are the 
fundamental approaches against smoking-related cancers. However, due to the powerful 
addictive property of nicotine, these strategies are only partially successful.73 Moreover, 
tobacco companies, in response to the more widely accepted smoke-free laws, have marketed 
alternative nicotine sources like smokeless tobacco products. However, the levels of 
carcinogens in some these products are frequently higher than normal tobacco products, thus 
have not been accepted as safe substitutes. The promotion of smoking cessation and smoke-
free environments should still remain as major efforts to reduce tobacco-related cancers.78 
Also it is important to further understand the carcinogens in tobacco products and their 





1.5.1 Tobacco smoke 
Tobacco smoke contains at lest 7000 chemicals, of which about 70 chemicals have 
been identified to cause cancers of various types.79 Nicotine is the major addictive component 
in cigarette smoke, and it plays a role in tobacco carcinogenesis. It involves promoting cancer 
activating signaling pathways to assist cancer growth, angiogenesis, migration and 
invasion.80 Furthermore, nicotine can undergo chemical conversion to carcinogenic, 4-
(methylnitrosamino)-1-(3-pyridyl)-1-butanone (NNK), 4-(methylnitrosamino)-1-(3-pyridyl)-
1-butanol (NNAL) and, N’- nitrosonicotine (NNN) during the process of curing or 
smoking.80, 81 Majority of the nicotine is metabolized to cotine by cytochrome P450 and 
aldehyde oxidase, and rest to other metabolites such as nicotine-N-oxides.75  
Besides nicotine, tobacco smoke contains an array of carcinogens, including 
polycyclic aromatic hydrocarbons (PAH), aza-arenes, N-nitrosamines, aldehydes, volatile 
hydrocarbons, nitro compounds, and miscellaneous organic and inorganic compounds. Other 
carcinogens that are not yet evaluated by IARC are also present.71, 82, 83 These metabolites are 
detoxified to more water-soluble forms by drug metabolizing enzymes, including cytochrome 
P450, glutathione S-transferase, and UDP-glucuronosyl, which are then excreted in urine. 
However, reactive electrophilic intermediates formed during this process attack to 
nucleophilic centers of DNA generating DNA adducts.84 This process known as metabolic 
activation is required to exert carcinogenic functions of reactive intermediates. If these DNA 
adducts remain unrepaired, they may lead to mutations during translesion synthesis process, 
the adduct bypass mechanism. Specifically, if these mutations occur in tumor suppressor 





1.5.2 NNK Carcinogenicity 
Nitrosation of nicotine and related alkaloids produce nitrosamines in tobacco. Among 
nitrosamines in tobacco smoke, NNK (“nicotine-derived nitrosaminoketone”) is the strongest 
systemic carcinogen found in rodents, which induces lung carcinogenesis regardless of the 
route of administration. NNK is a procarcinogen and require metabolic activation by 
cytochrome P450 (CPY) enzymes to be carcinogenic.87 As a carcinogen, it is very potent and 
was shown to induce lung cancers in rats with a total dose as low as 6 mg/kg (1.8 mg/kg 
when considered as a part of dose-response trend). This is similar to estimated 1.1 mg/kg 
dose of NNK from 40 years of smoking.88 
NNK along with several other nitrosamines were also found to be effective 
hepatocarcinogens in rats. NNAL, the primary metabolite of NNK, and NNK are the only 
pancreatic carcinogens found in tobacco products.89 Scientific evidence shows that 
metabolically activated NNK or PAH in cervix could lead to cervical carcinogenesis.90  
During metabolic detoxification process, NNK undergoes α-hydroxylation to form 
NNAL. Both NNK and NNAL are carcinogenic. Further metabolic processing and 
detoxification converts NNAL to non-carcinogenic glucuronidated form, [4-
(methylnitrosamino)-1-(3-pyridyl)but-1-yl]-β-O-D-glucosiduronic acid (NNAL-gluc), the 
ultimate detoxification product, which is rapidly excreted in the urine.91  
NNK is an unsymmetrical nitrosamine. Metabolic activation of NNK by multiple 
CPYs generates reactive intermediates that can induce methylation, pyridyloxobutylation and 
pyridylhydroxybutalation of nucleobases in DNA generating multiple DNA adducts. There 
are three primary pathways for NNK activation i) carbonyl reduction, ii) pyridine N-




pathways, (either α-methelhydroxylation or α-methylenehydroxylation) both of which form 
carcinogenic intermediates.92, 93  
1.5.3 Methylation Pathway: 
The α-methylenehydroxylation of NNK yields methane diazohydroxide and/or 
methyldiazonium ion, which leads to subsequent DNA methylation forming methyl (Me) 
DNA adducts.94  
 
 











































Some of the methyl (Me) DNA adducts have been studied and are well characterized. 
Several methyl DNA adducts have been identified, 7-methylguanine (7-Me-dG), O6-
methylguanine (O6-Me-dG), O2-methyl thymidine (O2-Me-dT), O4-methylthymine (O4-Me-
dT) and O2-methylcytidine (O2-Me-dC).96 The most abundant of these adducts in vivo is 7-
Me-dG followed by O6-Me-dG. Adduct formation from NNK shows great variation in rodent 
tissues depending on the activating enzymes.96  
The persistence of a DNA lesion is a critical determinant of lung tumor formation in 
the A/J mouse. In fact, there is a strong correlation between the persistence of O6-Me-dG and 
tumor formation in the lungs of A/J mice following exposure to NNK.97  
 
                                 
 
Figure 5: DNA adducts formed from the NNK methylating pathway 
The adduct O6-Me-dG is strongly mutagenic and has shown to induce primarily GC 
to AT transition mutations in codon 12 of the K-ras gene isolated from lung tumors of A/J 
mouse.98 This mutation is a known consequence of mispairing of O6-Me-dG with T. O6-Me-
dG has been shown to play a critical role in NNK-induced lung tumorigenesis in 
experimental animals as well as in human tissues. However, O4-Me-dT concentration was 
found to be low due to its rapid removal in the lung and may have a limited contribution for 
lung carcinogenesis. Furthermore, 7-Me-dG was found be rapidly removed by base excision 
repair and seems to have low mutagenic potency as there was no evidence for persistence of 
7-Me-dG adduct levels from NNK and incidence of liver tumors in rodents.99 100 
1.5.4 POB Pathway: 
The α-hydroxylation at the methyl carbon produces α-hydroxymethyl NNK, which in 
turn undergoes glucuronidation. The latter spontaneously loses formaldehyde, producing 
pyridyloxobutyldiazohydroxide, which reacts with DNA forming bulky pyridyloxobutylation 
(POB) adducts in DNA and proteins.101 Mild hydrolysis of these adducts would yield 4-
hydroxy-1-(3-pyridyl)-1-butanone (HPB).102 The carcinogenic properties of the 
pyridyloxobutylation pathway and the impact of the adducts formed from this pathway are 
not well understood. Four stable DNA adducts generated in this pathway have been 
identified. They are: 7-[4-3-(pyridyl)-4-oxobut-1-yl]-2’-deoxyguanosine (7-POB-dG), O2-[4-
3-(pyridyl)-4-oxobut-1-yl]-2’deoxycytosine (O2-POB-dC), O2-[4-3-(pyridyl)-4-oxobut-
1yl]thymidine (O2-POB-dT), and O6-[4-3-(pyridyl)-4-oxobut-1-yl]-2’-deoxyguanosine (O6-
POB-dG).103 
These POB adducts have recently been detected in DNA from tissues of NNK-treated 
rodents. Of these adducts, O6-POB-dG and O2-POB-dT are the most stable, while 7-POB-dG 




release HPB under neutral thermal hydrolysis conditions.104 Quantitation of the four POB 
adducts in NNK-treated calf thymus DNA indicates that 7-pobG is formed in the greatest 
relative amount in vitro, followed by O2-POB-dC, O2-POB-dT, and O6-POB-dG.105  
 
   
            
 
Figure 6:  DNA adducts formed from the NNK pyridyloxobutylating pathway 
 
POB DNA adducts have been detected in lung tissue and it persist for a significant 
period. Pyridyloxobutylating agents are also mutagenic in the Ames Assay. Mutagenicity of 
POB adducts showed considerable difference in mutations. Spontaneous depurination of 7-
POB-dG gives rise to apurinic sites.104 However, it was suspected that O2-POB-dT play a role 
in the etiology of tumors in the respiratory mucosa and esophagus in rats treated with higher 




Furthermore, the cytotoxic and mutagenic properties of the pyridyloxobutylating 
agent, 4-(acetoxymethylnitrosamino)-1-(3-pyridyl)-1-butanone (NNKOAc), were 
investigated in repair-proficient and -deficient Chinese hamster ovary cell lines (CHO). 
Analysis of the mutational spectra in the hprt gene showed mainly point mutations at AT 
base pairs, while GC to AT transitions were found in less frequent.106  
Despite these studies, there are only limited data as to which POB adducts cause these 
mutations and whether or not these mutations are critical to tumor initiation. It is known that 
the pyridyloxobutyl DNA adduct O6-POB-dG leads to mutations at GC base pairs. Site-
specific mutagenesis studies demonstrate that O6-POB-dG produces GC to AT transitional 
mutations in bacteria, while this adduct produces not only GC to AT transitional mutations 
but also GC to TA transversions and deletions in human kidney cells.107 However, O6-POB-
dG has shown to be efficiently repaired by O6-alkylguanineDNA-alkyltransferase (AGT).108 
Moreover, in vitro bypass of O2-POB-dT suggested that this adduct miscodes during DNA 
replication.109 While some information exists about mutations caused by POB DNA adducts, 
precise contribution of these adducts in carcinogenesis is yet to be investigated. 
 DNA Repair 1.6
Thousands of DNA damages arise every day challenging the integrity of the genome. 
DNA damage interferes with replication and transcription, inducing mutations and 
chromosomal aberrations. The toxic and mutagenic consequence of the DNA damage can be 
eliminated or minimized, however, by damage signaling and repair mechanisms, in order to 
preserve the integrity of the genome. These mechanisms are collectively known as DNA-
damage response (DDR) and are coordinated to detect lesions, signal their existence, and 
trigger repair. DDR responds to DNA damage by slowing or arresting cell-cycle progression 




also by transcriptional activation and posttranscriptional modification of DNA repair 
proteins.110 Defects in these pathways lead to extreme sensitivity towards DNA damaging 
agents and may lead to diseases. Although the choice of the response system differs 
depending on the type of the lesion and the cell-cycle phase, they usually occur by a common 
general mechanism. 110-112 
1.6.1 DNA Damage Signaling and Cell-cycle Checkpoints 
Cellular checkpoints coordinate DNA repair with chromosome metabolism and cell-cycle 
transitions. Theses checkpoints are cellular proteins that get recruited to DNA lesions by 
repair complexes to generate DNA intermediate structures. These structures subsequently 
activate checkpoint responses. Following activation, checkpoint signals are amplified and 
transmitted by the checkpoint transducers to downstream targets such as DNA repair 
apparatus and cell cycle machinery. 111 
Key DDR-signaling components of mammalian checkpoint machinery are the 
phosphoinositide 3-kinase like protein kinases, ataxia–telangiectasia mutated (ATM), ataxia–
telangiectasia Rad3-related (ATR) and DNA dependent protein kinase catalytic subunit 
(DNA-PKcs). ATM and DNA-PKcs are predominantly recruited to double-stand breaks 
(DSBs), while ATR responds to a wide variety of lesions and is activated by replication 
protein A (RPA)-coated single-stranded DNA (ssDNA). ATM and ATR target transducer 
kinases, CHK2 and CHK1, act together with ATM and ATR.  They reduce cyclin-dependent 
kinase (CDK) activity by different mechanisms, some of which are facilitated by p53 (a 
tumor suppressor gene) transcription factors.111-113 Once activated, ATM/ATR signaling 
triggers DNA repair by inducing certain DNA repair pathways. Upon effective removal of 




However, if damage cannot be removed, DDR triggers for apoptosis or cellular senescence. 
111  
1.6.2  DNA repair pathways 
 Repair of different types of DNA lesions rely on different DNA repair pathways. There 
are several DNA repair pathways, including DNA damage reversal to remove base alterations 
and also multiple distinct mechanisms for excising the damaged bases, termed base excision 
repair (BER), nucleotide excision repair (NER), and mismatch repair (MMR). Homologous 







































1.6.3 Reversion repair 
Mammalian reversion repair includes single-step removal of O6-alkylation lesions by 
O6-methylguanine-DNA methyltransferase (MGMT) and DNA-damage reversal by AlkB and 
its homologues proteins. Apart from protection from alkylating agents, MGMT also is 
involved in protection from sister chromatid exchange (SCEs) and chromosomal 
aberrations.115, 116 AlkB is specifically involved in oxidative demethylation of DNA 
alkylation damage, such as, 1-methyladenine and 3-methylcytosin in both single-stranded and 
double-stranded DNA.117 
1.6.4 Base Excision Repair 
Base excision repair is responsible for removing an array of DNA lesions formed by 
ROS, hydrolytic reactions, alkylating agents and single-strands breaks induced by ionizing 
radiation. Oxidized DNA lesions such as 8-oxo-7,8-hydroxyguanine (8oxoG) and thymine 
glycol, alkylated bases including 7-methylguanine, O6-methylguanine, 3-methylguanine, 3-
methyladenine, and lesions formed by hydrolysis like deoxyuracils and abasic sites (AP) are 
examples of lesions removed by BER. The first few steps in BER are to recognize the 
damaged base by DNA glycosylases, flip the suspected base out of the DNA helix, and 
remove it by hydrolyzing the N-glycosidic bond. This results in formation of an abasic site, 
which also can be formed spontaneously. 115, 118-120 Subsequent step involves strand incision 
at the AP site by AP endonuclease (APE1). After insertion of the appropriate base, repair 
could occur by one of the two different mechanisms, short-patch or long-patch repair. Short-
patch repair is usually the preferred repair pathway in mammals, in which DNA pol β 
performs a one–nucleotide gap filling reaction and subsequent removal of 5’deoxyrobose -5-
phosphate (baseless sugar moiety) by its lyase activity. Finally the nicks are sealed by 




(PCNA) are used for DNA synthesis in long-patch repair, resulting in a longer repair patch of 
2-10 nucleotides. Following DNA synthesis, flap endonuclease (FEN1) is used to displace 
DNA flap formed during polymerization and gaps are ligated by DNA ligase 1. 115, 120 
Although in some human tumors sporadic changes have been reported in POLB, there are no 
disorders in inherited deficiencies in BER. 120 
1.6.5  Nucleotide Excision Repair 
In terms of adaptability in lesion recognition, nucleotide excision repair (NER) is the 
most versatile DNA repair pathway, which is also a biochemically-complicated process. 
Unlike BER, NER process involves as many as 30 distinct proteins in a large complex known 
as nucleotide excision repairosome. NER plays an important role specifically in G1 phase to 
remove bulky, helix-distorting DNA lesions, such as the DNA adducts formed by the UV 
light as well as various DNA damages caused by carcinogenic and chemotherapeutic agents 
that are not repaired by BER. However, its activity is not just restricted to G1 phase of cell 
cycle.29, 112 
NER operates via two sub-pathways that depend on the initial lesion recognition 
events, transcription-coupled NER (TCR), which specifically target transcription-blocking 
lesions and global genomic repair (GGR).119 These repair sub-pathways essentially follow the 
same sequences except for the initial DNA damage recognition step. The damage recognition 
event in TCR is triggered by the lesion-induced stalling of RNA polymerase II (pol II) at the 
transcriptionally active strand. The damage recognition in GGR involves different set of 
proteins and is totally independent of transcriptional status of the DNA strand. After the 
initial damage recognition event, the two sub-pathways converge and use the same set of 
proteins and sequences for dual incision, repair, and the final ligation steps. A major 




22-30 base oligonucleotide producing a ssDNA fragment, and the gapped region is 
subsequently repaired by DNA polymerase and associated factors.121  
 NER is an important and vital DNA repair pathway and defects in NER are associated with 
several human (NER-deficiency) syndromes including Xeroderma pigmentosum (XP), 
Cockayne syndrome (CS), trichothiodystrophy (TTD), and UV-sensitive syndrome (UVSS), 
all of which show characteristic UV-sensitivity.122  
1.6.6 Mismatch Repair (MMR) 
The mismatch repair system removes nucleotide mismatches caused by spontaneous 
and induced base deamination, oxidation, methylation and replication errors. These 
replication errors include insertion/deletion loops (ranging from one to ten or more bases) 
resulting from slippage during replication of repetitive sequences or during recombination. 
There are four principal steps of MMR comprising: (1) initial mismatch recognition by 
MutSα (MSH2-MSH6), (2) recruitment of additional MMR factors, (3) search and recognize 
mismatched newly synthesized strand followed by degradation past the mismatch, and (4) 
final re-synthesis of the excised strand.123 
 MMR is an important strategy for maintaining genome integrity and stability and is 
clearly illustrated by MMR deficiency syndrome like hereditary non-polyposis colorectal 
cancer (HNPCC). Defects in MMR also increase the mutation rate leading to oncogenesis.124 
1.6.7 DNA Double-strand Break Repair 
DNA double strand breaks (DSB) are perhaps the most toxic damage found in 
genome and are repaired by different pathways including homologous recombination (HR) 




DSB can be formed from ionizing radiation or X-rays, free radicals, carcinogens and during 
replication of SSB.125 
Upon DSB detection, complex cascade of reactions trigger cell-cycle checkpoints and 
recruit repair factors to the site of the DNA damage.126 The choice of the repair pathway for 
DSB depends on the cell-cycle phase. The predominant DSB repair pathway in G0/G1 phase 
is NHEJ, due to lack of sister chromatids and highly condensed of structures of chromatin, 
whereas HR occurs during the late S and G2 phase of the cell-cycle.127 During NHEJ, two 
ends of DSB are recognized by Ku proteins, which in turn activate protein kinase DNA-PKcs 
that recruit end processing enzymes, polymerases and ligase IV. Furthermore, the presence of 
nucleosomes or other structures may assist NHEJ process as the broken ends are held 
together at a close proximity within the complex. This process occurs without any sequence 
homology between the two broken DNA ends. Therefore, it is error prone as few nucleotides 
could be gained or lost during the process.9, 128 
 In contrast, HR is restricted to S and G2 of the cell-cycle and is a high fidelity 
process, as it uses sequence homology of the sister chromatids as a template for damage 
repair. In HR, first DNA ends are resected in the 5’-3’ direction by nuclease activity. Then 
the damaged chromosome come in to contact with the region of sequence homology of the 
undamaged DNA molecule, which in turn is used as a template for re-synthesis of the 
damaged strands. After DNA synthesis, ligation, and branch migration, resulting Holiday 
junctions (DNA crossovers) are resolved to obtain two intact DNA molecules.126 
NHEJ and HR are the main repair modes for maintaining genome integrity. Defects in 
DSB repair are associated with many disorders including Ataxia telangiectasia (AT), AT- 
like disorder, Nijmegen breakage syndrome. Cancer predisposition, immunodeficiency, 




associated with these disorders.126 Inherited mutations in at least one of these repair proteins 




 Translesion Synthesis (TLS) 1.7
In all living organisms DNA is replicated with high efficiency and extraordinary fidelity. 
These replicative polymerases are comprised of a tight active site, enabling it to accurately match 
the incoming nucleotide to the template base by the appropriate Watson-Crick base pairing, 
conferring them the property of high fidelity. In addition, the 3’–5’ exonucleases activity of 
replicative polymerases removes any base that might, on rare occasions, be misinserted.130 
However, DNA is under constant attack by various endogenous and exogenous damaging agents. 
Despite the existence of highly refined DNA repair pathways, it is likely that some DNA 
damages escape repair and intervene replication machinery to stall replication fork progression. 
Stalled replication forks are highly unstable and can cause genome instability by chromosomal 
aberrations.131 To avoid such deleterious consequences, cells have developed an important 
specialized mechanism known as translesion synthesis (TLS), a mechanism that is able to 
tolerate such DNA damages.132-134 During TLS process, specialized DNA polymerases insert a 
base opposite the lesion and are able to continue DNA synthesis past damaged site. These 
specialized polymerases (TLS pols), most of which belongs to Y family, have low fidelity and 
operate at a lower speed with low processivity compared to the replicative DNA polymerases. 
Hence TLS is an error-prone process and is responsible for many of the point mutations in the 
cell and, in particular, increased point mutations found in the cancer genome.11, 134 The basic 
necessity for the presence of TLS pols reflects a trade-off between maintaining genomic 
instability and accumulation of mutations due to lesion bypass by TLS.135, 136 
It has been suggested that TLS is a multistep process, involving several “polymerase 
switches” where multiple TLS polymerase act in a sequential manner for lesion bypass. During 




specific TLS polymerase is recruited to the primer terminus of the damaged DNA strand. This 
TLS polymerase, the so called “inserter”, inserts a correct or an incorrect base opposite the 
lesion. The inserted base is subsequently extended past the lesion by an “extender”, the same 
TLS polymerase or a second TLS polymerase to complete TLS.137 After synthesizing a short 
tract of DNA, all TLS polymerases are dissociated from the primer terminus and replaced with 
replicative polymerase to resume DNA synthesis.138 
Figure 8: Evolutionary conserved role of DNA polymerase in translesion synthesis (TLS). 
Adapted from ref135 
 
It is unavoidable that all living cells are exposed to endogenous and exogenous damaging 







































tolerate such damages accompanied by undesirable mutagenesis. Therefore, it is crucial to 
strictly regulate activity of TLS pols to avoid any major deleterious consequences.  It has been 
found that all Y family DNA pols are concentrated in the nucleus. During the S phase of the cell-
cycle, pols ι, η and REV1 (mammalian Y-family pols) are transferred to replisome, where they 
co-localize with the polymerase sliding clamp, proliferating cell nuclear antigen (PCNA) and 
other accessory proteins. Only when necessary, these TLS pols are recruited to the replication 
fork replacing replicative polymerase.134, 138, 139 
TLS pols (mostly of the Y-family) are found in all domains of life, and their existence in 
higher organisms suggests an essential evolutionary conserved role.135 Y-family TLS 
polymerases include, archaeal Dpo4 from Sulfolobus solfataricus, bacterial, such as the 
Escherichia coli (E. coli) polymerase IV, V and mammalian pols η, ι, κ, REV1. In addition to Y-
family polymerases, mammalian polymerase ζ (of the B-family) is also considered a TLS pol. 
Further E. coli polymerase II (high fidelity with exonuclease proof-reading activity) is also 
implicated in TLS.132 A brief summery of individual TLS polymerase will be described in the 
following section. 
1.7.1 Y-family DNA polymerase 
On the basis of phylogenetic relationships, DNA polymerases have been grouped into six 
families, family A, B, C, D, X, or Y. Y-family polymerases (Y-family pols) are specialized DNA 
polymerases capable of incorporation of nucleotides opposite templates that are non-instructional 
to replicative enzymes. There are five sub families of Y-family pols including, UmuC, DinB, pol 
ι, pol η, and Rev1.140 Key features of Y-family pols that differ from other regular pols are: the 
ability to bypass damaged bases and their reduced fidelity on replicating undamaged templates. 




The general tertiary structure of replicative pols features a right hand topology with palm, 
finger and thumb domains and is conserved among different polymerase families. In addition to 
these sub domains, Y-family pols catalytic region is composed of an additional little finger 
domain. This little finger domain, also known as polymerase-associated domain (PAD), is 
unique to the Y-family pols, has more sequence variability than the catalytic core, implicated in 
polymerase specificity for certain lesions, involves in stabilization of template DNA with bulky 
lesions, and influence overall activity.143 Furthermore, the decreased processivity and the poor 
fidelity is associated with the “stubbier” finger and thumb domains of Y-pols, as they make 
fewer contacts with the incoming nucleotide and the template DNA. Collectively, all these 
features allow Y-family pols to (mis)incorporate a nucleotide opposite a damaged DNA and 
extend past the lesion by a TLS polymerase.  Additionally, lack of 3’-5’ proofreading 
exonuclease activity of these Y-family pols results in increased mutagenicity during TLS.135 
 The error rate of replicative polymerases of families A, B, and C are extremely low and 
lies between 10-6 to 10-8 and further decreased to 10-8 to 10-10 by auxiliary proteins such as 
PCNA, replication protein A (RP-A) and postreplicative MMR. On the other hand, the error rate 
of TLS pols ranges from 10-1 to 10-3 for replication of undamaged DNA.144  
1.7.2 Mammalian Y-family DNA polymerase 
1.7.2.1 Polymerase eta (pol η) 
Pol η encoded by POLH is considered to be one of main TLS pols found and plays a key 
role in the accurate replication of the UV-induced DNA damage, the cyclobutane pyrimidine 
dimers (CPDs). It is noteworthy that pol η is capable of inserting A-A opposite a cis-syn T-T 
CPD with similar accuracy to unmodified T-T. Nevertheless, on undamaged template pol η is 




syndrome Xeroderma pigmentosum variant (XPV), characterized by hypersensitivity to UV-
induced skin pigmentation change and increased sensitivity to skin cancer. It has been suggested 
that in the absence of pol η, pol κ or ι in cooperation with pol ζ, serve as an error prone TLS 
polymerase to bypass UV-induced lesions.146 Recent structural studies on pol η reveal that its 
active site is large enough to accommodate both of the linked T-T dimer and also stabilize 
incoming dA opposite the lesion. Furthermore, specialized β clamp (positively charged) in the 
little finger domain that acts as a splint, ensures proper reading frame without any template 
slippage. To avoid any erroneous replication of the undamaged template, pol η is displaced from 
the DNA when three bases beyond the lesion have been inserted.147 
1.7.2.2 Polymerase iota (pol ι) 
Human pol ι encoded by POLI, exhibits 10-5 fidelity depending on the lesion and is 
considered unique among Y family pols. Pol ι incorporates nucleotides opposite the four 
template bases with varying efficiency and fidelity. It incorporates nucleotides opposite template 
purines with a much higher efficiency and fidelity than that for pyrimidines. When copying dA it 
has misincorporation fidelity of 1-2×10-4. But while replicating dT, the enzyme misinserts dG 3-
10 times more accurately than correct dA. This is mainly due to structural features of key 
residues in the finger domain that uses Hoogesteen base-paring for DNA synthesis.148 
Additionally, it has been postulated that these specialized configurations of pol ι may have 
implications on BER.149  It has been reported that opposite an abasic site and the 3′T of the (6-4) 
TT photoproducts, pol ι incorporates a G, an A, or a T with an equal efficiencies.150 Furthermore, 




1.7.2.3 Polymerase kappa (pol κ) 
 Human pol κ encoded by POLK belongs to DinB subfamily of Y-family pols.152 It is one 
of the highly conserved polymerase in the Y-family with homologs in bacteria, archaea, and 
eukaryotes. Pol κ is considered to be the most accurate on undamaged DNA amongst Y-family 
pols and has a lower tendency to make one base deletions as compared to bacterial homolog 
dinB.134 Its catalytic site can accommodate only a single Watson-Crick base pair; therefore, pol κ 
is blocked by photodimers. Nevertheless, it is capable of accurately bypassing many lesions 
including some N2-dG adducts, albeit with low efficiency.136, 153 Furthermore, it was suggested 
that pol κ cooperates with pol δ during NER being recruited by ubiquitinated PCNA and scaffold 
proteins.154 
1.7.2.4 REV1 
REV1, which is encoded by REV1, is usually restricted to incorporation of dC opposite 
template dG or a narrow range of lesions including abasic sites and N2-dG adducts.155, 156 
However, this is an unusual process, where there is no direct pairing of incoming dC with the dG 
in the template strand. Instead, template dG is swung out of the helix and temporally coordinates 
it with a specialized loop within the little finger domain. Then Arg324 of REV1 fill the space 
previously occupied by the dG, or provided by abasic site, forming hydrogen bonding with 
incoming dCTP. Therefore, this mechanism allows bypass of bulky dG, maintaining the 
specificity for the correct base and also template-independent dC transferase activity.135, 136, 157 In 
addition to the catalytic role of REV1, it has been proposed that key non-catalytic function of 
REV1 in vertebrates is to help coordinate polymerase switch between the replicative polymerase 




1.7.3 Polymerase zeta (pol ζ) 
Pol ζ belongs to family B, which includes high fidelity replicative polymerases pol delta 
(δ), epsilon (ε) and alpha (α). Unlike replicative pols, pol ζ is error-prone and lacks 3’-5’ 
exonuclease activity, albeit belonging to the same family of high fidelity enzymes. Both human 
and yeast pol ζ are heterodimeric proteins containing a catalytic subunit (REV3) and the 
accessory subunit (REV7). Accessory subunit stimulates the activity of REV3 and links pol ζ to 
REV1 during TLS.136 In vitro kinetic studies have shown that pol ζ is generally inefficient in 
incorporation of nucleotides opposite the lesion but have higher extension efficiency of the 
mismatched primer termini.159  
Both subunits of Pol ζ, REV3 and REV7, are indispensible for UV-induced mutagenesis, 
abasic site mutagenesis, and chemically-induced mutagenesis. Compared to the other TLS pols, 
pol ζ’s action, however, is not limited to the error-prone bypass of DNA lesions, it also facilitates 
error-free bypass of a variety of DNA lesions.136, 140 
 
1.7.4 Bacterial (Escherichia coli) Y-family Polymerase 
1.7.5 Polymerase IV (pol IV) 
Escherichia coli (E. coli) pol IV is encoded by SOS-controlled DinB gene and was first 
identified by Kenyon and Walker in 1980.160 However, its function remained unclear till late 
1990.161 Later, it was found that it is involved in damaged tolerance pathway in E. coli. DinB 
orthologs are found in all domains of life and are the most ubiquitous of Y-family DNA pols. 
Similar to all Y-family pols, pol IV also lacks 3’-5’ exonuclease proofreading activity, and 




2500 molecules/cell) during bacterial SOS induction (a damage tolerance mechanism).162 
Experimental evidences have shown that –1 frameshift mutation occurred within short stretches 
of G residues with overexpressed DinB levels.163 Furthermore, pol IV is able to bypass various 
lesions, particularly found in minor grove of DNA, including 8-oxo-dG, O6-medG, abasic site 
(AP), N-2-acetyaminofluorene (AAF), cyclobutane pyrimidine dimer (CPD), 6-4 photoproducts, 
and many others.164 Experimental observations under normal physiological conditions have 
shown that, pol IV does not contribute to chromosomal mutations.165 However, pol IV is able to 
specifically extend replication errors made by pol III (replicative polymerase).166 In addition to 
its role in TLS, pol IV appears to be involved in non TLS processes including adaptive 
mutagenesis, competitive fitness during stationary phase, recovery of arrested transcription 
events, prevention of hydroxyurea-induced cell death, and also in AP lyase activity.164 
1.7.6 Polymerase V (pol V) 
Pol V encoded by umuD’2C is the major TLS polymerase found in E. coli. and by far one 
of the most studied bacterial TLS polymerases. Pol V is able to bypass a variety of lesions with 
low fidelity leading to increased cellular mutagenesis after DNA damage.167 It is a heterotrimeric 
complex that has shown to require RecA nuclear protein filament for optimal activity. 
Furthermore, it is evident that expression of pol V is limited to SOS induction and occurs about 
40-50 min after UV irradiation. Expression of pol V during SOS response is highly regulated by 
umuDC operon, which contains UmuC and UmuD’ homodimer, an accessory subunit derived 
from UmuD. This kind of tight control is achieved at several levels including regulation of 
transcription level by LexA repressor, requirement of posttranslational modification from UmuD 




1.7.7 Escherichia coli Polymerase II (pol II) 
E. coli pol II is encoded by polB, is a high fidelity DNA polymerase that is involved in 
bacterial TLS. Unlike most TLS pols, pol II possesses 3’-5’ exonuclease proofreading activity, 
although its expression is increased with SOS induction. Compared to other replicative 
polymerases in E. coli (pol I and pol III), pol II can efficiently bypass abasic sites. Even though 
poll II is a high fidelity polymerase, it can generate -2 frameshift mutations to bypass C8-guanine 
adduct of N-2-acetylaminofluorene (G-AAF). Additionally, pol II is involved in TLS of 3,N4-
ethenocytosine, intra-strand cross-links induced by butadiene, and inter-strand cross-links.169  
 Bacterial SOS Response 1.8
In nature different bacterial species have adapted to live in environments of harsh 
conditions like high temperature, pH shifts, and extreme chemical stress. As part of adaptation, 
bacteria respond to such hostile environments by switching global pattern of gene expression and 
have developed distinct response systems, including stress response, SOS response, and heat-
shock response. Similarly, bacterial genome is constantly exposed to endogenous and exogenous 
damaging agents and DNA replication is impaired due to DNA damage.  Bacteria, such as E. 
coli, respond to such DNA damage through SOS response. SOS gene products are involved in 
multiple DNA metabolism processes, such as, recombination, repair and replication.  
During SOS induction, more than 40 genes are expressed, which are regulated by the 
LexA protein. Under physiological conditions, LexA dimer, in its native state, is bound to 20bp 
consensus sequence, conventionally called the SOS box in the promoter region of the SOS genes, 
limiting their expression levels.170 Upon DNA damage, single-stranded regions of DNA are 




protease and forms a filament around the single-stranded DNA regions in an ATP dependent 
manner and becomes conformationally active. The activated RecA facilitates self-cleavage of 
LexA. Cleavage of LexA decreases repressor levels and increases the expression of SOS genes, 
including three low fidelity polymerases, which are involved in translesion synthesis, pol II, pol 
IV and pol V. This system, though quite complex and intricate, is also error-prone.169, 171 
 
 
Figure 9: SOS response mechanism in bacteria. Adapted form ref 169 
inactive LexA!











2 Scope of the Dissertation 
Chapter one of this dissertation is focused on the replicative bypass of an abasic site 
[apurinic/apyrimidinic (AP)] in Escherichia coli and in human embryonic kidney (HEK293T) 
cells.  Abasic sites are the most common DNA damages, opposite which dAMP is frequently 
inserted (‘A-rule’) in Escherichia coli. Nucleotide insertion opposite the AP-site in eukaryotic 
cells is less certain. Depending on the assay system and the type of cells, a ‘C-rule’, ‘A-rule’, or 
the lack of specificity have been reported. Several studies also show that the sequence context 
modulates nucleotide insertion opposite AP-site. In this work, using an extra-chromosomal probe 
I have compared replication of tetrahydrofuran (Z), a stable analog of AP-site, in E. coli and 
human embryonic kidney 293T cells in two sequence contexts. I determined that efficiency of 
translesion synthesis or viability of the AP-site construct in E. coli was less than 1%; yet their 
magnitude was significantly different for the two sequence. The difference in viability increased 
even more in pol V-deficient strains. In uninduced E. coli, for both sequences targeted one-base 
deletions occurred as the predominant mutation, which was decreased significantly upon 
induction of the SOS functions. The full-length products with SOS primarily involved dAMP 
insertion opposite the AP-site, which was largely carried out by pol V. In contrast to these results 
in E. coli, I found that the viability is 2 to 3 orders of magnitude higher in the human cells, and 
the ‘A-rule’ is more rigidly followed as Z→T substitutions occurred as the major mutation for 
both sequences. Furthermore, in HEK293T cells, I found that targeted one-base deletions are 
negligible. siRNA knockdown of Rev1 or pol ζ established that both these polymerases are vital 
for AP-site bypass. However, neither polymerase is indispensable, suggesting roles of additional 




The focus of chapter 2 is to investigate the replicative bypass of γ radiation or oxidatively 
induced 8,5’-cyclopuries in E. coli and HEK293T cells. Ionizing radiation and other processes 
that give rise to reactive oxygen species generate many lesions in DNA, including 8,5’-cyclo-2’-
deoxyadenosine (S-cdA) and 8,5’-cyclo-2’-deoxyguanosine (S-cdG) tandem lesions. In this 
study, I have replicated a plasmid containing either S-cdA or S-cdG in Escherichia coli and 
HEK293T cells. I found that S-cdA is mutagenic and highly genotoxic in E. coli. Furthermore, 
viability and mutagenicity of S-cdA are dependent on functional pol V, but mutational 
frequencies (MF) and types varied in pol II- and pol IV-deficient strains. Furthermore, the 
analysis of progeny from HEK293T cells showed that S-cdG is much more mutagenic compared 
to S-cdA and the major types of mutations are S-cdG→T followed by S-cdG→A. In the case of 
S-cdA, A→ T substitutions are observed as the predominant type of mutations followed by A → 
G transitions. Interestingly, I also found that for S-cdA, a significant number of semi-targeted 
mutations occurred 5’ to the lesion. Using si-RNA induced knockdown of TLS polymerases in 
HEK293T cells, I found that pol ι or pol η are involved in the nucleotide incorporation opposite 
the cyclopurines, whereas pol κ or pol ζ are involved in the extension past the lesions. 
 
Chapter 3 discusses the replicative bypass of O2-alkylthymidine lesions generated by the 
tobacco-specific nitrosamines 4-(methylnitrosamino)-1-(3-pyridyl)-1-butanone (NNK). 
Metabolic activation of NNK generates a variety of DNA adducts including O2-methylthymidine 
(O2-Me-dT) and O2-{4-(3-pyridyl-4-oxobut-1-yl]thymidine (O2-POB-dT) lesions. In this study, I 
have investigated the mutagenic and genotoxic properties of these O2-alkylthymidine lesions by 
replicating single-stranded plasmids containing a site-specifically incorporated O2-Me-dT or O2-




cells, while O2-Me-dT showed much lower genotoxicity. Furthermore, I found that in HEK293T 
cells, O2-Me-dT and O2-POB-dT are highly mutagenic and the major type of mutations observed 
for both lesions are targeted T→A substitutions. Using siRNA induced knockdown of TLS pols, 
I determined that pol η, pol ζ, and REV1 are involved in the lesion bypass of both O2-Me-dT and 
O2-POB-dT. In conclusion, these studies provide the identities of the DNA polymerases that play 
important roles in both error-free and error-prone bypass of these lesions. These investigations 
also provide additional information on the interplay of the various TLS polymerases in lesion 





3 Materials and Methods 
 Materials  3.1
3.1.1 Chemicals, enzymes, plasmid DNA, cells, siRNA and instruments 
All chemicals and reagents, unless otherwise specified, used for gel electrophoresis (e.g., 
agarose, Tris base, boric acid, Na2EDTA, urea, acrylamide, N,N’-methylene bisacrylamide, 
TEMED, APS), and preparation of biological media (e.g., agar, yeast extract, bactotryptone, 
sodium chloride) were purchased from Fisher Scientific (Agawam, MA). Phenol (UltrapureTM 
Buffer-Saturated Phenol) for phenol-chloroform extraction was obtained from Invitrogen. 
Hybridization buffer (PerfectHybTM Hybridization Buffer 1X) chloroform and isoamyl alcohol 
were purchased from Sigma-Aldrich (St. Louis, MO). [γ-32P] ATP for gel assays and 
hybridization were obtained from PerkinElmer Life and Analytical Sciences (Boston, MA). 
The media required for mammalian cell culture such as fetal bovine serum (FBS), 
Dulbecco’s modified Eagle’s medium (DMEM), non-essential amino acids (NEAA), 
penicillin/streptomycin (PS), Dulbecco’s phosphate buffer saline (D-PBS) solution, 0.25% 
trypsin-EDTA, Opti-MEM I Reduced Serum Medium and transfection reagent (LipofectamineTM 
2000) were purchased from Invitrogen Corp. (Carlsbad, CA).   
All enzymes needed for construct preparation and radiolabeling including EcoRV, EcoRI 
T4 DNA ligase, T4 polynucleotide kinase (PNK), uracil DNA glycosylase (UDG), and 
exonuclease III (exo III) were obtained from New England Biolabs (Beverly, MA).  




Escherichia coli strain DH10B and DH12S were purchased from Invitrogen (Carlsbad, 
CA). HEK 293T cells were obtained from ATCC (Manassas, VA). 
The E. coli strains used were AB1157 [F- thr-1 araC14 leuB6(Am) ∆(gpt-proA)62lacY1 
tsx-33 supE44(AS) galK2(Oc) hisG4(Oc) rfbD1 mgl51 rpoS396(Am) rpsL31(Strr) kdgK51 xylA5 
mtl-1 argE3(Oc) thi-1], pol II- (AB1157 but polB∆1::Ω Sm-Sp), pol IV- (AB1157 but 
∆dinBW2::cat), GW8017 (AB1157 but umuDC595::cat), and pol II-/pol IV-/pol V- (AB1157 but 
polB∆1::Ω Sm-Sp dinB umuDC595::cat). All E. coli strains were provided by G. Walker (MIT, 
Cambridge, MA). 
The unmodified oligodeoxynucleotides were purchased from Integrated DNA 
Technology (Coralville, IA) and Midland Certified Reagent Company (Midland, TX).  The 
modified oligonucleotides were prepared as reported. Oligonucleotides were desalted using a 
Sep-Pak C18 cartridge from Waters Corp. (Milford, MA). 
Synthetic siRNA duplexes against POLH (SI02663619), POLK (SI04930884), POLI 
(SI03033310), REV1 (SI00115311), and AllStars Negative control siRNA (1027280) were 
purchased from Qiagen (Valencia, CA), whereas the same for REV3 was purchased from 
Integrated DNA Technologies (Coralville, IA). Sequences of all the siRNAs are listed in Table 1 











 Total RNA isolation was performed using Qiagen’s RNeasy plus kit. Primers required 
for amplifying cDNA of pol η, κ, ι, REV1 were purchased from Qiagen. Quantitect SYBR RT-
PCR kit from Qiagen was used for quantitative RT-PCR.  
BioRad Gene Pulser II electroporator was used for transformation of E. coli cells. PCR 
amplification of ds DNA from DH10B transformants was performed on Applied Biosystems 
Gene Amp PCR System 2700. Extraction of ds DNA from DH10B transformants and DNA 
sequencing were performed in QIAGEN BioRobotic system and Beckman Coulter CEQ 2000XL 
capillary DNA sequencers, respectively, located at BioTech Center, University of Connecticut, 
Storrs, CT. For Real-time quantitative RT-PCR analysis, CFX-96 Real-Time PCR Detection 
System in Dr. Rahul Kanadia’s lab (Physiology and Neurobiology Department, UConn, Storrs) 
was used. Quantification of ds DNA samples in 96-well UV plate was performed in Molecular 
Device SPECTRAmax 384-plus UV/VIS micro plate reader also located at UConn Biotech 
Center. 
 
3.1.2   Synthesis and characterization of oligonucleotides 
3.1.3 Abasic site (Z) lesion containing oligonucleotides 
 Z containing and control dodecamers of the sequences 5'-TGCAGZGTCAGC-3', 5'-
TGCAGTGZCAGC-3', and 5'-TGCAGTGTCAGC-3' were synthesized by the Midland Certified 
Reagent Company, Inc (Midland, TX). The oligonucleotides were purified by C18 reverse phase 
HPLC followed by denaturing polyacrylamide gel electrophoresis. Mass spectrometric analysis 




Additionally, MS and polyacrylamide gel electrophoresis analyses indicated that the Z 
containing oligonucleotides were more than 99% pure.          
3.1.4 S-cdA and S-cdG lesion containing oligonucleotides 
The S-cdA -modified oligonucleotide 5’-GTGCA*TGTTTGT-3’ and S-cdG modified 
oligonucleotide 5’-GTGCG*TGTTTGT-3’ containing the DNA sequence of p53 codons 272-
275 in which the lesions were located in codon 273 were synthesized and characterized as 
reported.48,172 The unmodified oligonucleotides were analyzed by MALDI-TOF MS analysis, 
which gave a molecular ion with a mass within 0.005% of theoretical, whereas adducted 
oligonucleotides were analyzed by ESI-MS in addition to digestion followed by HPLC analysis.  
3.1.5 O2-Me-dT and O2-POB-dT containing oligonucleotides  
The O2-POB-dT-modified oligonucleotides 5’-GTGCGT*GTTTGT-3’, (where T* 
represents O2-POB-dT) containing the DNA sequence of p53 codons 272-275 in which the 
lesion was located in codon 273, was synthesized and characterized as reported.173 The synthesis 
of the phosphoramidite of O2-Me-dT was performed as reported.103 Incorporation into the 
oligodeoxynucleotide 5’-GTGCGT*GTTTGT-3’, where T* represents O2-Me-dT, was 
accomplished as described for O2-POB-dT. Oligonucleotides were analyzed by MALDI-TOF 
MS analysis, which gave a molecular ion with a mass within 0.005% of theoretical. The M+1 for 
the O2-Me-dT oligodeoxynucleotide is 3713 and we found an m/z of 3712. The M+1 for the O2-
POB-dT oligodeoxynucleotide is 3846 and we found an m/z of 3847. Unmodified 
oligonucleotides were analyzed by MALDI-TOF MS analysis, which gave a molecular ion with 





 Methods  3.2
3.2.1 Purification and analysis of oligomers with polyacrylamide gel electrophoresis 
Purity of the site specifically incorporated lesions containing 12mer oligonucleotides 
were determined by denaturing (containing 8M urea) polyacrylamide gel electrophoresis (20%). 
A “cold gel” (with unlabeled oligomers) was performed to remove any contaminant oligomers 
from the desired 12mer. The unlabeled modified oligomers as well as a standard unmodified 
12mer containing loading dye (xylene cyanol and bromophenol blue in formamide) were loaded 
onto 20% PAGE (50 cm length) containing 8M urea. The gel was run at 2250 V (45V/cm2) for 
5~6 hours at room temperature until the leading dye bromophenol blue (which runs 
approximately with a 6mer) reached the bottom of the gel. The desired oligomer-containing band 
was visualized using a UV (254 nm) light and excised from the gel. The oligonucleotides were 
extracted from the excised gel by Spin-X (Costar Corning) columns and eluted with water, and 
subsequently desalted by passing through Sep-Pak C18 cartridges (Waters) with 
acetonitrile:water (60:40) . The elute from each sample was dried in a speed-vac and the 
concentration was determined by UV absorbance measurements. A “ hot gel” (with radiolabeled 
oligomers) was performed to analyze the purity of the purified oligomers. The purified oligomers 
were 5’-labeled with [γ-32 P] ATP, mixed with 2 µL of loading dye and run on 20 % denaturing 
PAGE using above-mentioned conditions. Finally the 32P-labeled oligomers were analyzed by 






3.2.2 Agarose gel electrophoresis for single-stranded vector analysis 
Agarose gel electrophoresis was performed to analyze purity of the plasmid preparations 
and to determine the construct concentration. The ss-pMS2 vector analysis was performed in 
1.1% agarose gels and the ss-M13 vector analysis was performed in 1% agarose gels. The 
agarose gel (1.1% w/v, 0.66 mg agarose in 60 mL of 1x TBE) was casted on a horizontal gel 
apparatus and gel was allowed to solidify for 30 min. The sample was prepared by mixing 0.2 µg 
(2 µL) of the plasmid DNA with 2 µL of 6x loading dye (10 mM Tris-HCl (pH 7.6), 
0.03% bromophenol blue, 0.03% xylene cyanol FF, 60% glycerol, 60 mM EDTA) diluted to 10 
µL with water. For ss-pMS2 analysis, gel was run at 110 V for 3 hours at room temperature and 
for ss-M13 analysis it was run at 100 V for 1h at room temperature followed by 4h at 80 V in 
cold room (4°C), in 1x TBE buffer. Following electrophoresis, the gel was stained with ethidium 
bromide (25 µg/µL in 500 mL water) for five minutes, de-stained for 30 min in 1x TBE, and the 
DNA bands were visualized by UV-light. Based on the net intensity of the standard sample, the 
concentration of band of interest was determined as follows.  
           Known amount of standard DNA (µg)   =    x µg of DNA 
           Intensity of the standard DNA band           Band intensity of the DNA of interest 
3.2.3 Bacterial electro-competent cell preparation and SOS induction 
Four milliliters of overnight E. coli culture, prepared from a single colony, was 
transferred to 200 mL of 1x LB media. E. coli cells were grown to 1 × 108 cells/mL (~ 2 h ) and 
then harvested by centrifugation at 5000g for 15 min at 0 oC. This procedure was repeated twice 
except the cells were resuspended in 40 mL ice-cold deionized water. The bacterial pellet was 




response, the following additional steps were introduced after the first centrifugation. The cells 
were resuspended in 50 mL 10 mM MgSO4 and treated with 50 J/m2 or 20 J/m2 of UV light (254 
nm) in 25 mL aliquots in 150 × 50 mm plastic petri dishes. The cultures were incubated in Luria 
broth at 37 oC for 40 min in order to express SOS functions maximally. Following SOS 
induction, these cells were centrifuged, deionized, and resuspended in glycerol/water in a similar 
manner as described earlier except all manipulations were carried out in subdued light.  
3.2.4 M13mp7L2 vector containing site specifically incorporate abasic site (Z) 
3.2.5 Large scale M13mp7L2 vector preparation 
M13mp7L2 ss-DNA was prepared by infection of E. coli cells by phage DNA. A single 
plaque of M13mp7L2 was picked from 1x LB plate containing IPTG and X-gal and re-
suspended in 1 mL of sterile distilled water. Hundred milliliters of 2x YT media was inoculated 
with 100 µL of GW5100 overnight culture, prepared from a single colony, and infected with 300 
µL of phage solution. Following incubation of the infected culture at 37 oC, 230 rpm, for 6 h, the 
phage supernatant was recovered by centrifugation at 10 000 rpm for 30 min. The supernatant 
was transferred to a 2-L flask. Four grams of PEG8000 (final concentration, Cf, of 4%) and 2.9 g 
of NaCl (Cf = 0.5M) were added to the collected supernatant. The mixture was kept in ice with 
stirring for 1.5 h, transferred into centrifuge bottles and centrifuged at 10000 rpm, 0 °C for 30 
min. The supernatant was discarded and the pellet was re-suspended in 4 ml of 1x TE (pH=8). 
From the resulting solution, the ss-M13 DNA was purified by extracting twice with phenol-
chloroform, once with phenol: chloroform: iso-amyl alcohol (25:24:1) and precipitated with 
ethanol. Final DNA pallet was dissolved in 200 µL of 1xTE (pH=8), the DNA concentration was 




3.2.6 Construction of ss-M13mp7L2 genome containing a single abasic site 
The ssM13mp7L2 (75 µg) DNA was linearized by digestion with large excess of EcoRI 
(750 units) restriction enzyme in 100 mM Tris-HCI (pH7.5), 5 mM MgCI2 and 50 mM NaCI at 
room temperature overnight. The sample was analyzed on 1% agarose gel to ensure complete 
linearization of the vector. After digestion, two fold molar excess of a scaffold 50-mer and 1 M 
NaCI (Cf = 0.025M) were added to the linear ssDNA at a concentration of 100 ng/µL to form a 
gapped-duplex by annealing of the scaffold. The annealing was carried out by incubating the 
mixture for 5 min at 70 °C followed by slow cooling to room temperature over a period of 3-4 h 
and to 4 °C overnight (16h). The proportion of the circularized vector as determined by the 
agarose gel electrophoresis was 35-45%. The scaffolded sample was divided in to three equal 
parts (25 µg each) to perform annealing of the 12mer oligonucleotide, either modified or 
unmodified. Then a 20 molar excess of 12mer insert, either modified or unmodified, was 
phosphorylated at its 5' end in the presence of 75.6 U of T4 polynucleotide kinase and ligase 
buffer (Cf= 1x) at 37 °C for 30 min. The kinase enzyme was then inactivated at 65°C for 20 min. 
The phosphorylated insert, 3200 U of T4 DNA ligase and 10x ligase buffer (Cf = 1x) were 
combined with the mixture containing the gapped-duplex and incubated at 16°C for 16 h to allow 
annealing and ligation of the insert into the appropriate gap on the gapped-duplex. Unligated 
oligonucleotides were removed by being passed through a Centricon -100 apparatus. Any 
residual uncut-circular or re-ligated DNA was removed by additional round of EcoRI digestion. 
The scaffold that was annealed to the M13 DNA was removed by adding 50x molar excess of 
anti-scaffold, then heating the mixture at 90 °C for 45 sec, followed by rapid cooling in ice for 
30 min. A “mock ligation” was performed with 5 µg of ssM13mp7L2, in which no 




modified 12-mer. The crude construct was purified by phenol-chloroform extraction followed by 
ethanol precipitation. Finally the concentration of the purified construct was assessed on 1% 
agarose gel by comparing the net intensity of the circular band to the net-intensity of the known 
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3.2.7 Transformation of ss-M13mp7L2 vector containing a site specifically incorporated 
abasic site in E. coli 
Competent E. coli cells were prepared as described above. To induce SOS, the cells were 
re-suspended in 10 mM MgSO4 solution and aliquots were treated with UV light (254 nm) (50 
J/m2) in plastic Petri dishes. 
For each transformation, 40 µL of the cell suspension was mixed with 1 µL (100 ng) DNA 
solution and transferred to the bottom of a cold Bio-Rad Gene-Pulser cuvette. Electroporation of 
cells was carried out in a Bio-Rad Gene-Pulser apparatus at 25 µF and 2.5 kV with the pulse 
controller set at 200 Ω. Immediately after electroporation, 1 ml SOC medium was added and the 
mixture was transferred to 14 mL culture tubes. The cells were incubated for 1 h at 37 oC to 
allow for phage replication and subsequently transferred to 1.5 mL centrifuge tubes and 
centrifuged at 15000 × g (5 min) to isolate the phage-containing supernatant. The supernatant 
was kept at 4 oC was used to prepare plates for cytotoxicity and mutation scoring analysis. In 
order to prepare LB plates containing phage particles, a predetermined volume of the phage 
solution (diluted to some degree when necessary), was mixed together with 3 mL of molten LB 
top agar (kept at 45°C), 1 mL of E. coli GW5100 culture, and 50 µL of ChromoMax™ IPTG/X-
Gal solution and the mixture was poured onto pre-warmed (37 oC) LB agar plates. The plates 
were allowed to solidify at room temperature and incubated at 37 oC overnight (16-18 h) until 
individual plaques were visible. Progeny plaques were then analyzed by plaque lift hybridization 
and DNA sequencing. Lesion bypass efficiency was calculated by comparing the transformation 
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3.2.8 Plaque lift hybridization for mutational screening 
 Plaque lift hybridization method was performed to distinguish possible mutants at the 
lesion site and nearby location from the plaques containing unmodified vector. Prior to the 
transfer of plaques to nylon membrane, the plaques containing plates were chilled at 4°C at least 
for 1h. Then a labeled sterile Magnagraph nylon transfer membrane (Osmonics, Inc.), marked 
with two asymmetry cuts, was carefully laid on the surface of the plaque-containing plate, with 
out introducing any air bubbles in-between the surface and the membrane. The two cuts in the 
filter paper were marked on the outer surface of the LB plate, which were later used to align the 
plate with the autoradiograph. After 30 seconds, the membrane was carefully lifted from the 
plate and placed plaque-side up on a paper towel. Three replica filters were made for each plate.   
The filters were then placed (plaque-side up) sequentially on Whatman filter papers that were 
saturated with the following solutions: (1) denaturing buffer (0.5 M NaOH,1.5 M NaCI), 30 sec; 
(2) neutralizing solution (0.5 M Tris-HCI, pH=8, 1.5 M NaCI), 5 min; and (3) wash solution (2x 
SSC), 12 min. The membranes were allowed to air-dry for 30 minutes, and the liberated M13 
DNAs were cross-linked to the membrane with UV light (12000 x 100 µJ/cm2) using a UV-
crosslinker (FB-UVXL- 1000). 
 The processed membranes were placed (without overlapping) inside 12-inch 
hybridization roller bottles (Robbins Scientific, Sunnyvale, CA), 6 filters each. To each bottle, 20 
mL of pre-hybridization solution (6x SSC, 5x Denhardt's) was added and incubated for 3 h at the 
hybridization temperature (THyb, 51°C) in a rotary hybridization oven (Robbinson scientific). 
After 3 hours, prehybridization solution was replaced with 20 ml PerfectHybe™ hybridization 
buffer (Sigma) containing corresponding 32P radiolabeled probe (50 pmol). Hybridization was 




washing filters three times with 20 ml of the wash solution (6x SSC, 0.05% Na pyrophosphate, 
0.1% SDS) for 30 min, once at THyb-10°C and twice at THyb. The washed membranes were air-
dried and analyzed by autoradiography. The oligonucleotide probes containing the 
complementary sequence were used for analysis. Two left and right probes were used to select 
phages containing the correct insert, and transformants that did not hybridize with both the left 
and right probes were omitted. Any transformants that hybridized with the left and right probes 
but failed to hybridize with the 15-mer wild-type probe were subjected to DNA sequence 
analysis. Lesion bypass efficiency was calculated by comparing the transformation efficiency of 
the lesion-containing construct to that of the control, whereas mutation frequency (MF) was 
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3.2.9 Single-stranded pMS2 vector containing site specifically incorporated abasic site/S-
cdA/S-cdG/O2-Me-dT or O2-POB-dT lesion 
3.2.10 Large scale preparation of single-stranded pMS2 (sspMS2) vector  
Single-stranded phagemid pMS2 DNA was prepared from E. coli JM109 with the aid of 
the helper phage M13K07 (NEB, Beverly, MA) as reported by Moriya.174 The pMS2 vector 
contains origins of replication for f1, ColE1, and SV40, which can be used for single stranded 
replication in E. coli, double stranded replication in E. coli and mammalian cells. It also contains 
neomycin-resistant (neo) and ampicillin-resistant (amp) genes, which can be used for the 
selection of the cells containing the vector in mammalian and bacterial cells, respectively. In 
addition, it has the SV40 early promoter, SV40 small tumor (T) antigen splice sites, SV40 early 
polyadenylylation sites, and a multiple cloning site with a hairpin loop, that allow digestion of 
the single-stranded vector with EcoRV 
 
Figure 13: Structure of pMS2. MCS represent a multiple cloning site where hairpin 





A brief description of large-scale preparation of pMS2 vector is described below. 
Electrocompetent E. coli DH12S (Invitrogen) cells were thawed on ice and 50 µL of cells were 
mixed with 50 ng of double stranded replicative form (RF) of pMS2.  Then this mixture was 
transferred to a pre-chilled 1-mm gapped electroporation cuvette and the electroporation was 
carried out under following conditions: 1.8 kV, 25 µF and 200 Ω. Immediately after 
electroporation 1 mL of pre-warmed (37 °C) SOC medium (Invitrogen) was added, transferred to 
14 mL culture tube and was grown at 37 °C in an orbital shaker at 225-250 rpm for 1 hour. From 
the resulting culture, 5.0 µL aliquot was plated on lx YT + ampicillin (100µg/ml) and incubated 
overnight at 37 °C. The following day, about 100 colonies were scraped from the 1x YT plate 
using a sterile loop, inoculated to 2 L of ampicillin containing 2xYT media along with 1 mL of 
M13K07 helper phage (Invitrogen) and incubated at 37 °C. After two hours of growth, 
100µg/mL kanamycin was added and the culture was incubated overnight for another 16 hours.  
The phage-infected culture was transferred to 250 mL centrifuge bottles, spun down at 
10,000 rcf (20 min, 15°C), the resulting supernatant was transferred to another 250 mL 
centrifuge bottle and centrifuged at the same condition. Supernatant from the second spin was 
transferred 2L flask containing 4% (w/v) polyethylene glycol (PEG) and 3.5 M NaCl. The 
mixture was stirred in ice for at least one hour to precipitate the phage particles. The resulting 
cloudy solution was centrifuged at 10,000 rcf (20 min, 4 °C) and the pellet obtained was re-
suspended in the minimum volume (6 mL) of 1x Tris-EDTA (pH 7.6) buffer. Then the phage 
particles were re-precipitated with ice-cold 4% (w/v) PEG and 4 M NaCl for an hour and 
centrifuged at 10,000 rcf (20 min, 4°C). The pallet obtained was re-suspended in 2.4mL of 
freshly prepared 1x Tris-EDTA (pH 7.6) buffer and centrifuged for 10 min at 4°C and 10000 




proteinase K (Invitrogen) for 16 hours and single-stranded pMS2 was purified from the digested 
phage solution by a series of phenol: chloroform extractions, followed by ethanol precipitation. 
Finally sspMS2 was re-suspended in 200 µL sterile deionized water and quantified on the UV 
spectrometer. After purification, the purity of the ss-pMS2 was determined by the absorbance 
ratio of 260 nm to 280 nm followed by analysis on 1.1 % agarose gel. 
3.2.11 ss-pMS2 construct preparation 
The construction of modified pMS2 vectors containing site-specifically incorporated 
adducts were performed following the method developed by Moriya (Figure 14). For 
construction of the pMS2 with modified or unmodified 12mer insert, l00 µg (58 pmols) of 
sspMS2 DNA was digested with 800 units of EcoRV at 37 °C for 3 h followed by room 
temperature overnight (16h).  An aliquot of the reaction mixture was run on an l% agarose gel to 
confirm the complete linearization of the circular vector. An equimolar ratio of a 58-mer scaffold 
containing deoxyuridinies in place of deoxythymidines was annealed to linear ssDNA in 50 mM 
NaCl by heating at 90 °C for 5 min followed by slow cooling to 9 °C over 16 h. Annealing of the 
scaffold generated a gapped duplex that contained a 12mer-gap with complementary sequence of 
the lesion to be incorporated. An aliquot of the gapped duplex was run on 1% agarose gel with a 
known amount of control plasmid (ss-pMS2). The amount of the gapped duplex was determined 
by comparing the net-intensity of the gapped duplex band to the net-intensity of the known 
control plasmid using the KODAK Digital Science™-1D program. After determining the gapped 
duplex concentration, a 20-fold molar excess of the modified or unmodified 5'-phosphorylated 
12mer insert was added and ligated at 16°C overnight with 2800 units of T4 DNA ligase. 
Unligated oligonucleotides were removed by being passed through Centricon 100 apparatus. Any 




The scaffold was removed by enzymatic digestion with uracil DNA glycosylase (UDG, 05 
units/µl) and exonuclease-III (0.5 units/µL) at 16°C overnight. The resulting constructs were 
extracted with phenol: chloroform and precipitated with ethanol. The final constructs were 
resuspended in deionized distilled-water and were run on 1% agarose gel. The amount of 
construct was quantified in a manner similar to the way gapped duplex was quantified. 
3.2.12 Transformation of site specifically incorporated lesion (S-cdA) containing ss-
pMS2 vector in E. coli and progeny analysis:  
Competent E. coli cells were prepared as described earlier. To induce SOS, the cells were 
re-suspended in 10 mM MgSO4 solution and aliquots were treated with UV light (254 nm) (20 
J/m2) in plastic Petri dishes. The combined aliquots were incubated in Luria broth at 37 oC for 40 
min for maximum SOS induction. Following SOS induction, these cells were processed in a 
similar manner, except the procedure was carried out in subdued light. Then transformation of 
cells was carried out in a Bio-Rad Gene-Pulser apparatus by mixing vector DNA and un-induced 
cells or SOS-induced cells. Cells were grown for 1 h at 37 oC after adding SOC medium and then 



































Figure 14: General protocol for making pMS2 construct followed by replication and 






3.2.13 Mutant screening by dot-blot hybridization 
 Dot- blot hybridization was performed to identify the possible mutations at the lesion-
site or at nearby locations in the progeny. In brief, appropriate amounts of liquid culture were 
plated on lx YT + ampicillin (100µg/mL) plates and incubated at 37 °C overnight (16-18 h). The 
resulting individual colonies were picked using sterile toothpicks into single wells of a 96-well 
plate (Fisher Scientific) containing 200 µl lx YT + ampicillin (100 µg/mL). The inoculated 96-
well plate was then incubated at 37°C for a minimum of 3 hrs before blotting colonies onto filter 
paper. Using a 96-well replicator (Boekel Scientific, Feasterville, PA), cultures in the 96-well 
plate were blotted onto sterile labeled Whatmann chromatography papers placed on lx YT + 
ampicillin (100 µg/mL) plates, in triplicates. The plates were incubated at 37 °C for 16 h for 
colonies to be replication on the filter paper. After overnight incubation, following procedure 
was carried out to fix DNA onto the filter paper. The filters were carefully lifted from the plates 
and subsequently transferred to (colony side up) 0.5 N NaOH, denaturing solution, for 12 mins, 
and to 0.5 M Tris-HCl (pH 7.5), neutralizing solution for 7 mins. Then the filters were washed 
twice with lx SSC for 4 mins with slow agitation (50 rpm) and once with 100% ethanol for 30 
seconds before they were baked for 2 hours at 80 °C. In-between each washing steps, except for 
two SSC washes, filters were drained and damped dry on paper towels (colony side up).  
Thereafter, each filter was placed separately in a heat sealable bag and sealed with 6 mL of 
PerfectHybe™ hybridization buffer (Sigma) containing corresponding left, right or wild-type 
32P-radiolabeled probe (10 pmol of probe/filter). Liquid in the sealed bags were spread evenly to 
entirely cover the filters and were allowed to hybridize to corresponding probe at its optimum 
hybridization temperature for a minimum of 4 hours in the hybridization oven (Problot™ 12). 




SSC+0.1% SDS, preheated to the hybridization temperature (THyb), for 10 mins. Finally the 
filters were removed from the SSC solution, dried and exposed to autoradiography. Two left and 
right probes were used to select phages containing the correct insert, and transformants that did 
not hybridize with both the left and right probes were omitted. Any transformants that hybridized 
with the left and right probes but failed to hybridize with the wild-type probes were subjected to 
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Figure 15: Mutational analysis by dod blot hybridizaton. A. The general scheme for dot 
blot hybridization; B. Sequences used for mutant analysis; C. A representation of 
hybridization results used for selection mutants. Green circles shows insert without 





3.2.14 Replication and analysis of site specifically incorporated abasic site/ S-cdA/ S-cdG/ 
O2-Me-dT or O2-POB-dT containing ss-pMS2 in human embryonic kidney 293T 
cells and siRNA induced TLS knockdown cells 
3.2.15 Replication and analysis of site specifically incorporated lesion containing ss-
pMS2 in HEK293T cells  
The HEK293T cells were maintained in Dulbecco’s modified Eagle’s medium 
supplemented with 4 mM L-glutamine, and adjusted to contain 1.5 g/L sodium bicarbonate, 4.5 
g/L glucose, and 10% fetal bovine serum in. When it was about ~80% confluent, cells were 
washed with PBS (Invitrogen), harvested with 6 mL of Accutase and was seeded in 24-well plate 
(approximately 1 x 105 cells). The cells were grown to ~80% confluency in the 24 well plate and 
transfected with 100 ng of each construct using Lipofectamine cationic lipid reagent (Invitrogen) 
according to manufacture’s instruction. Subsequent to transfection with control or lesion 
containing pMS2, the cells were allowed to grow at 37oC, 5% CO2 for 24 hours and the plasmid 
DNA was collected and purified by the method of Hirt175 as described below. It was used to 
transform E. coli DH10B and the colonies were analyzed by dot blot hybridization and DNA 
sequencing.  
3.2.16 Isolation of progeny pMS2 from HEK293T and its amplification  
The progeny plasmid-DNA was harvested by a method described by Hirt.175 Briefly, the 
HEK293T/17 cells were centrifuged at 14,000 rpm for 30 sec at room temperature. The 
supernatant was discarded, and pellet was gently re-suspended in 100µL of ice cold buffer P1 
(50 mM Tris-HCl, pH 8.0, 10 mM EDTA, 100 µg/mL RNase A). The cells were then lysed by 




incubated for 2 min at room temperature. The reaction was neutralized by the addition of ice-
cold 120 µl of P3 buffer (3.0 M potassium acetate, pH 5.5) and incubated on ice for 10 min. The 
cell lysate was centrifuged at 14000 rpm (10 min) at room temperature for 2 min and the 
resulting supernatant containing the double stranded progeny DNA was transferred to a new 
tube. The DNA was extracted with phenol/chloroform (3X) and precipitated by ethanol 
precipitation. Final DNA pallet was air-dried, resuspended in sterile distilled water, and 
transformed to DH10B cells (Invitrogen) by electroporation. Immediately after transformation, 1 
mL of SOC media was added, grown for 1h and plated on 1x YT + ampicillin (100 µg/mL) 
plates. The resulting colonies were analyzed by dot blot hybridization and DNA sequencing 
(discussed in previous sections).  
3.2.17 siRNA induced knockdown of TLS polymerases in HEK293T/17 cells and 
mutational analysis of TLS products 
Prior to transfection of the control or the lesion containing vectors, synthetic siRNA 
duplexes were transfected into HEK293T cells using Lipofectamine. HEK293T cells were plated 
in 6-well plates at 50% confluence. After 24 h incubation, they were transfected with 100 pmoles 
of siRNA duplex mixed with Lipofectamine, diluted in Opti-MEM (Gibco), per well. One day 
before transfection of the plasmid, cells (1×105) were seeded in 24-well plates at 70% 
confluence. Cells were then co-transfected with another aliquot of siRNA and either control 
plasmid or lesion containing plasmid. After 24 h – 36 h incubation period, progeny plasmids 




3.2.18 TLS assay in HEK293T cells and siRNA induces TLS knockdown cells   
The lesion containing or the control pMS2 construct was mixed at a 1:2 ratio with a 
single-stranded pMS2 DNA containing a similar DNA sequence 5'-GTCCGTGTTTGT-3' in the 
place of the 12mer insert, which was used as an internal control to determine the TLS events. 
This was instead of 5'-TGCAGTGTCAGC-3' in the region where abasic site was placed and 
instead of 5’-GTGCGTGTTTGT-3’ in the region where O2-Me-dT or O2-POB-dT was placed. 
The mixed DNA was used to transfect either HEK293T cells or TLS knockdown cells and 
processed as described earlier. Oligonucleotide probes complementary to the wild type and the 
mutant plasmid were used to analyze the progeny. The mutant DNA (internal control) gave 
approximately equal number of progeny as the control construct.        
3.2.19 Total RNA isolation with RNeasy Plus Mini Kit: 
Total RNA was successfully isolated from mammalian cells using the RNeasy Plus Mini 
Kit from Qiagen, according to manufacture’s instructions. A brief description of the protocol is 
as follows. Seventy-two hours after the first transfection of siRNA duplexes, 350 µL of RLT 
Plus buffer containing β-mercaptoethanol was added to each well of the 24 well plate to lyse 
cells, and the lysate was homogenized by vortexing for 1 min. Then the lysate was passed 
through a gDNA Eliminator spin column by centrifugation, and equal volume of ethanol was 
added to the flow-through. After that the sample was applied to an RNeasy spin column, 
centrifuged and flow through was discarded. Subsequently, column was washed with provided 
washing buffers. Finally, RNeasy spin column was transferred to a sterile RNase free column 




3.2.20 Quantification of RNA 
RNA yield was quantified by spectrophotometric analysis using the convention that 1 
absorbance unit at 260nm equals 40µg/ml RNA. Sample purity and concentration were 
determined by the absorbance measurements at 260 and 280nm. The A260/A280 ratio should be 
close to 2.0 for pure RNA (ratios between 1.9 and 2.1 are acceptable). UV absorbance 
measurements were obtained using Nanodrop2000c (Thermo Scientific). 
3.2.21 Reverse Transcription Polymerase Chain Reaction (RT- PCR) Analysis.  
Total RNA was extracted from the cells 72 h after the first transfection of siRNA duplexes, using 
the All Prep DNA/RNA/Protein Kit (Qiagen). RT-PCR analysis was performed with 100 ng of 
total RNA using One Step RT-PCR Kit (Qiagen) according to the manufacturer’s instructions. 
Primer sequences used for RT-PCR are listed in Table 2. Using primers specific to TLS DNA 
polymerases and control gene GAPDH, the siRNA knockdown efficiency was determined as 
previously described. Reverse transcription and the PCR initial activation step were performed 
for 30 min at 50 °C and 15 min at 95 °C, respectively. For PolH, PolK, PolI, and Rev1, 
amplification was conducted at 94°C for 30s, 55°C for 45s, and 72°C for 60s for 26 cycles and 
Rev3 was amplified for 32 cycles. Amplification of GAPDH was conducted at 94 °C for 30 s, 
55°C for 45s, and 72°C for 45s for 24 cycles. RT-PCR products were analyzed on a 2% agarose 



































3.2.22 Quantification of knockdown by Real-time Quantitative RT-PCR 
Using the RNeasy Mini Kit (Qiagen), total RNA was extracted from the cells 72h after 
transfection with siRNA. Then the cDNA synthesis and RT-PCR were performed on a Bio-Rad 
CFX-96 Real-Time PCR Detection System using Quantitect SYBR Green RT-PCR Kit (Qiagen) 
according to manufacturer’s recommended procedure: one cycle for reverse transcription, 30min 
(50oC); one cycle for PCR initial activation step, 15 min (95oC); 40 cycles for denaturation, 
annealing and extension, 15 sec (94oC), 30 sec (55oC), 30 sec (72oC) respectively. 
Glyceraldehyde-3-phosphate dehydrogenase (GAPDH) was used as an internal control for 
analysis. Relative quantification of gene expression was performed using the comparative cycle 





4   Chapter 1† : Replicative Bypass of Abasic Site in Escherichia coli and 












†The text and figures in Chapter 1, in part or in full, are a reprint of the material as it appears in 
Weerasooriya, S.; Jasti, V. P.; Basu, A. K., Replicative Bypass of Abasic Site in Escherichia coli 
and Human Cells: Similarities and Differences. PLoS ONE 2014, 9, (9), e107915. 
 






Abasic [apurinic/apyrimidinic (AP)] sites are the most common DNA damages, opposite 
which dAMP is frequently inserted (‘A-rule’) in Escherichia coli.  Nucleotide insertion opposite 
the AP-site in eukaryotic cells depends on the assay system and the type of cells. Accordingly, a 
‘C-rule’, ‘A-rule’, or the lack of specificity has been reported.  DNA sequence context also 
modulates nucleotide insertion opposite AP-site.  Herein, we have compared replication of 
tetrahydrofuran (Z), a stable analog of AP-site, in E. coli and human embryonic kidney 293T 
cells in two different sequences.  The efficiency of translesion synthesis or viability of the AP-
site construct in E. coli was less than 1%, but it was 7- to 8-fold higher in the GZGTC sequence 
than in the GTGZC sequence.  The difference in viability increased even more in pol V-deficient 
strains. Targeted one-base deletions occurred in 63% frequency in the GZG and 68% frequency 
in GZC sequence, which dropped to 49% and 21%, respectively, upon induction of SOS.  The 
full-length products with SOS primarily involved dAMP insertion opposite the AP-site, which 
occurred in 49% and 71% frequency, respectively, in the GZG and GZC sequence. dAMP 
insertion, largely carried out by pol V, was more efficient when the AP-site was a stronger 
replication block. In contrast to these results in E. coli, viability was 2 to 3 orders of magnitude 
higher in human cells, and the ‘A-rule’ was more rigidly followed. The AP-site in the GZG and 
GZC sequences gave 76% and 89%, respectively, Z→T substitutions.  In human cells, targeted 
one-base deletion was undetectable, and dTMP > dCMP were the next preferred nucleotides 
inserted opposite Z.  siRNA knockdown of Rev1 or pol ζ established that both these polymerases 
are vital for AP-site bypass, as demonstrated by 36-67% reduction in bypass efficiency.  
However, neither polymerase was indispensable, suggesting roles of additional DNA 





 AP-sites are non-coding and they strongly block DNA replication by replicative DNA 
polymerases (pols). A specialized class of pols, known as the translesion synthesis (TLS) 
enzymes, however, can bypass DNA damages, including AP-sites. 176 But AP-sites lack the 
information necessary to identify the correct base. So, when a nucleotide is incorporated opposite 
AP-site, it frequently results in a mutation. 177, 178   
In Escherichia coli cells, AP-site bypass is largely SOS-dependent 177 and dAMP is most 
commonly inserted opposite it, which led to the so-called ‘A-rule’. 179    Site-specific studies in 
E. coli showed that the preferential dAMP insertion occurs with SOS. 180  In Saccharomyces 
cerevisiae, dCMP is inserted (‘C-rule) when the AP-site is located in the single-stranded gap of a 
gapped duplex plasmid 181, but in duplex DNA dAMP is inserted preferentially opposite the AP-
site in both the leading and lagging strand. 182  In simian kidney cells, some studies suggest a 
lack of specificity in nucleotide insertion opposite AP-sites. 183-185 In human cells, by contrast, in 
the single-stranded gap region of a gapped duplex plasmid, the majority of the bypass involved 
insertion of dAMP opposite AP-sites. 186  The natural AP-site remains in ring-chain equilibrium 
of the cyclic hemiacetal with an open chain aldehyde form, which is highly labile to heat and 
alkaline pH. 187 Because of its instability, a tetrahydrofuran (Z), as a stable model of the cyclic 
form of abasic site, has been used in many studies.  A comparison of DNA replication past the 
natural AP-site and Z, the stable analog, in E. coli showed that the biological effects of these two 
lesions are similar in SOS-induced E. coli, but their replication characteristics are distinct in 
uninduced cells.188   
The discovery of the Y-family polymerases 189, 190 that can efficiently bypass DNA 




templates. Pol V (UmuD’2C complex) can bypass AP-site efficiently in vitro incorporating 
dAMP preferentially opposite it, whereas pol III and pol IV failed to bypass it on the same time 
scale.191 But pol IV incorporates a nucleotide opposite the AP-site and so another polymerase 
may carry out the extension step.191 Both yeast and human pol η can efficiently bypass AP-sites 
and both prefer to insert purine nucleotides.182, 192 The yeast enzyme, in addition, causes high 
frequency of -1 and -2 frameshifts.193 Dpo4 and human pol κ also bypass AP-sites, although with 
significantly reduced efficiency.194, 195 For human pol κ, however, accessory proteins such as 
PCNA, RFC, and RPA increase efficiency by more than an order of magnitude.195 Human pol ι 
also bypasses AP-sites inserting either dGTP or dTTP with 10-fold reduced efficiency.150 Pol δ 
and REV1, in the presence of pol ζ, can bypass AP-sites.196, 197 It was suggested that pol δ inserts 
dAMP preferentially opposite the AP-site, and pol ζ subsequently extends from the inserted 
nucleotide 196, but arguments against this model have been presented.197                         
Despite the wealth of data from the in vitro experiments described above, the mechanism 
of AP-site bypass in a cell remains unclear.  Additional complications arise from the fact that 
nucleotide insertion opposite the AP-site is greatly dependent on the DNA sequence context and 
the type of cells. Consequently, evaluation of data from different laboratories using different 






















5’ – TGCAGZGTCAGC       (GZG) 
5’ – TGCAGTGZCAGC       (GZC) 
5’ – TGCAGTGTCAGC        (Ctrl) 
 
Naturally occurring  basic site Tetrahydrofuran analog of 





4.3.1 PAGE analysis of the purified lesion containing oligonucleotide 
The gel purified 12-mer oligodeoxynucleotides containing site-specifically incorporated 
tetrahydrofuran, adduct in the sequence 5'-TGCAGZGTCAGC-3', and 5'-TGCAGTGZCAGC-3', 
were analyzed in denaturing 20% polyacrylamide gel electrophoresis (PAGE) containing 8M 
urea. The unmodified oligodeoxynucleotide containing same sequence, 5'-TGCAGTGTCAGC-3' 
was used as a control. The 12-mer samples were radiolabeled at 5’-end with [γ-32P] ATP using 
T4 PNK enzyme and unlabeled free [γ-32P] ATP were removed using Sephadex G-10 columns. 
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Figure 17: A representative 20% denaturing-PAGE [γ-32P] ATP labeled oligonucleotide 
samples containing tetrahydrofuran along with the unmodified 12-mer control. Key: 1. 
Unmodified 12mer-control, 2. Purified 12mer control, 3. Crude oligonucleotide 
containing GZG sequence, 4. PAGE-purified oligonucleotide containing GZG sequence, 





4.3.2 Construction of the AP-site containing vector and its replication  
 We used the M13mp7L2 vector 198 to investigate TLS of Z in E. coli cells, whereas the 
same in HEK 293T was carried out using the pMS2 shuttle vector plasmid containing the origins 
of replication for f1, ColE1, and SV40, and the genes for neo and amp resistance.199, 200 Both 
single-stranded vectors contain a hairpin region that, upon digestion with the appropriate 
restriction enzyme followed by scaffolding with an oligonucleotide, generates the desired gapped 
DNA. The Z containing 12-mer is ligated to this gap and the scaffold is removed before 
replication. Each step of the construct preparation process was monitored on 1% agarose gel. 
Finally the concentration of the each construct was determined by comparing the net intensity of 
the circular band to the net intensity of a known amount of standard DNA. A representative 






Figure 18: A representative agarose gel analysis of the M13 constructs. Lane 1 shows ss-
M13 DNA where as lane 2 show same after digestion with EcoRI. Lanes 3 and 4 
represent circular constructs. Lanes 5 and 6 represent the construct after and 
before scaffold removal, respectively, of a mock ligation mixture 
 




4.3.3 TLS of Z in E. coli 
Magnitude of TLS or viability was determined by comparing the transformation efficiencies of 
Z-containing and control constructs. As shown in Figure 19 and Table 3, Z is a highly toxic 
lesion, and in the absence of SOS-induction, viability was only 0.04% and 0.3%, respectively, in 
the GZC and GZG sequence. With SOS, viability increased by 50-75%. The increase in viability 
with SOS is lower than what others have reported with either natural abasic site or Z.180, 188, 193 
Since SOS induction was considered optimal by parallel replication of other lesions 201, 202, we 
suspect that the sequence context may have played a role in this relatively modest enhancement 
in viability. What we found noteworthy, however, is that the viability of the GZC construct was 
7- to 8-fold lower than that of the GZG sequence, in both uninduced and SOS-induced E. coli 
(Figure 19 and Table 3), which suggests that the GZC sequence poses a stronger replication 
block than the GZG sequence. Viability followed a similar trend in pol II- or pol IV-deficient 
cells, although it was increased nearly 3-fold with SOS in the GZG sequence.  For the GZC 
sequence, viability was 3- to 4-fold lower in the pol V-deficient strain, whereas it was 8- to 14-
fold lower in the triple knockout (TKO) strain that lacks pol II, pol IV, and pol V (Figure 19) But 
such pronounced decrease in viability was not detected in the GZG sequence, so that the viability 
in GZC sequence relative to GZG sequence was reduced by at least 15-fold and 48-fold, 
respectively, in pol V-deficient and TKO cells lines (Figure 19 and Table 3). These results 
suggest that pol V plays a particularly critical role in bypassing Z in the stronger replication 
blocking GZC sequence compared to the GZG sequence and that in the absence of pol V, the 
other Y-family pols such as pol II and pol IV also have a role in TLS of Z in this sequence 





   
Figure 19:TLS frequencies for GZGTC and GTGZC constructs in wild type and pol II-, 





Table 3: Viability of abasic site in E. coli cells 
Strain SOS    GZGTC   GTGZC  
WT 
- 0.3 ± 0.2 0.04 ± 0.01 
+ 0.48 ± 0.06 0.07 ± 0.002 
pol II- 
- 0.26 ± 0.03 0.03 ± 0.004 
+ 0.9 ± 0.1 0.07 ± 0.04 
pol IV- 
- 0.21 ± 0.06 0.04 ± 0.01 
+ 0.44 ± 0.01 0.05 ± 0.01 
pol V- 
- 0.2 ± 0.02 0.01 ± 0.01 
+ 0.29 ± 0.09 0.02 ± 0.009 
TKO 
- 0.22 ± 0.01 0.005 ± 0.002 
+ 0.24 ± 0.07 0.005 ± 0.006 
 
4.3.4 Mutations resulting from bypass of Z in E. coli  
Analyses of the progeny plaques were carried out by oligonucleotide hybridization 
followed by DNA sequencing 201. In the absence of SOS, the major type of mutation in both 
sequences was targeted one-base deletions (63% in GZG and 68% in GZC) (Figure 20 and Table 
4). Of the rest, most were Z→T (dAMP insertion), which occurred in 35% and 24% frequency, 
respectively, in GZG and GZC sequences. In the GZC sequence, multiple deletions were 
detected in 6% progeny, but they were undetectable in GZG sequence. dCMP, dTMP, and dGMP 
insertions were rare and occurred in <1% frequency. In the GZC sequence, Z→T increased from 
24% in uninduced cells to 71% in SOS-induced cells, and one-base deletions dropped to 21%. In 
the GZG sequence, however, Z→T events increased to 49%, and one-base deletions also 
occurred at approximately 49% frequency. SOS had relatively minor effect on the other types of 
mutations. It is worth noting that significant differences in the TLS efficiency and nucleotide 
incorporation pattern opposite the AP-site depending on the DNA sequence context were 




observed differences in TLS between the GZG and GZC sites. Since 92% and 98%, respectively, 
of the progeny in the GZC and GZG construct gave Z→T mutations and one-base deletions, for 
the polymerase-knockout strains, we only focused on these two types of mutations. In Figure 21, 
we report percent MF normalized by TLS to display both the relative proportion of the two main 
mutations combined with the bypass efficiency (whereas the % MF only is shown in Figure 22). 
As shown in Figure 21, Table 5 and Table 6, in pol II- or pol IV-deficient cells, there were only 
minor changes in the relative proportion of the Z→T mutations or one-base deletions in GZG 
sequence. However, there were significant changes in the relative proportion of these two events 
in the GZC sequence.  Without SOS, Z→T mutations increased from 24% in the wild type strain 
to 32% and 39%, respectively, in the pol II- and pol IV-deficient strains. With SOS, Z→T 
mutations increased from 71% in the wild type strain to 83% and 76%, respectively, in the pol II- 
and pol IV-deficient strains. In uninduced pol V-deficient strain also (Figure 21 and Table 7), 
Z→T mutations occurred at a higher frequency (38% in both sequences) than in the wild type 
cells (24% and 35%, respectively, in GZC and GZG sequence). In contrast, in both sequence 
contexts, the relative proportion of Z→T mutations dropped with SOS in pol V-deficient and 
TKO cells, except for GZG in TKO strain, where it remained approximately the same (Figure 21, 
Table 7 and Table 8). These results indicate the major function of pol V is to insert dAMP 
opposite AP-sites, particularly with SOS when this pol is present in substantial concentration. 
But our results also suggest that in addition to the TLS pols, replicative pols are able to bypass 
AP-sites. Furthermore, substantial dAMP insertion occurred in the absence of pol V as well as 
other TLS pols, which suggests that replicative pols are able to insert dAMP across AP-sites. 
While the results of this study show pol V’s primary role is to insert dAMP opposite AP-sites, it 






Figure 20: Mutations induced by Z in GZGTC and GTGZC sequence contexts in E. coli 





Table 4: Mutational frequency in wild type E. coli cells† 










1 85 31a (37) 52 (61) 2 (2) 0 (0.0) 0 (0.0) 0 (0.0) 
2 101 34b (34) 65 (64) 0 (0.0) 1 (1) 1c (1) 0
 (0.0) 
Total 186 65 (35) 117 (63) 2 (1) 1 (0.5) 1 (0.5) 0 (0.0) 
               
+ 
1 156 74 (47) 77 (49) 1 (1) 1d (1) 1 (1) 2e (1) 
2 124 62 (50) 60 (48) 1 (1) 0 (0.0) 1 (1) 0 (0.0) 
Total 280 136 (49) 133 (49) 2 (0.7) 1 (0.4) 2 (0.7) 2 (0.7) 




1 54 11f (20) 41g (76) 0 (0.0) 0 (0.0) 0 (0.0) 2h (4) 
2 57 16 (28) 34i (60) 1 (2) 0 (0.0) 1j (2) 5h,k,l (9) 
Total 107 27 (24) 74 (68) 1 (1) 0 (0.0) 1 (1) 7 (6) 
               
+ 
1 71 51m (72) 13 (19) 2 (3) 0 (0.0) 3j,n (4) 2k,o (3) 
2 38 26 (68) 10 (26) 0 (0.0) 0 (0.0) 1
j (3) 1p (3) 
Total 109 77 (71) 23 (21) 2 (2) 0 (0.0) 4 (4) 3 (3) 
               
  
†The superscript indicates one or more mutants containing mutation elsewhere shown below and 
the number in parenthesis shows the number of events detected. 
 
(a)	  TGC	  AGT	  TTC	  CGT	  (1),	  (b)	  CGC	  AGT	  GTC	  CGT	  (1),	  (c)	  TGC	  AGA	  ATC	  CGT	  (1),	  (d)	  TAG	  AAG	  GTC	  ACG	  (1),	  (e)	  TG	  _	  _	  _	  _	  _	  _	  _	  	  
AGC,	  _	  _	  _	  _	  _	  _	  _	  TG	  AGC	  (1),(f)	  TGC	  	  AG	  _	  GTC	  AGC	  (1),	  	  TGC	  A	  _	  _	  GTC	  AGC	  (1),	  	  TGC	  A	  _	  _	  CTC	  AGC	  (1),(	  g)	  TGC	  AG	  _	  G	  _	  C	  
AGC	  (1),	  T_	  G	  AGT	  G_C	  AGC	  (1),	  (h)TGC	  AG	  _	  _	  _	  _	  _	  _	  _	  (2	  in	  expt	  1	  and	  2	  in	  expt	  2),	  	  (i)	  TGC	  AGT	  _	  _C	  AGC,	  TGC	  AGT	  G_	  C	  CGC	  
(1),(j)	  TGC	  AGT	  _	  AC	  AGC	  (2	  in	  expt	  1	  and	  1	  in	  expt	  2),	  (k)	  _	  _	  _	  _	  _	  _	  	  _	  _	  _	  	  _	  GC	  (1),	  (l)TGC	  _	  _	  _	  _	  _	  _	  AGC,	  TG_	  _	  _	  _	  	  _	  _	  C	  AGC	  (1)	  







Figure 21: A comparison of the frequency of Z→T versus targeted Z deletion (i.e., Z→Δ) 
multiplied with % TLS for GZGTC and GTGZC constructs in wild type and pol II-, 








Figure 22: A comparison of the frequency of Z→T versus targeted Z deletion (i.e., Z→Δ) 
for GZGTC and GTGZC constructs in wild type and pol II-, pol IV-, pol V-, and 






Table 5: Mutational frequency in pol II- deficient E. coli strain 










      
1 86 27 (31) 59 (69) 
2 268 75 (28) 193 (72) 
Total 354 102 (29) 252 (71) 
       
+  
1 211 99 (47) 112 (53) 
2 63 29 (46) 34 (54) 
3 117 62 (53) 55 (47) 
Total 391 190 (49) 201 (51) 
       
GTGZC 
       
- 1 25 9 (36) 16 (64) 
2 13 3 (23) 10 (77) 
 Total 38 12 (32) 26 (68) 
       
+  
1 45 33 (73) 12 (27) 
2 85 78 (92) 7 (8) 
3 56 44 (79) 12 (21) 
Total 186 155 (83) 31 (17) 






Table 6: Mutational frequency in pol IV- deficient E. coli strain 









1 115 39 (34) 76 (66) 
2 89 34 (38) 55 (62) 
 Total 204 73 (36) 131 (64) 
       
+ 
 
1 175 87 (50) 88 (50) 
2 190 103 (54) 87 (46) 
Total 365 190 (52) 175 (48) 
        
GTGZC 
-  
1 30 12 (40) 18 (60) 
2 29 11 (38) 18 (62) 
 Total 59 23 (39) 36 (61) 
       
+ 
1 80 60 (75) 20 (25) 
2 37 29 (78) 8 (22) 
 Total 117 89 (76) 28 (24) 
 






Table 7: Mutational frequency in pol V- deficient E. coli strain 










1 77 29 (38) 48 (62) 
2 146 53 (36) 93 (64) 
 3 225 87 (39) 138 (61) 
 Total 448 169 (38) 279 (62) 
 
+ 
      
1 34 10 (29) 24 (71) 
 2 236 78 (33) 158 (67) 
 3 117 35 (30) 82 (70) 
 Total 387 123 (32) 264 (68) 
       
GTGZC 
- 1 
18 5 (28) 13 (72) 
2 40 17 (43) 23 (58) 
 Total 58 22 (38) 36 (62) 
       
+ 1 20 4 (20) 16 (80) 
 
 
2 59 12 (20) 47 (80) 
3 87 21 (24) 66 (76) 
  Total 166 37 (22) 129 (78) 






Table 8: Mutational frequency in triple knockout E. coli strain 








1 137 48 (35) 89 (65) 
2 178 59 (33) 119 (67) 
Total 315 107 (34) 208 (66) 
  
  
        
+ 
1 73 23 (32) 50 (68) 
2 92 33 (36) 59 (64) 
Total 165 56 (34) 109 (66) 
  
  
        
GTGZC 
- 
1 11 3 (27) 8 (73) 
2 58 19 (33) 39 (67) 
Total 69 22 (32) 47 (68) 
  
  
        
+ 
1 17 5 (29) 12 (71) 
2 21 4 (19) 17 (81) 





4.3.5 TLS of AP-site in human cells.  
To determine the magnitude of TLS in HEK 293T cells, we have mixed 2:1 ratio of the 
AP-site construct and unmodified plasmid that contained a different sequence at the Z-containing 
12-mer region.  The unmodified plasmid was used as an internal control. The percentages of the 
colonies originating from the lesion-containing construct relative to the unmodified plasmid, 
reflecting the percentage of TLS, were determined by oligonucleotide hybridization. In stark 
contrast to E. coli cells, which gave less than 1% progeny for the Z-containing construct even 
with SOS, the frequency of TLS in HEK 293T cells was 23% and 33%, respectively, for the 
GZC and GZG sequence contexts (Figure 23 and Table 9).  Even though Z in the GZC sequence 
posed a stronger replication block relative to GZG sequence in both E. coli and human cells, the 







Figure 23: Effects of siRNA knockdowns of pol ζ and Rev1 on the extent of replicative 
bypass of Z for GZGTC and GTGZC constructs. Percent TLS in the pol 
knockdowns was measured using an internal control of unmodified plasmid 
containing a different sequence near the lesion site.  When control siRNA was used, 
the % bypass remained the same as in HEK293T cells. 





Table 9: TLS % in different polymerase knockdown HEK293T cells 









































4.3.6 AP-site mutagenesis in HEK293T cells 
 Figure 24 shows the percent MF normalized by TLS to display the relative proportions 
of various types of mutations combined with the bypass efficiencies in HEK 293T cells. Unlike 
the progeny from E. coli cells, the TLS of Z more rigidly followed the ‘A-rule.’ In the GZG and 
GZC sequence contexts, 89% and 76% Z→T, respectively, were detected (Figure 24, Figure 22, 
Table 10 and Table 11). Moreover, unlike in E. coli, targeted one-base deletions were 
undetectable in both sequence contexts.  The lesion in GZG and GZC sequences, respectively, 
yielded 6% and 13% Z→A, showing that dTMP insertion opposite Z was the second most 
prevalent event. dCMP insertion opposite the AP-site occurred at 2.5% and 10% frequency, 
respectively, in the GZG and GZC sequence. Of all the nucleotides inserted opposite the AP-site, 
dGMP was least favored, which occurred at 2% frequency in GZG sequence, but it was 
undetectable in the GZC sequence.     
4.3.7 Contribution of pol ζ and Rev1 in TLS of AP-site  
 In yeast, pol ζ was found essential for AP-site bypass.182 It was also determined that 
Rev1 can proficiently insert a C opposite an AP-site, but it is unable to extend the replication 
product from there, whereas pol η is highly inefficient at both the insertion and extension steps of 
AP-site bypass.182, 196, 203 To investigate the roles of pol ζ and Rev1 in AP-site bypass in HEK 
293T cells, we employed siRNA knockdown approach to constrain the expression of these pols. 
The extent of siRNA knockdown was determined by RT-PCR and by Western blotting analysis.  
For each pol, the knockdown was at least 75% efficient. When the cells were treated with a 
control siRNA, the extent of TLS of AP-site remained the same. By contrast, in the GZC 
sequence, knockdown of either pol ζ or Rev1 resulted in more than 40% reduction in TLS( 




in the Rev1 and pol ζ knockdown cells, respectively( Figure 23 and Table 9). Therefore, similar 
to the result in yeast 182, in human cells, pol ζ plays a key role; yet, it does not appear to be 
indispensable for AP-site bypass, because 30-57% bypass occurred in the absence of pol ζ. 
Whether the remaining low concentration of the enzyme in pol ζ knockdown cells is enough to 
carry out this level of TLS is a question we cannot address at this time. Rev1 also is important 
for TLS in human cells, but it does not insert dCMP opposite the AP-site. Rev1’s likely role in 
AP-site bypass is the scaffolding function of the C-terminal domain that interacts with the Rev1-
interacting region of other pols, including the Rev7 subunit of pol ζ.204 The type of mutations in 
the Rev1 and pol ζ knockdown cells, however, did not change appreciably from that in HEK 
293T cells (Figure 24, Figure 25, Table 10 and Table 11). 







Figure 24: Percent mutations induced by Z in GZGTC and GTGZC sequence contexts 
multiplied with % TLS for GZGTC and GTGZC constructs in HEK293T cells 






Figure 25: Percent mutations induced by Z in GZGTC and GTGZC sequence contexts in 





Table 10: Mutation frequency of GZGTC in TLS polymerase knockdown HEK293T cells† 
 
 Lesion   Trial  Total  Signals Z →T   (%) Z→A (%) Z→G (%) Z→C (%) Z→Del (%) Other (%) 
 
GZGTC 
293T 1 43 37a,b (86) 3 (7) 3c (7) 0 (0) 0 (0) 0 (0) 
 2 61 54
d (89) 4 (7) 0 (0) 1 (2) 0 (0) 2e (3) 
 3 53 48
f (91) 2 (4) 1 (2) 2 (4) 0 (0) 0 (0) 
Total  157 139 (89) 9 (6) 4 (3) 3 (2) 0 (0) 2 (1) 
                              
Rev 1 1 41 37b (90) 2 (5) 0 (0) 1 (2) 0 (0) 1g (2) 
 2 53 47
a (89) 2 (4) 0 (0) 1 (2) 0 (0) 3g (6) 
Total   94 84 (89) 4 (4) 0 (0) 2 (2) 0 (0) 4 (4) 
Pol ζ 1 82 74b (90) 3 (4) 0 (0) 2 (2) 0 (0) 3g (4) 
 2 46 43
b,h (94) 2 (4) 0 (0) 1 (2) 0 (0) 0 (0) 
Total   128 117 (91) 5 (4) 0 (0) 3 (2) 0 (0) 3 (2) 
 
†The superscript indicates one or more mutants containing mutation elsewhere shown below and 
the number in parenthesis shows the number of events detected.  
(a) TGC CGT GTC AGC (1), (b) TGC ATT GTC AGC (1) (c) TGC GAG GTC AGC (2), (d) 
TGC  _  _ T GTC AGC (1), (e)_ _ _ _ _ _ GTC AGC (1), (f) TGC GAT GTC AGC (2), (g) _ _ _ 
_ _ _ _ _  C AGC (1 in expt 1, 3 in expt 2 of Rev1; 3 in expt 1 of pol ζ  ), (h) _ _ _  AGT GTC 
AGC (1) 




Table 11: Mutation frequency of GTGZC in TLS polymerase knockdown HEK293T cells† 
Lesion    Trial  Total Signals Z →T   (%) Z→A (%) Z→G (%) Z→C (%) Z→ Del (%) Other (%) 
GTGZC 
293T 1 27 20 (74) 4 (15) 3 (11) 0 (0) 0 (0) 0 (0) 
       2 51 39i (77) 6 (12) 5 (10) 0 (0) 0 (0) 1j (2) 
Total  78 59 (76) 10 (13) 8 (10) 0 (0) 0 (0) 1 (1) 
                              
REV1  1 78 56i (72) 9 (12) 10 (13) 2k (3) 0 (0) 1l (1) 
  2 39 25i (64) 4 (10) 6 (15) 1m (3) 3 (8) 0 (0) 
  3 59 45i,n (76) 2 (3) 4 (7) 2 (3) 1 (2) 5l,o   (9) 
Total  176 126 (72) 15 (9) 20 (11) 5 (3) 4 (2) 6 (3) 
pol ζ 1 54 48 (89) 3 (6) 3 (6) 0 (0) 0 (0) 0 (0) 
  2 34 28 (82) 2
p (6) 3q (9) 0 (0) 0 (0) 1o (3) 
Total   88 76 (86) 5 (6) 6 (7) 0 (0) 0 (0) 1 (1) 
                
  
†The superscript indicates one or more mutants containing mutation elsewhere shown below and 
the number in parenthesis shows the number of events detected.  
 
(i) TGC AAT GTC AGC (1 in 293T, 1 each in expt 1 & 3 and 2 in expt 2 of Rev1), (j) TG -  - - -  
G- C AGC (1) ,(k)  TGC AG-   CCC AGC (1) ,(l) - - - - - -  - - - C AGC (4), (m) TGC AGT ACC 
AGC (1), (n) _ _ _  _ _ _  TT C ACG(1), TGC TGT GTC AGC(1),  _ _ _ AGT GTC AGC (1), 




 Discussion and Conclusions 4.4
Analysis of bypass efficiency in E. coli indicated that TLS of AP-site is a particularly rare 
event and that pol V is required for 60-70% of the bypass in the GZC sequence, but it plays a 
less critical role in the GZG sequence. In vitro studies have shown that pol V can insert dAMP 
opposite an AP-site much more proficiently than pol III or pol IV 191, which was also indicated in 
our in vivo experiments. Thermodynamic studies have established that an A opposite the AP-site 
is enthalpically more favorable than a T 205, but it is likely that a pol can override thermodynamic 
considerations in the active site of the enzyme. In the absence of SOS in the current study, the 
major bypass involved one-base deletions. The mechanism of one-base deletion is not clear.  
Although dCMP insertion opposite the AP-site followed by slippage in GZN sequence to pair 
with the 5’G can be postulated, it cannot account for the lack of slippage when dAMP is 
incorporated opposite AP-site in TZG sequence used in another study.188 Perhaps the GC pair 
can stabilize the slippage more efficiently than the AT pair.  The role of pol II, pol IV, or both in 
one-base deletion is likely, but more experiments are needed to rationalize the context effects. 
With SOS, the full-length products were increased to 49% in GZG and 71% in GZC sequence, 
with predominantly dAMP inserted opposite the AP-site. In the GZG sequence, one-base 
deletions occurred at the same frequency as dAMP insertions.  Livneh and coworkers have 
analyzed TLS of AP-site in a GZG sequence, but except for the immediate neighbors, the 
sequence was different from this study.206 Furthermore, the lesion was located in the single-
stranded gap region of a gapped duplex plasmid, and TLS gave 76% dAMP insertions opposite 
the AP-site and 21% targeted one-base deletions with SOS. While both pol IV and pol V can 
bypass Z in vitro 206, 207, pol V is much more efficient than pol IV 191, and pol V and not pol IV 




pol V results in base substitutions, whereas deletions are more likely to result from bypass by pol 
IV or even pol III, although the latter is much less efficient in bypassing AP-sites.191, 206 In our 
study a clear-cut role of pol IV in deletion was not identified.       
TLS studies on AP-site from different laboratories have shown that less than 1% TLS in 
E. coli occur in the absence of SOS, which increased 2- to 10-fold with SOS, whereas about 6% 
TLS takes place in yeast cells in double-stranded DNA.180, 182, 188 In contrast, in the single-
stranded gap region of a gapped duplex plasmid, 20-90% TLS of AP-site have been reported to 
occur in human cells.208 Our comparative study in E. coli and human cells using the same 
sequence context is consistent with these reports. In contrast to E. coli, in which less than 1% 
TLS occurred, in HEK 293T cells we observed 23% and 33% TLS in the GZC and GZG 
sequence contexts. As in E. coli, GZC site was a stronger replication block than GZG, but much 
higher TLS in both sites suggests that the pols in human cells are more proficient in bypassing 
AP-sites.  dAMP insertion opposite the AP-site was the dominant incidence in both sites with 
>75% Z→T substitutions. The second and third most prevalent events were dTMP and dCMP 
insertions, respectively, whereas dGMP insertion occurred at a very low frequency. One-base 
deletion, the major outcome noted in E. coli, was undetectable. This is noteworthy because in 
vitro studies on AP-site templates show that pol β and pol λ can promote template slippage to 
generate -1 frameshifts.209 Our result, therefore, implies that these X-family pols are not involved 
in TLS of AP-site during replication in HEK 293T cells, although they might be important for re-
synthesis step of repair pathways. Evidently, the bypass polymerases in mammalian cells can 
avoid the deleterious consequence of frameshift mutations, which parallels our earlier 
observation in simian kidney cells.210 Using a gapped plasmid vector system in human 




observed in HEK 293T cells.  We also determined that pol ζ is a critical bypass pol for TLS of 
AP-site in human cells, since 44-67% drop in TLS have occurred in pol ζ knockdown cells. 
Likewise, Rev1 also is important for AP-site bypass, as shown by 36-43% reduction in TLS in 
Rev1 knockdown cells. Since Rev1 does not serve as a deoxycytidyl transferase in TLS of AP-
sites, it probably acts as a structural element for another pol such as pol ζ. But, unlike in yeast 182, 
neither pol ζ nor Rev1 was deemed indispensable in human cells. However, future experiments 
with pol ζ- and Rev1-knockout cells will be required to address this question with certainty. It 
was suggested that AP-site bypass in human cells requires at least one of the replicative pols, α, 
δ, or ε.208 Although we did not investigate the roles of the replicative pols in AP-site bypass in 













5   Chapter 2†: Mutagenicity and Genotoxicity of (5’S)-8,5’-Cyclo-2’- 










†The text and figures in Chapter 2, in part or in full, are a reprint of the material as it appears in 
Pednekar, V.; Weerasooriya, S.; Jasti, V. P.; Basu, A. K., Mutagenicity and Genotoxicity of (5 ' 
S)-8,5 '-Cyclo-2 '-deoxyadenosine in Escherichia coli and Replication of (5'S)-8,5 '-Cyclopurine-
2 '-deoxynucleosides in Vitro by DNA Polymerase IV, Exo-Free Klenow Fragment, and Dpo4. 
Chemical Research in Toxicology 2014, 27, (2), 200-210. 
 





Ionizing radiation and other processes that give rise to reactive oxygen species generate 
many lesions in DNA, including 8,5’-cyclo-2’-deoxyadenosine (cdA) and 8,5’-cyclo-2’-
deoxyguanosine (cdG) tandem lesions. Herein the result of replication of a plasmid containing S-
cdA in Escherichia coli is reported. We found S-cdA mutagenic and highly genotoxic. Viability 
and mutagenicity of S-cdA, as we have previously noted with S-cdG, are dependent on functional 
pol V, but mutational frequencies (MF) and types varied in pol II- and pol IV-deficient strains. In 
repair and replication-competent strain, both S-cdA→T and S-cdA→G substitutions occurred in 
equal frequency, but the frequency of the latter mutation dropped in pol IV-deficient strain, 
especially when it was SOS-induced. This suggests that pol IV plays a role in S-cdA→G 
mutations. MF increased significantly in pol II-deficient strain, suggesting its likely role in error-
free translesion synthesis. Furthermore, the analysis of progeny from HEK293T cells showed 
that S-cdG (~81%) was much more mutagenic compared to S-cdA (21%), and the major types of 
mutations induced were S-cdG→T (43.4%) followed by S-cdG→A (28.5%). In the case of S-
cdA, A→ T (7.9%) substitutions were observed as predominant mutation followed by A → G 
(4.9%). Interestingly, for S-cdA a significant number of semi-targeted mutations occurred 5’ to 
the lesion, whereas, for S-cdG, it was observed at a low frequency of about 2%. si-RNA induced 
knockdown of TLS polymerases indicated that pol ι or pol η may be involved in the nucleotide 







The tandem DNA lesions, 8,5’-cyclo-2’-deoxyadenosine (cdA) and 8,5’-cyclo-2’-
deoxyguanosine (cdG) diastereomers (Figure 1), have been detected in DNA derived from 
various cells and organisms.52 A characteristic of these lesions is that both the 2’-deoxyribose 
and the purine base are damaged, and the C5’-C8 intramolecular cyclization induces an unusual 
O4’-exo (west) pseudorotation in DNA.48 The O4’-exo (west) pseudorotation causes a 
perturbation in the helical twist and base pair stacking of DNA, resulting in thermodynamic 
destabilization of the DNA duplex. However, Watson-Crick base-pairing can be maintained. 
Owing to the presence of the C5’-C8 covalent bond between the base and the sugar, base 
excision repair cannot excise cdA and cdG and, indeed, no glycosylase has been found to repair 
these tandem lesions.49, 54 But nucleotide excision repair (NER) system can repair these DNA 
damages,49, 54 and the efficiency of repair varies with the base located opposite them in the 
complementary strand.56 These lesions are suspected to play a role in neurologic diseases in 
Xeroderma Pigmentosum patients with defects in NER.50 S-cdA accumulates in genomic DNA 
of csb-/- mice, signifying that the cyclopurine lesions may accumulate in Cockayne syndrome 
patients.211 S-cdA is also a strong block of gene expression in human cells.54    
In a previous investigation, we found that S-cdG is highly toxic and mutagenic in 
Escherichia coli.212 High toxicity of this lesion was unexpected, since the C5’-C8 bond locks the 
base in the anti-orientation but does not adversely affect Watson-Crick base-paring.48 We also 
determined that error-prone bypass by DNA polymerase V (pol V) is essential for its viability 
and mutagenesis. Replication blocking and mutagenic properties S-cdG and S-cdA were reported 
also by others.213 In E. coli, pol V is one of the three SOS polymerases, which carry out 




pol IV and pol V in E. coli, belong to the Y-family of specialized DNA polymerases,139, 190 
whereas pol II belongs to the B-family.214 The TLS polymerases have more spacious active sites 
allowing them to accommodate many DNA lesions.  Unlike the replicative polymerases, the lack 
of proofreading exonucleolytic function of the TLS polymerases permits them to continue DNA 
synthesis, albeit with a lower fidelity.  For S-cdG and S-cdA, in vitro primer extension studies 
were performed with Saccharomyces cerevisiae and human polymerase η, and both bypass these 
lesions accurately and efficiently.215         
In the current work, we have evaluated error-free and error-prone TLS of S-cdA in E. coli 
and mutagenic properties of both S-cdA and S-cdG in human embryonic kidney cells (HEK 
293T) that are either untreated or siRNA knockdown in TLS polymerases. We show that, like S-
cdG, S-cdA is a strong block of replication and its bypass is entirely dependent on pol V in E. 
coli. Further in mammalian cells S-cdG is more mutagenic as compared to S-cdA and multiple 










































       5’ – GTGCGXGTTTGT – 3’ 
 






5.3.1 Viability of S-cdA in E. coli  
Compared to the control, viability of S-cdA construct was 0.8% in E. coli with normal 
repair and replication functions, which increased ten-fold with SOS. Viability was even less in 
pol II- and pol IV- deficient strains.  Upon induction of SOS, in pol II-deficient strain viability 
increased only four-fold, whereas in pol IV-deficient strain viability increased nearly seventeen-
fold. Furthermore, no progeny was recovered from pol V-deficient strain or the strain deficient in 
all three SOS polymerases.  These results are similar to what was observed with replication of S-
cdG construct reported earlier, and we conclude that pol V (UmuD’2C) is required for replication 
of both S-cdA and S-cdG.  The role of pol II may be more complex in that it plays a secondary 
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Figure 27: Viability of S-cdA in E. coli. Viability was determined by comparing 
transformation efficiency of the S-cdA plasmid with that of the control construct.  
The data represent  average of four independent experiments. SOS was induced 










Table 12: Viability of  S-cdA in E. colia 
Polymerase knocked out -SOS +SOSb 
None 0.5 ± 0.2 8.7 ± 2.5 
pol II 0.6 ± 0.1 1.7 ± 0.3 
pol IV 0.4 ± 0.2 10.6 ± 1.4 
pol V <0.001 <0.005 
pol II / pol IV / pol V <0.001 <0.001 
 
aViability was determined by comparing transformation efficiency of the S-cdA plasmid with 
that of the control construct.  The data represent average of four independent experiments.    





5.3.2 Mutagenicity of S-cdA in E. coli 
The progeny from each transfection was analyzed by oligonucleotide hybridization 
followed by DNA sequencing.  Mutational frequency (MF) in repair and replication proficient 
strain was 6.2% and 8.4% without and with SOS, respectively, and equal fraction of mutants 
carried S-cdA→T and S-cdA→G in each case. In pol II-deficient strain, the MF increased to 
more than 15% in the absence of SOS, which did not increase with SOS and, in fact, dropped 
slightly to 13%.  But the increase in MF in the pol II-deficient strain was mainly due to the 
increase in the S-cdA→T events. In contrast, MF was lower in pol IV-deficient strain with 4.2% 
and 5.6% without and with SOS, respectively, and the major type of mutation with SOS was S-
cdA→T. Although a clear picture of the type of errors by individual polymerases did not emerge, 
it seems likely that pol IV plays a role in most S-cdA→G mutations, whereas both pol IV and pol 
V may be involved in S-cdA→T mutations. The role of pol II is less certain, but it seems to play 
a role in error-free bypass.  Increased MF in pol II-deficient strain in the absence of SOS was 











































Figure 28: Total mutation frequency of S-cdA in different E. coli strains with out or 
with SOS induction. Data from several transformations have been combined 
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Figure 29: Progeny analysis of the replication of S-cdA construct in different E. coli 
strains with out and with SOS. Data from several transformations have been 
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aSOS was induced with 20 J/m2 UV irradiation. 
 
bFor each strain MF of control construct was <1% (data not shown). 
 
cA*T → TG 
 






5.3.3 Mutagenicity of S-cdA and S-cdG in HEK293T cells 
We investigated the mechanism of translesion synthesis past both S-cdG and S-cdA in 
mammalian cells by constructing ss-pMS2 vectors containing a site specifically incorporated S-
cdA, S-cdG and the corresponding unmodified oligomers. The modified and control vectors were 
replicated in HEK293T cells and the progeny double stranded plasmids were recovered. The 
recovered plasmids were further amplified in DH10B E. coli cells and the resulting colonies 
were analyzed the by dot-blot hybridization followed by DNA sequencing. Two left and right 
probes were used to select plasmids containing the correct insert, and transformants that did not 
hybridize with both the left and right probes were omitted. Any transformant that hybridized 
with the left and right probes but failed to hybridize with the corresponding wild-type probe was 
subjected to DNA sequence analysis. The wild type probes used would recognize any progeny 
that contains a G at the S-cdG site or an A at the S-cdA site, indicating correct read-through past 
the lesion by DNA polymerase and are considered non-mutants. The progeny that failed to 
hybridize to the respective wild type probes were considered mutants and the type of mutations 
were determined by DNA sequencing.  
The mutational frequency (MF) was estimated by comparing the number of mutants 
obtained to the total number of colonies screened. As shown in Figure 30 and Table 14, we 
observed that S-cdG exhibited significant mutagenicity in HEK293T cells showing a total 
mutation frequency (MF) of 81%. In contrast, for S-cdA, 79% progeny contained an A opposite 
the S-cdA site indicating accurate lesion bypass by DNA polymerases and showed a total MF of 
only 21% (Figure 30 and  Table 15). The predominant types of mutations caused by S-cdG were 
base substitutions, and G → T (43.4%) transversions were the major event followed by G →A 




occurred (Figure 30 and Table 1). In the case of S-cdA, A→ T (7.9%) substitutions were the 
major mutations followed by A → G (4.9%) transitions (Figure 30 and  Table 15). A striking 
feature of the mutational spectrum of S-cdA was that a significant number of mutations occurred 
5’ to the lesion, which we describe as semi-targeted mutations. The most prevalent semi-targeted 
mutations involved a C → T transition immediately 5’ to S-cdA at a frequency (4.9%) similar to 
that of A → G targeted mutations (4.9%) (Figure 30 and  Table 15). However, for S-cdG, semi-
targeted and other mutations occurred at a low frequency of about 2%, which accounts to less 
than 3% of the targeted base substitution events (Figure 30). It is also important to note that no 
mutations were detected within the 12mer sequence of the control constructs of approximately 




























Figure 30: Analysis of progeny derived from replicating either S-cdG or S-cdA containing 
ss-pMS2 construct in HEK293T cells treated with NC siRNA. The data from three 





5.3.4 Mutational specificity of S-cdG and S-cdA in TLS polymerase knockdown 
HEK293T cells 
We employed a siRNA induced TLS polymerase knockdown approach to find out the 
involvement of specific TLS polymerases in the lesion bypass. The siRNA against a specific 
TLS polymerase was introduced to HEK293T cells and the knockdown efficiency was 
determined by quantitative reverse transcription PCR and Western blot analysis. Consistent with 
a previous study from our group, knockdown efficiency for individual polymerase was 
determined to be at least 70% efficient.216  
Relative to untreated or treated with a negative control siRNA (NC-siRNA) HEK293T 
cells, we observed only a modest effect on the total MF in TLS pols knockdown cells (Figure 
31). The total MF of S-cdG (of ~81%) increased by ~12% to 90% in pol κ knockdown cells 
compared to the NC-siRNA treated (or untreated) cells, and this was mainly due to a significant 
increase in G → A mutations, which increased by 33%. Whereas the total MF of S-cdG in pol ι 
remained approximately the same as in NC-treated cells, there was a ~7-8% increase in the total 
MF in pol η, REV1 or pol ζ knockdown cells, and the MF increased to  ~86%. (Figure 31, Figure 
32, and Table 14). However, in pol ζ-knockdown cells, targeted G → T mutations were increased 
by 18% compared to the same in NC-treated HEK293T, whereas in pol η knockdown cells the 
increase in MF was due to an increase in semi-targeted mutations (Figure 32 and Table 14). The 
reduction in total MF in pol ι knockdown cells was due to a 20% reduction in G → A mutations 
(Figure 32 and Table 14). Above results suggest that pol η, pol κ, pol ι and pol ζ likely contribute 
to mutagenicity of S-cdG in mammalian cells, although no single TLS polymerase is critical for 




Similarly, compared to NC-treated HEK293T cells, S-cdA exhibited no significant 
change in MF with knockdown of either pol η or REV1 (Figure 31, Figure 32 and Table 14). In 
stark contrast to the increase in MF in the case of S-cdG in pol κ and pol ζ knockdown cells, MF 
decreased by 39% and 30%, respectively, in the progeny from the S-cdA construct. This 
reduction was mainly attributed to decrease in A→T mutations. In addition to this, decrease of 
semi-targeted mutations in pol κ knockdown cells and A → G mutation in pol ζ knockdown cells 
were also observed. Further, A → C events were undetected in pol κ or pol ζ knockdown cells 







Figure 31: Effect of siRNA knockdowns of TLS pols on mutational frequency of S-cdG and 
S-cdA in HEK293T cells. The 293T represents HEK293T cells treated with NC 
siRNA. Data from several independent transformations have been combined (shown 























































Figure 32: Mutational frequency of S-cdG and S-cdA in HEK293T cells treated with NC 
siRNA (293T) and siRNA against TLS polymerase. The data represent combined 
mutational frequency from several independent experiments (Shown in table 14 and 
























































Table 14: Mutational frequency of S-cdG in HEK293T cells treated with siRNA against 








G (%) A (%) T (%) C (%) Other (%) 
NC-siRNA 
















3 86 72 (83.7) 14 (16.3) 27i (31.4) 33
j
 (38.4) 9 (10.5) 3
k
 (3.5) 
Total 350 282 (80.6) 68 (19.4) 98 (28.0) 152 (43.4) 25 (7.14) 7 (2.0) 








G (%) A (%) T (%) C (%) Other (%) 
POLH 
1 138 122 (88.4) 16 (11.6) 41a  29.7) 67
b  (48.6) 8 (8.8)  6
c  (4.3)  
2 110 94 (85.5) 16 (14.5) 26e  (23.6) 51
f  (46.4) 11
g  (10.0) 6
h  (5.5) 
3 115 98 (85.2) 17 (14.8)  28i  (24.3) 56
j  (48.7) 10 (8.7)  4
k  (3.5) 
Total 363 314 (86.5) 49 (13.5)  95 (26.2) 174 (47.9)  29 (8.0)  16 (4.4)  








G (%) A (%) T (%) C (%) Other (%) 
POLK 
1 92 81 (88.0) 11 (12.0) 30a  (32.6) 41
b
 (44.6) 4 (4.3) 6
c
 (6.5) 
2 95 88 (92.6) 7 (7.4) 41d (43.1) 31 (32.6) 10 (10.5) 6
f
 (6.3) 
3 98 88 (89.8) 10 (10.0) 35g (35.7) 40
h
 (40.8) 6 (6.1) 7
i
 (7.1) 
Total 285 257 (90.2) 28 (10.0) 106 (37.2) 112 (39.3) 20 (7.0) 19 (6.7) 








G (%) A (%) T (%) C (%) Other (%) 
POLI 












3 109 94 (86.2) 15 (13.8) 23h (21.1) 52
i
 (47.7) 17 (15.6) 2
j
 (1.8) 
Total 339 275 (81.7) 64 (18.9) 76 (22.4) 152 (44.8) 34 (10.0) 13 (3.8) 









G (%) A (%) T (%) C (%) Other (%) 
REV1 
1 105 87 (82.9) 18 (17.1) 31 (29.5) 46a (43.8) 4 (3.8) 6
b
 (5.7) 







Total 206 177 (86.0) 29 (14.0) 65 (31.6) 87 (42.2) 14 (6.8) 11 (5.3) 








G (%) A (%) T (%) C (%) Other (%) 
REV3L 
1 107 89 (83.2) 18 (16.8) 22 (20.6) 55a (51.4) 8 (7.5) 4
b
 (3.7) 
2 102 90 (88.2) 12 (11.8) 33 (32.4) 52c (51.0) 3 (2.9) 2
d
 (2.0) 
Total 209 179 (85.6) 30 (14.4) 55 (26.3) 107 (51.2) 11 (5.3) 6 (2.9) 
†The superscript indicates one or more mutants containing mutation elsewhere shown in Table 16 





 Table 15: Mutational frequency of S-cdA in HEK293T cells treated with siRNA against 







A*→ Semi-targeted and other 
A (%) T (%) G (%) C (%) CA*→TA*(%) CA*→GA*(%) Other (%) 
NC-siRNA 
1 88 21 (23.9) 67 (76.1) 5 (5.7) 5
a
 (5.7) 1 (1.1) 5 (6.0) 3 (3.4) 2
b
 (2.3) 
2 93 17 (18.3) 76 (81.7) 5
c
 (5.4) 3 (3.2) 0 0.0  8 (8.6) 1 (1.1) 0 0.0  






 (0.8) 2 (1.6) 2 (1.6) 0 0.0  
Total 305 64 (21.0) 241 (79.0) 24 (7.9) 15 (4.9) 2 (0.7) 15 (4.9) 6 (2.0) 2 (0.7) 







A*→ Semi-targeted and other 
A (%) T (%) G (%) C (%) CA*→TA*(%) CA*→GA*(%) Other (%) 
POLH 
1 80 18 (22.5) 62 (77.5) 5
a
 (6.3) 5 (6.3) 1 (1.3) 6 (7.5) 1 (1.3) 0   
2 118 25 (21.2) 93 (78.8) 7
b
 (5.9) 7 (5.9) 1 (0.8) 9
c
 (7.6) 1 (0.8) 0   
3 121 23 (19.0) 98 (81.0) 11
d
 (9.1) 4 (3.3) 2 (1.7) 5 (4.1) 1 (0.8) 0   
Total 319 66 (20.7) 253 (79.3) 23 (7.2) 16 (5.0) 4 (1.3) 20 (6.3) 3 (0.9) 0   







A*→ Semi-targeted and other 
A (%) T (%) G (%) C (%) CA*→TA*(%) CA*→GA*(%) Other (%) 
POLK 
1 101 14 (13.9) 87 (86.1) 4
a
 (4.0) 8 (7.9) 0   1 (1.0) 0 0.0  1
b
 (1.0) 
2 133 16 (12.0) 114 (85.7) 9 (6.8) 3 (2.3) 0   5 (3.8) 1 (0.8) 1
c
 (0.8) 
Total 234 30 (12.8) 201 (85.9) 13 (5.6) 11 (4.7) 0   6 (2.6) 1 (0.4) 2 (0.9) 







A*→ Semi-targeted and other 
A (%) T (%) G (%) C (%) CA*→TA*(%) CA*→GA*(%) Other (%) 
POLI 
1 50 8 (16.0) 42  (84.0) 3
a
 (6.0) 5 (10.0) 0   0 0.0  0   0 0.0  
2 106 20 (18.9) 86  (81.1) 8 (7.5) 1 (0.9) 3 (2.8) 5 (4.7) 2 (1.9) 1
b
 (0.9) 
Total 156 28 (17.9) 128  (82.1) 11 (7.1) 6 (3.8) 3 (1.9) 5 (3.2) 2 (1.3) 1 (0.6) 








A*→ Semi-targeted and other 
A (%) T (%) G (%) C (%) CA*→TA*(%) CA*→GA*(%) Other (%) 
REV1 
1 43 9 (20.9) 34  (79.1) 3
a
 (7.0) 3 (7.0) 1 (2.3) 2 (4.7) 0   0 0.0  
2 86 16 (18.6) 70  (81.4) 8
b
 (9.3) 2 (2.3) 2 (2.3) 0   3 (3.5) 1
c
 (1.2) 
Total 129 25 (19.4) 104  (80.6) 11 (8.5) 5 (3.9) 3 (2.3) 2 (1.6) 3 (2.3) 1 (0.8) 







A*→ Semi-targeted and other 
A (%) T (%) G (%) C (%) CA*→TA*(%) CA*→GA*(%) Other (%) 
REV3L 
1 125 17 (13.6) 108 (86.4) 4 (3.2) 2
a
 (1.6) 0   10 (8.0) 1 (0.8) 0   
2 66 11 (16.7) 55 (83.3) 5 (7.6) 2 (3.0) 0   3 (4.5) 1 (1.5) 0   
Total 191 28 (14.7) 163 (85.3) 9 (4.7) 4 (2.1) 0   13 (6.8) 2 (1.0) 0   
†The superscript indicates one or more mutants containing mutation elsewhere shown in Table 17 





Table 16: Semi-targeted and other mutations induced by S-cdG in TLS polymerase 




Semi targeted and other mutations as indicated by superscript 
NC-siRNA 
(a) ATT CGT GTT TGT [1]                 
(b) GTT TAT GTT TGT [1], GTG _AT GTT TGT [1], CGA GATGTTTGT [1], 5’GTG C_T GTT TGT [1] 
(c) ATGCTTGTTTGT [1] 
       
  
(d) GTG TTA ATT TGT [1], GTG CTTT TTTGT [2] 
    
  
(e) GTG CGG GTT TGT [1], GTG CGA GTT TGT [1] 
    
  
(F) GTG GCT GTT TGT [1] 
       
  
(g) GTT GAT GTT TGT [1], GTT TAT GTT TGT [1]       
POLH 
          
  
(a) GTG CAA GTT TGT [1], GTA GAT GTT TGT [1], GTG GAT GTT TGT [1]  
  
  
(b) GTG ATT GTT TGT [1], GTT GTT GTT TGT [2] 
    
  
(c) GTG TGT GTT TGT [1], GTG GGT GTT TGT [5] 
    
  
(d) GTG _GT GTT TGT [1], GTG TGT GTT TGT [1] 
    
  
(e) ATG CAT GTT TGT [1] 
       
  
(f) GTG GTG GTT TGT [1], GTA CTT GTT TGT [2], ATG CTT GTT TGT [1] 
  
  
(g) GTG TCT GTT TGT [1], GTT GCT GTT TGT [1] 
    
  
(h) GTG GGT GTT TGT [1], GTG TGT GTT TGT [1] 
    
  
(i) GTT CAT GTT TGT [1] 
       
  
(j) GTG TTT GTT TGT [1] 
       
  
(k) GTG GGT GTT TGT [2], GTG TGT GTT TGT       
POLK 
          
  
(a) GTT GAT GTT TGT [1], 
       
  
(b) GTG CTT CTT TGT [1], GTG GTT GTT TGT [2],  
    
  
(c) GTG CGC TTG TGT [1], GTG TGT GTT TGT [2], ___ ___ GTT TGT [1], GTG GGT GTT TGT [2]  
(d) GTA CTT GTT TGT [1] 
       
  
(e) GTG TCT GTT TGT [3], GTG GCT GTT TGT 1],  
    
  
(f) GTG GGT GTT TGT [3], GTG TGT GTT TGT [2], GTT GGT GTT TGT [1] 
  
  
(g) GTG GAT GTT TGT [2], GTA GAT GTT TGT [1] 
    
  
(h) GTT GTT GTT TGT [1] 
       
  
(i) GTG GGT GTT TGT [2], GTT GGT GTT TGT [1], GTG TGT GTT TGT [1], TTG _ GT GTT TGT [1] 
POLI 
                      
(a) ATG CAT GTT TGT [1], GAG CAT GTT TGT [1]  
    
  
(b) GTT GTT GTT TGT [1], GTT CTT GTT TGT [1]  
    
  
(c) GTG TCT GTT TGT [1] 
       
  
(d) GTG – GA GTT TGT [1], GTG TGT GTT TGT [2], GTG – GT GTT TGT [1] 
  
  
(e) GTG GAT GTT TGT [1], GTA CAT GTT TGT [1] 
    
  
(f) GTT GCT GTT TGT [1], GTG TCT GTT TGT [1] 
    
  
(g) GTG GGT GTT TGT [2], GTT GGT GTT TGT [2], GTG TGT GTT TGT [2], GTG _ GT GTT TGT [1] 
(h) GTG GAT GTT TGT [2], GTG  -AT GTT TGT [1] 
    
  
(i) GTG GTT GTTTGT [1], GTA CTT GTT TGT [1] 
    
  
(j) GTG TGT GTT TGT [1], GTT GGT GTT TGT [1]       
REV1 
                      
(a) GTT GTT GTT TGT [1], TTG CTT GTT TGT [1], 
    
  
(b) GTT GGT GTT TGT [4], GTG GGT GTT TGT [2] 
    
  
(c) GTT TAT GTT TGT [1] 
       
  
(d) GTG ATT GTT TGT [1] 
       
  
(e) GTG TCT GTT TGT [1] 
       
  
(f) GTG TGT GTT TGT [1], GTG GGT GTT TGT [2], GTG AGT GTTTGT  [1] ------ GTT TGT [1]   
REV3L 
                      
(a) GTG ATT GTT TGT [2] 
       
  
(b) GTT GGT GTT TGT [4], GTG CGT GTG CTT [1] 
    
  
(c) GTT GTT GTT TGT [2] 
       
  





Table 17: Semi-targeted and other mutations induced by S-cdA in TLS polymerase 
knockdown HEK293T cells  
siRNA  Semi-targeted and other mutations as indicated by superscript 
NC-siRNA 
(a) ATT CGT GTT TGT 
(b) GTG _AT GTT TGT [1], GTG C_T GTT TGT [1] 
(c) ATG CTG TTTGT [1] 
(d) GTG TTA ATT TGT [1], GTG CTT TTT TGT [2] 
(e) GTG CGG GTT TGT [1], GTG CGA GTT TGT [1] 
(f) 5’GTG GCT GTT TGT [1] 
(g) GTT GAT GTT TGT [1], GTT TAT GTT TGT [1] 
POLH 
(a) GTG ATT GTT TGT 
(b) GTG TTT GTT TGT 
(c) GTG TAT ATT TGT 
POLK 
(a) GTG CTT TTT TGT [1] 
(b) GTG CAT GAT TGT [1],  
(c) GTC CAT GTT TGT 
POLI 
(a) GTG TGT GTT TGT [1] 
(b) GTT CAT GTT TGT [1] 
REV1 
(a) GTG GTT GTT TGT [1] 
(b) GTG TTT GTT TGT [4], GTG GTT GTT TGT [1] 
(c) GTG CAT ATT TGT [1] 
REV3L 
 (a) GTG TGT GTT TGT [1] 








 Discussion and Conclusions 5.4
5.4.1 Mutagenicity and cytotoxicity of S-cdA in E. coli  
Both S-cdG and S-cdA contain an extra covalent bond between the base and the sugar. 
Therefore, it is not surprising that some of their chemical and biological characteristics are 
similar. Even so, they exhibit distinct biological properties as well. In terms of similarities, S-
cdG and S-cdA are highly genotoxic in E. coli, with viability less than 1% relative to control, 
which increased several-fold with SOS (Table 1 and ref212 ). Furthermore, they are mutagenic in 
E. coli, but S-cdG is considerably more mutagenic than S-cdA (Table 2 and ref212 ). TLS of both 
lesions is entirely dependent on pol V since in pol V-deficient strains viability dropped to nearly 
0%. With respect to their differences, in E. coli, the major class of mutations induced by S-cdG is 
G → A transitions,212, 213 whereas S-cdA induced both A → T and A → G base substitutions 
(Table 2). S-cdA induced A → T transversions and A → G transitions in equal frequency in cells 
with normal repair and replication functions, which remained the same with SOS induction, but 
A → T was the dominant mutation in pol II-deficient and SOS-induced pol IV-deficient strains. 
The A → G mutations dropped considerably in pol IV- deficient strains, suggesting that pol IV 
may be able to incorporate dCMP opposite S-cdA, but it needs pol V for further extension. In 
contrast, pol II seems to play a role in error-free replication, but it also is dependent on pol V. 
It is worth noting that another study of TLS of S-cdG and S-cdA in E. coli has been 
published.213 However, this investigation concentrated only on SOS-induced E. coli, whereas our 
study also determined the bypass and mutagenicity in the absence of SOS. While the pattern of 
bypass efficiency and mutagenicity in SOS-induced E. coli of the earlier report and our results 
show similar trend, there are significant quantitative differences between the results of these 




experimental systems. The reported study exhibited a high background on both the bypass 
efficiency and error rate,213 whereas the background in our approach has been very low. As a 
result, we could determine the absolute requirement of pol V in TLS of S-cdA (this study) and S-
cdG (ref 212), which the other study was unable to ascertain. The bypass efficiency of S-cdA in 
the pol V-deficient strain was 13% in this earlier work,213 whereas we determined it to be less 
than 1%. Furthermore, the substantial reduction in MF of A → G mutations in pol IV- deficient 
strain noted in the current work was not identified, presumably due to the high background MF. 
However, some of the differences between the studies may also have been due to the location of 
the lesions in different sequence contexts. 
5.4.2 Mutagenicity in HEK293T cells 
Our results suggested that both S-cdA and S-cdG is genotoxic and mutagenic lesions in 
HEK293T cells. Similar to the results in E. coli,212 S-cdG (~81%) was much more mutagenic 
than S-cdA202 (21%) in human cells (Figure 30). However, both lesions showed increased 
mutagenicity in HEK293T cells than in E. coli cells.202, 212, 213 The major mutation induced by S-
cdA was A→T transversions at a frequency of ~8%, followed by 5% A→G transitions, a pattern 
similar to what was observed in E. coli.202 Unlike in E. coli212, however, in which G→A (26%) 
was the major base substitution mutations induced by S-cdG, in HEK293T cells, G →T 
tranversions were the predominant mutations, which occurred at a frequency of 43%. Another 
study reported similar pattern of mutations in human cells.217 The second and third most 
prevalent events were G → A (28%) and G →C (7%) mutations as shown in Figure 30. These 
results indicate that cyclopurine lesions are much more mutagenic in human cells in comparison 




efficient replication across these lesions, albeit with low fidelity. We speculate that these 
endogenous lesions play an important role in the development of human diseases owing to their 
high mutagenicity. 
 We employed siRNA knockdown approach to investigate the effect of individual TLS 
pol in lesion bypass of cyclopurines. We found that the MF of both S-cdG and S-cdA in pol 
knockdown cells was comparable to that in HEK293T cells, although minor differences were 
observed in the mutational patterns of the these lesions. Approximately ~10% increase in the 
total MF of S-cdG occurred in pol κ knockdown cells. This increase in the MF was due to 
increase in G→A events by 33% as compared to HEK293T cells (Figure 3, and Table 1).We 
hypothesize that pol κ, which was reported to act as an extender for several other lesions,196, 218, 
219 may be, at least partially, involved in error-free bypass of S-cdG in vivo. In contrast, it was 
noted that the MF of S-cdA decreased in pol κ and pol ζ knockdown cells compared to that in 
NC-treated HEK293T cells. Hence it is conceivable that these pols are involved in error-prone 
bypass of S-cdA. TLS is a multistep process involving several polymerase switches, where 
multiple polymerases act in a sequential manner for lesion bypass.135, 220 It is generally 
considered that pol ζ is involved in the extension step, subsequent to incorporation of a base 
opposite a DNA lesion.221 Therefore, one can hypothesize that pol ζ is involved in the extension 
of the A*:A mismatch pair more efficiently than the correct A*:T pair for S-cdA. Furthermore, in 
the absence of pol ζ, pol κ may take part in the extension of the mismatched primer termini of S-
cdA. In a previous in vitro study by You et al,217  pol κ exhibited its ability to extend past the 
cyclopurines, which is consistent with what we have observed in the current study. However, in 




bypass in vivo. This difference may stem from the effect of the sequence context222, 223 as well as 
difference between the two experimental systems. 
 Furthermore, MF of both S-cdA and S-cdG was not affected in pol η knockdown cells. 
Swanson et.al215 suggested a role of pol η in the error-free bypass of the cyclopurine lesions in 
vitro, which was not supported by the current study or the in the cellular studies performed by 
You et al.217 The difference between the in vitro study using purified DNA polymerases and 
cellular studies may arise due to several reasons. Presences of multiple TLS pols in cells,  which 
may act collectively with accessory proteins, in the presence of all four nucleotides, modulate the 
fidelity and efficiency of lesion bypass. On the other hand, in vitro experiments with purified 
pols are often carried out with a single polymerase and one type of nucleotide, which could 
affect the nature of lesion bypass experiments.217 Nevertheless, it is also uncertain whether the 
residual pol η might be sufficient for lesion bypass.  
In pol ι knockdown cells, the targeted G→A substitution observed for S-cdG decreased 
by 20% compared to that in HEK293T cells. This indicates that pol ι preferentially incorporates 
dTMP opposite S-cdG, leading to erroneous replication, which was also observed by You et 
al217. Furthermore, knockdown of either REV1 or pol ζ displayed no significant effect on the S-
cdG mutagenesis except a slight increase in the MF. The MF of S-cdA was not affected by 
siRNA-induced knockdown of pol ι or REV1 indicating that these pols may not be involved in 
TLS of S-cdA. 
 Based on our findings, it was evident that both S-cdA and S-cdG were highly mutagenic 
lesions in mammalian cells. Inability to distinguish critical roles of individual TLS pols during 




involved in the lesion bypass. Yet, based on the current data, one can hypothesize that pol ι or 
pol η is involved in the nucleotide incorporation opposite the cyclopurines and pol κ or pol ζ is 
involved in the extension past the lesions.  Therefore, these results support the current hypothesis 
that multiple pols take part in the lesion bypass.224-226 Additional experiments will be needed to 






6   Chapter 3: Mutagenicity and Cytotoxicity of Tobacco-Specific 
Nitrosamine, 4-(methylnitrosamino)-1-(3-pyridyl)-1-butanone (NNK) -





The tobacco-specific nitrosamines 4-(methylnitrosamino)-1-(3-pyridyl)-1-butanone 
(NNK) is a potent human carcinogen. Metabolic activation of NNK generates a variety of DNA 
adducts including O2-Methylthymidine (O2-Me-dT) and O2-{4-(3-pyridyl-4-oxobut-1-
yl]thymidine (O2-POB-dT) lesions. To investigate the mutagenic and cytotoxic properties of 
these O2-Alkylthymidine lesions, we have replicated single-stranded plasmids containing a site 
specifically incorporated O2-Me-dT or O2-POB-dT in human embryonic kidney 293T 
(HEK293T) cells. The bulkier O2-POB-dT was found highly genotoxic in mammalian cells, 
showing bypass efficiency of only 26%, while O2-Me-dT showed much lower genotoxicity as 
the bypass efficiency was ~55%. In mammalian cells, O2-Me-dT and O2-POB-dT induced 64% 
and 53% mutations, respectively, and the major type of mutations observed for both lesions was 
targeted T→A followed by T→G. A low level T→C mutation was also observed for O2-POB-
dT, which was undetected in the progeny from the O2-Me-dT construct. siRNA induced 
knockdown of translesion synthesis (TLS) polymerases (pols) indicated that pol η, pol ζ, and 
REV1 are involved in the lesion bypass of both O2-Me-dT and O2-POB-dT as the TLS efficiency 
was decreased with knockdown of each pol. The mutation frequency (MF) of O2-Me-dT was 
decreased in pol ζ and REV1 knockdown cells by 24% and 25%, respectively, while for O2-
POB-dT, it was decreased by 44% only in pol ζ knockdown cells, indicating that these TLS pols 
are involved in the mutagenesis of O2-alkylthymidine lesions in mammalian cells. Therefore, this 
study provides important mechanistic details about how these lesions are bypassed in 





Tobacco products contain an array of chemicals including nicotine and several chemical 
carcinogens that trigger a cascade of events leading to tobacco-induced carcinogenesis.{Hecht, 
1999 #518} Although nicotine is the major constituent of all tobacco products, nicotine itself is 
not carcinogenic;227 however, it is responsible for activating tumor-initiation signaling pathways. 
Amongst the carcinogens present in tobacco, the likely candidates for causing cancers are 
tobacco-specific nitrosamines, including (4-(methylnitrosamine)-1-(3-pyridyl)-1-butanone 
(NNK)) and N’-nitrosonornicotine (NNN).78, 85, 227, 228 Intermediates formed during metabolic 
activation of these compounds by P450 may covalently bind to DNA forming DNA adducts.70, 71, 
229, 230 NNK thus far is the only carcinogen found in tobacco products that is specific to lung 
carcinogenesis, irrespective of the route of administration.93, 231 
 NNK can be metabolically activated by either methylation pathway to generate 
methylating agents or by pyridyloxobutylation pathway to generate pyridyloxobutyalting agents. 
These agents react with DNA generating methyl (Me) and 4-(3-pyridyl)-4-oxobutyl (POB) 
adducts, respectively. The most common methylated adducts formed in the methylation pathway 
include 7-Me-dG and O6-Me-dG;97, 103, 232 however, other methylation products such as O2-Me-
dC and O2-Me-dT have also been detected.233, 234 While mutagenicity and carcinogenicity of 
NNK-induced O6-Me-dG is well established,231, 235, 236 the biological consequence of other 
methylated adducts are yet to be investigated. 
   Pyridyloxobutyalting pathway generates four POB adducts including O2-POB-dT, 
O2-POB-dC, O6-POB-dG and 7-POB-dG, which were detected in NNK treated rats and mice.104, 
237, 238 A/J mice treated with a pyridyloxobutyalting agent, 4(acetoxymethyl-nitrosamino)-1-(3-




pyridyloxobutyalting DNA adducts, O2-POB-dT, O6-POB-dG and 7-POB-dG, form and persist 
in lung DNA at significant levels, suggesting their contribution in  lung carcinogenesis.239 
Further, O2-POB-dT was identified as the most abundant POB adduct in lung tissues of A/J 
female mice240 as well as the most persistent adduct in lung and liver of male F344 rats treated 
with NNK.241 NNKOAc treated CHO cells produced point mutations mainly at the AT base 
pairs, suggesting that O2-POB-dT might be responsible for these mutation.106 
In vivo mutagenesis study of O2-Me-dT and O2-POB-dT using a single-stranded plasmid 
showed that these lesions were highly mutagenic in E. coli cells.242 Both survival and the 
mutagenicity were increased with SOS induction, indicating involvement of TLS pols for their 
bypass and mutagenesis. Replication of O2-alkylthymidine lesions with varying side chains in E. 
coli showed that bypass efficiency decreased as the chain length of the alkyl group increased243 
and pol V was indispensable for T→A mutations.242, 243 In vitro kinetics using E. coli DNA 
polymerase I (Kf-), Sulfolobus solfataricus DNA polymerase IV (Dpo4), human polymerase 
kappa (pol κ) and yeast polymerase eta (pol η) established that O2-Me-dT is a strong block to 
DNA synthesis and that dATP is preferentially incorporated opposite O2-Me-dT.109, 244 
Furthermore, bypass of O2-POB-dT also is inefficient by Kf- and Dpo4, and dTTP is the most 
preferred nucleotide opposite O2-POB-dT, indicating low fidelity bypass.109  
In vivo mutagenesis studies in E. coli and in vitro replication data showed that O2-Me-dT and O2-
POB-dT are highly mutagenic and replication blocking lesions. However, their mutagenic and 
cytotoxic properties in mammalian cells are not well characterized. In order to investigate the 
replication properties of these two lesions in mammalian cells, we have replicated single-
stranded pMS2 constructs containing a single O2-Me-dT or O2-POB-dT in human embryonic 




including pol η, κ, ι, ζ and REV1 for lesion bypass and mutagenesis in HEK293T cells by 





       5’ – GTGCGXGTTTGT – 3’ 
 
    X = dT (or) O2-Me-dT (or) O2-POB-dT 
 
(Thymidine)           (O2-Methylthymidine)        (O2-Pyridyloxobutylthymidine) 
O2-POB-dT O2-Me-dT dT 
Figure 33: Oligonucleotides and lesions used for the study. Oligonucleotides were provided 






6.3.1 Inhibition of replication by O2-Me-dT and O2-POB-dT adducts and contribution of 
pols η, ζ and REV1 for lesion bypass. 
To investigate the mutagenic and cytotoxic properties of two O2-alkyl-dT adducts formed 
by tobacco-specific nitrosamine during methylation and pyridyloxobutylation pathway, we have 
constructed single-stranded pMS2 plasmids containing a single O2-Me-dT or O2-POB-dT, which 
were replicated in HEK293T cells. Replication of adduct containing single-stranded vectors 
allow to study the effect of TLS polymerases in the absence of repair, as ss-plasmids are 
inefficiently repaired by DNA repair pathways. 
To determine the roles of individual TLS polymerases in the bypass of these two lesions, 
we employed siRNA knockdown approach to suppress their expression. In agreement with 
previous studies, our real time and RT-PCR and Western blot analysis showed that, for each 
polymerase, the knockdown was at least 70% efficient.216 Prior to replication of the lesion 
containing vectors, HEK293T cell were treated with siRNA for a specific TLS polymerase and 
allowed 48 h to reduce their expression. A non-specific siRNA was used as the negative control. 
After 48 h, another aliquot of siRNA was added along with the lesion containing vectors, to 
ensure efficient knockdown of the desired pol during replication of the ss-vector. 
The relative TLS efficiency of the lesion bypass was determined by a previously reported 
procedure. Briefly, the lesion-containing ss-pMS2 construct was mixed in a 2:1 ratio with 
another modified ss-pMS2 plasmid, in which the 12mer insert contained a C instead of G, two 
nucleotides 5’ to the lesion site and cotransfected into siRNA treated cells. This unmodified 




After transfection, the plasmids were allowed to replicate for 24 h, the progeny plasmids were 
recovered, transformed to E. coli DH 10B cells and the resulting colonies were analyzed by 
oligonucleotide hybridization. TLS efficiency for lesion bypass was estimated as the percentage 
of the colonies originating from the lesion bearing plasmid relative to the internal control 
plasmid containing colonies.  
As shown in Figure 34 (Table 18 and Table 19) the TLS efficiencies of O2-Me-dT and 
O2-POB-dT in HEK293T cells transfected with negative control siRNA were 55% and 26% 
respectively, relative to 100% progeny generated from the control construct. This is similar to 
what we have observed in E. coli in that the bulkier O2-POB-dT is more toxic. In fact, in 
mammalian cells it is about 2 fold more toxic than O2-Me-dT. Furthermore, the abundance of 
TLS pols in mammalian cells resulted in ~12 to ~9 folds higher TLS efficiency as compared to 
E. coli.  
Relative to HEK293T cells that were treated with NC-siRNA (or untreated), the TLS 
efficiency for O2-Me-dT decreased by 45% - 53% in pol η, ζ and REV1 knockdown cells (Figure 
34 and Table 18 ). Similarly, the relative TLS % of O2-POB-dT dropped by 35% - 46% in pol η, 
ζ and REV1 knockdown cells (Figure 34 and Table 19). However knockdown of pol κ or ι did 
not show significant difference in TLS of both O2-Me-dT and O2-POB-dT (Figure 34, Table 18 
and Table 19). These results indicate that multiple TLS pol play important roles in bypassing O2-
Me-dT and O2-POB-dT, albeit none of the pols are indispensible for lesion bypass. However, it 
is uncertain whether the remaining low concentrations of enzymes in knockdown cells were able 




6.3.2 Mutational specificity of O2-Me-dT and O2-POB-dT in HEK293T cells 
Figure 2 shows the DNA sequence analysis results of the TLS products of O2-Me-dT and 
O2-POB-dT from the HEK293T cells. In stark contrast to less than 4% mutagenicity observed in 
E. coli cells, these results showed that both O2-Me-dT and O2-POB-dT were highly mutagenic in 
mammalian cells. For O2-Me-dT, 64% of the progeny analyzed were mutants and only ~36% 
progeny yielded accurate replication across the lesion in cells transfected with NC siRNA (Table 
20). Similarly, O2-POB-dT generated ~53% mutated progeny (Figure 35 and Table 21). 
Therefore, we conclude that, though O2-POB-dT is a strong block to DNA replication, its 
replication is more accurate relative to O2-Me-dT in human cells. Most mutations observed were 
targeted one-base substitution, although a low frequency of semi-targeted mutations were also 
observed (Figure 36, Table 20 and Table 21). Unlike in E. coli, the major type of mutation 
observed for both O2-Me-dT and O2-POB-dT in HEK293T cells was T → A, 56% and 47%, 
respectively (Figure 36, Table 20 and Table 21). dCMP incorporation opposite the O2-Me-dT 
lesion was the second most prevalent mutation, which occurred at 7% frequency, however, it 
occurred only at ~2% for O2-POB-dT (Figure 36, Table 20 and Table 21). A low level of T → C 
(1.5%) and semi-targeted (2.3%) mutations were observed for O2-POB-dT, but T → C events 
were undetected for O2-Me-dT (Figure 36, Table 20 and Table 21). Also it is important to note 
that no mutations were observed within the 12mer sequence of the control construct in 





6.3.3 Contribution of pols η, ζ and REV1 in mutagenesis of O2-Me-dT and O2-POB-dT 
To determine the possible roles of TLS polymerase in O2-alky-dT mutagenesis, we 
analyzed the TLS products obtained from the TLS pol knockdown cells. MF for O2-Me-dT 
dropped in pol ζ and REV1 knockdown cells by approximately 24% - 25% relative to HEK293T 
cells treated with NC siRNA (Figure 35 and Table 20). In contrast, a significant 44% reduction 
in MF was observed in pol ζ knockdown cells for O2-POB-dT, though no significant change was 
observed in REV1 knockdown cells (Figure 35 and Table 21). However, for both O2-Me-dT and 
O2-POB-dT, the decrease in MF in different pol knockdown strains was mainly due to reduced T 
→ A mutation (Figure 36, Table 20 and Table 21). Furthermore, a modest 17% decrease in MF 
was noted with knockdown of pol η for O2-POB-dT, while knockdown of neither pol κ nor pol ι 
had a significant effect on MF for the same (Figure 35 and Table 20). For O2-Me-dT, 
intermediate MF values of 56%, 55% and 57%, respectively, were observed in pol η, κ and ι 






Figure 34: Effect of siRNA-induced knockdowns of TLS pols on the replicative bypass of 
O2-Me-dT and O2-POB-dT in HEK293T cells. The TLS % in various pol 
knockdown s was estimated using an internal control of an unmodified plasmid 
containing a mutation two nucleotides 5’ to the lesion site. The data represent the 
mean and the standard deviation of results from at least 3 independent experiments 
± S.D. HEK293T cells were treated with negative control (NC-si) siRNA whereas the 
other single knockdowns are as indicated. The statistical significance between NC-
siRNA treated HEK293T and TLS pols knockdowns were calculated using a two-






























Figure 35: Total mutational frequency (MF) of O2-Me-dT and O2-POB-dT in HEK293T 
cells treated with negative control siRNA (NC-si) or siRNA for TLS pols. The data 
represent the average of at least three independent experiments (except for pol ι, as 
shown in Table 20 and 21) ±S.D. The p values were calculated by using two-tailed, 























































Figure 36: Types of mutations observed in HEK293T cells treated with NC 
siRNA (NC-si) or siRNA for individual TLS pols. The data represent the 
average of at least three independent experiments (except for pol ι, as 



















































1 56   
2 51   
3 58   
AVG 55 (±3) 
POLH 
1 34   
2 22   
3 25   
4 38   
AVG 30 (±7) 
POLK 
1 50   
2 56   
3 48   
AVG 51 (±4) 
POLI 
1 62   
2 64   
3 47   
AVG 58 (±9) 
REV3L 
1 34   
2 25   
3 31   
AVG 30 (±5) 
REV1 
1 30   
2 30   
3 19   





Table 18: TLS % of O2-Me-dT in HEK293T cells in which the expression of 





Adduct siRNA Trial TLS  % 
O2-POB-dT 
NC-si 
1 25   
2 31   
3 21   
AVG 26 (±5) 
POLH 
1 17   
2 16.7   
3 17.4   
AVG 17 (±0.4) 
POLK 
1 26   
2 24   
3 19   
4 25   
5 22   
AVG 23 (±3) 
POLI 
1 26   
2 22   
3 14   
AVG 21 (±6) 
REV3L 
1 13   
2 16   
3 15   
AVG 15 (±1) 
REV1 
1 14   
2 16   
3 10   





Table 19: TLS % of O2-POB-dT in HEK293T cells in which the expression of specific 




Table 20: DNA sequence analysis of TLS across a O2-Me-dT in HEK293T cells, in which 
the expression of defined TLS DNA polymerases was knocked-down using siRNA† 




Mutation  (%) 
T → 
T (%)   A (%)   G (%)   C (%)   Others (%) 
O2-Me-dT 
NC-si 
1 119 76 (63.9)  43 (36.1)  69 (58.0)  5 (4.2)  0 0.0  2
a (1.7)  
2 108 62 (57.4)  46 (42.6)  53 (49.1)  8 (7.4)  0 0.0  1
b (0.9)  
3 155 111 (71.6)  44 (28.4)  96 (61.9)  15 (9.7)  0 0.0  0 0.0  
Avg  (64.3) ±7  (35.7) ±7  (56.3) ±7  (7.1) ±3  0.0   (0.9) ±1 
POLH 




0 0.0  0 0.0  




1 (0.7)  0 0.0  




0 0.0  3
c (2.0)  
Avg  (55.8) ±3  (44.2) ±3  (46.9) ±3  (8.0) ±2  (0.2) ±0.4  (0.7) ±1 
POLK 




1 (0.8)  0 0.0  








0 0.0  1
d (1.4)  








0 0.0  0 0.0  
Avg  (55.3) ±4  (44.7) ±4  (46.1) ±1  (8.4) ±2  (0.3) ±0.5  (0.5) ±0.8 
POLI 








0 0.0  1
e (1.5)  








1 (0.7)  0 0.0  
Avg  (56.5) ±5  (43.5) ±5  (50.6) ±5  (4.9) ±2  (0.4) ±0.4  (0.8) ±0.8 
REV3L 








1 (0.8)  0 0.0  








1 (0.8)  1
f (0.8)  








3 (3.7)  0 0.0  
Avg  (48.1) ±5  (51.9) ±5  (40.6) ±6  (5.4) ±1  (1.8) ±2  (0.3) ±0.5 
REV1 








0 0.0  0 0.0  








0 0.0  0 0.0  








0 0.0  0 0.0  
Avg  (48.7) ±4  (51.3) ±4  (39.4) ±2  (9.3) 3  0.0   0.0  
 
†The superscript indicates one or more mutants containing mutation elsewhere shown below and 
the number in parenthesis shows the number of events detected. 
(a) CGT* → TGT [1], GTG→_A_ [1] , (b) T*G → TT [1], (c) T*G →T_ [2]; GTG CGT → _CG CTG [1], (d) 







Table 21: DNA sequence analysis of TLS across a O2-POB-dT in HEK293T cells, in which 
the expression of defined TLS DNA polymerases was knocked-down using siRNA† 






T (%)  A (%)  G (%)  C (%)  Others (%) 
O2-POB-dT 
NC-si 
1 110 63 (57.3)   47 (42.7)  56 (50.9)  1 (0.9)  3 (2.7)  3
a (2.7)  
2 105 47 (44.8)  58 (55.2)  42 (40.0)  3 (2.9)  1 (1.0)  1
b (1.0)  
3 150 85 (56.7)   65 (43.3)  77 (51.3)  2 (1.3)  1 (0.7)  5
c (3.3)  
Avg  (52.9) ±7  (47.1) ±7  (47.4) ±6  (1.7) ±1  (1.5) ±1  (2.3) ±1 
POLH 
1 97 38 (39.2)   59 (60.8) 
 
32 (33.0)  4 (4.1)  1 (1.0)  1
d (1.0)  
2 130 60 (46.2)  70 (53.8) 
 
45 (34.6)  6 (4.6)  4 (3.1)  5
e (3.8)  
3 133 62 (46.6)   71 (53.4) 
 
53 (39.8)  3 (2.3)  4 (3.0)  2
f (1.5)  
Avg  (44.0) ±4  (56.0) ±4  (35.8) ±4  (3.7) ±1  (2.4) ±1  (2.1) ±2 
POLK 
1 102 55 (53.9)   47 (46.1) 
 
42 (41.2)  3 (2.9)  2 (2.0)  8
g (7.8)  
2 109 48 (44.0)  61 (56.0) 
 
45 (41.3)  2 (1.8)  1 (0.9)  0 0.0  
3 46 25 (54.3)  21 (45.7) 
 
20 (43.5)  0 0.0  3 (6.5)  2
h (4.3)  
4 63 29 (46.0)   34 (54.0) 
 
27 (42.9)  2 (3.2)  0 0.0  0 0.0  
Avg  (49.6) ±5  (50.5) ±6  (42.2) ±1  (2.0) ±1  (2.4) ±3  (3.0) ±4 
POLI 
1 122 62 (50.8)   60 (49.2) 
 
53 (43.4)  1 (0.8)  5 (4.1)  3
i (2.5)  
2 121 55 (45.5)   66 (54.5) 
 
48 (39.7)  2 (1.7)  3 (2.5)  2
j (1.7)  
Avg  (48.2) ±3  (51.9) ±3  (41.6) ±2  (1.3) ±0.6  (3.3) ±1  (2.1) ±0.7 
REV3L 
1 88 25 (28.4)   63 (71.6) 
 
21 (23.9)  0 0.0 
 
2 (2.3)  2
k (2.3)  
2 80 29 (36.3)  51 (63.8) 
 
26 (32.5)  1 (1.3)  1 (1.3)  1
l (1.3)  
3 38 9 (23.7)   29 (76.3) 
 
6 (15.8)  0 0.0  0 0.0  3
m (7.9)  
Avg  (29.5) ±6  (70.6) ±6  (24.1) ±8  (0.4) ±0.8  (1.2) ±1  (3.8) ±4 
REV1 
1 60 37 (61.7)   23 (38.3) 
 
26 (43.3)  3 (5.0)  7 (11.7)  1
n (1.7)  
2 48 22 (45.8)  26 (54.2) 
 
19 (39.6)  1 (2.1)  2 (4.2)  0 0.0  
3 26 14 (53.8)  12 (46.2) 
 
11 (42.3)  3 (11.5)  0 0.0  0 0.0  
4 56 30 (53.6)   26 (46.4) 
 
22 (39.3)  3 (5.4)  1 (1.8)  4
o (7.1)  
Avg  (53.7) ±6  (46.3) ±5  (41.1) ±2  (6.0) ±4  (4.4) ±5  (2.2) ±3 
	  
†The superscript indicates one or more mutants containing mutation elsewhere shown below and 
the number in parenthesis shows the number of events detected. 
(a) GT* → AA [1]; GT* → AT [1]; GTG CGT* G → _ _ _ _ _ _ G [1], (b) T*G → TT [1], (c) G T* →TA [3]; CG 
T* → GGT [1]; G T* → TG [1], (d) T*G → TT [1], (e) CG T* → TGT [1]; GTG CG T* → _ _ _ _ _ T [1]; GT*→ 
TT [2]; GTG CGT* GTT → Long deletion [1], (f) GT* → TA [1]; GT*  → CA [1], (g) GT*  → AT [2]; GTG 
CGT*  G → _ _ _ _ _ _ _ [2]; GTG CG T*   → _ _ _ CAA [1]; CG T*   → TGT [1];, GT* → TA [1]; G T*   → TT 
[1], (h) CG T*   → AGA [2], (i) GTG CG T*   → _ _ _ _ AG [1]; CG T*  → TGT [1]; G T*   → TC [1], (j) G T*   
→ AA [1]; G T*   → CA [1], (k) G T*   → TT [2], (l) G T*  → TT [1], (m) G T*   → TA [2]; CG T*   → TGA [1], 





 Discussion and Conclusions 6.4
6.4.1 Involvement of pol η, ζ and REV1 for bypass of O2-Me-dT and O2-POB-dT  
It is well established that NNK, a tobacco specific nitrosamine, is a potent carcinogen in 
human and animal models.103, 228, 245 During metabolic activation of NNK, multiple reactive 
intermediates are generated that react with DNA, forming adducts, which are believed to play a 
role in chemical carcinogenesis.173 In this study we investigated the replication properties of O2-
Me-dT and O2-POB-dT, two O2-alkyl thymidine lesions formed during metabolic activation of 
tobacco specific nitrosamine, in human cells. From our data (Figure 34), it is evident that TLS 
polymerase examined in this work including Y-family pols η, and REV1 and B-family pol ζ, 
have a role in lesion bypass as indicated by a decrease in TLS efficiency with knockdown of any 
of these TLS polymerases. The TLS efficiency for O2-Me-dT and O2-POB-dT in NC-siRNA 
treated cells were 55% and 26%, respectively Figure 34. We observed a similar pattern of 
cytotoxicity in SOS uninduced E. coli, where the bypass efficiencies were 4.5% and 2.7%, 
respectively, for O2-Me-dT and O2-POB-dT, using the same constructs.242 These TLS 
efficiencies are approximately 10-12 fold lower than the bypass efficiencies in mammalian cells. 
Similar increase in TLS efficiency in human cells compared to E. coli has been observed in 
bypass of abasic site.222, 246 This indicates that TLS efficiency is grater in mammalian cells than 
in E. coli cells, presumably due to an abundance of bypass pols in the former. Furthermore, we 
observed that the bulkier O2-POB-dT was highly cytotoxic and bypassed less efficiently in 
human cells than O2-Me-dT. In a separate study using E. coli, it was established that the 
replication bypass efficiency was decreased with longer chain lengths of O2-alkydT,243 which is 




We observed that the TLS efficiency for O2-Me-dT in pol η, ζ and REV1 knockdown 
cells decreased by approximately 45% - 53% and for O2-POB-dT by 35% - 46% (Figure 34). 
This indicates an involvement of multiple TLS pols for lesion bypass, which supports the current 
hypothesis, that more than one polymerase may be involved in multiple pol switches during TLS 
process.226, 247-249 The TLS efficiency dropped by 45% and 35%, respectively, for O2-Me-dT and 
O2-POB-dT in pol η knockdown cells (Figure 34).  Pol η is considered as one of the main pol 
involved in bypass of many lesions due to its capacious catalytic site.133, 145, 192 Reduced TLS 
efficiency for both lesions in pol η knockdown cells indicates involvement of this pol for lesion 
bypass. This is comparable to what we observed in E. coli,242 that is pol V, ortholog250 of pol η, 
is essential for bypass of these lesions.  
We also established that pol ζ is essential for TLS of both O2-Me-dT and O2-POB-dT 
since the TLS efficiency was reduced in pol ζ knockdown cells by 45% and 42%, respectively 
(Figure 34). Pol ζ has been reported to perform extension220 after incorporation of a nucleotide 
opposite a lesion during TLS process. Therefore, it is conceivable that, it could function 
efficiently in the extension of the nucleotides that were preferentially incorporated by pol η and 
by pol κ or ι. Likewise, REV1 is equally important for O2-Me-dT and O2-POB-dT bypass, as 
shown by 46% - 53% reduction in TLS in REV1 knockdown cells. Based on experimental 
evidences it is accepted that REV1 functionally interact with all other Y family pols during TLS 
process.251-253  Therefore, it is likely that REV1 acts as a structural element to form a bridge 
between the inserter, specifically pol η, and the extender, pol ζ, during TLS of O2-Me-dT and O2-





6.4.2 Mutagenicity of O2-Me-dT and O2-POB-dT and error prone bypass by pol η, ζ and 
REV1 
 Analysis of the progeny showed that both O2-Me-dT and O2-POB-dT are highly 
mutagenic lesions in HEK 293T cells and showed MF of 65% and 53%, respectively (Figure 35). 
This was highly different to what we have observed in SOS un-induced E. coli, where 
mutagenicity was less than 4%.242 This may be due to higher TLS efficiency in mammalian cells 
could have resulted in low fidelity replication of the two lesions. Further, based on the MF data, 
it was evident that, although bulkier O2-POB-dT was a highly replication-blocking lesion, it was 
bypassed accurately as compared to its analogue, O2-Me-dT. It could be rationalized that, owing 
to the small size of the alkyl chain of the O2-Me-dT, it is easily accommodated by the capacious 
catalytic site135 of the TLS pols, thereby replicated efficiently, albeit with low fidelity.  
In HEK293T cells treated with NC-siRNA, the major type of mutation induced by both 
O2-Me-dT and O2-POB-dT is T→ A transversion, at a frequency of 56.3% and 47.4%, 
respectively (Figure 36). The second most prevalent event for O2-Me-dT was T→ G (7.1%) 
followed by low levels of semi-targeted mutations (0.9%). O2-POB-dT generated approximately 
same amounts of T→ G, T→ C and other semi-targeted mutations, which ranged from 1.5% to 
2.3% (Figure 36, Table 20 and Table 21). It has been reported that in NNK treated, AT → TA 
mutations occurred 2 to 3 times more often than AT → CG or AT → GC mutation.254, 255  
Furthermore, in vitro kinetics showed that dTTP incorporation opposite O2-POB-dT was more 
efficient than dCTP or dGTP by both E. coli Kf- and Sulfolobus solfataricus DNA pol IV 
(Dpo4), two model DNA pols.109 Our in vivo results for O2-POB-dT are consistent with the 




vitro replication study on O2-Me-dT, in a different sequence context, showed that it was a strong 
block to DNA replication by E. coli DNA polymerase I (Kf-), yeast pol η, and human pol κ. Also, 
Kf- and yeast pol η preferentially incorporated the correct nucleotide, dAMP, while human pol κ 
preferred dCMP opposite the lesion.244 The involvement of pol κ in T → G mutation was not 
distinct in our study. This may be due to difference in the sequence context as well as the 
presence of multiple pols in vivo as opposed to a single pol in in vitro. 
The targeted T → A events changed in different pol knockdown cells for both O2-Me-dT 
and O2-POB-dT, however, the pattern of the mutations remained comparable in most knockdown 
experiments (Figure 36). Although, the TLS efficiency was reduced in pol η knockdown cells, 
the MF was only slightly reduced for both lesions. It has been shown that pol η involves in error 
prone bypass of different DNA lesions.192 Therefore, it could be postulated that it involved in the 
mis-incorporation of dTMP opposite both lesions. However, other than pol η, pol ι or κ could 
also be involved in mis-incorporation opposite the lesion. Nonetheless, it is challenging at this 
time to distinguish the role of each TLS pol in nucleotide insertion step, as residual enzyme may 
also be able to carry out TLS across the lesions. Evidently, further experiments with TLS pols 
knockout cells will be needed to distinguish the role of individual pol for lesion bypass.  
In pol ζ knockdown cells, the MF for O2-Me-dT and O2-POB-dT decreased appreciably 
by 25% and 44%, respectively, in addition to the drop in TLS efficiency (Figure 35). Pol ζ is 
relatively tolerant of abnormal structure at the primer terminus.256 Hence it is plausible that, it 
involved in the extension of T*: T miss-matched base pair more efficiently than T*: A pair, 
leading to error prone replication. This was more prominent across the TLS of bulkier O2-POB-




similar extent as MF in pol ζ knockdown cells for O2-Me-dT, indicating that REV1 plays an 
indispensable structural role in pol ζ dependent bypass of O2-Me-dT (Figure 35). 
In conclusion, the O2-Me-dT and O2-POB-dT formed by tobacco specific nitrosamine 
were found to be cytotoxic and highly mutagenic in HEK293T cells. Among these two, bulkier 
O2-POB-dT was strong replication blocking lesion compared to O2-Me-dT. T → A was observed 
as the major type of mutation, although low frequencies of T → G, T → C, and semi- targeted 
mutations were also observed for both lesions. siRNA knockdown of TLS pols established that 




7 Summary and Future Work 
In this dissertation, I have investigated the mutagenicity and translesion synthesis of 
abasic site, 8,5’-Cycopurine and O2-alkylthymidine DNA lesions in E. coli and HEK293T cells. 
These studies provided important mechanistic details about lesion bypass and mutagenesis of 
these lesions; it also opened up several attractive avenues for future studies. 
In chapter one of this dissertation, I have investigated the replicative bypass of an abasic 
(apurinic/apyrimididnic (AP)) site, one of the most common lesions in DNA. Since I found a 
major effect of the sequence context in TLS of abasic site, it will be interesting in the future to 
investigate in vitro replication properties of the abasic site in the two sequences for better 
understanding of the effect of the local sequences in the replication bypass. Moreover, molecular 
dynamics and thermodynamic investigations will also provide important information for 
plausible mechanism responsible for this difference and would strengthen the current 
observations. 
In human cells, I employed the siRNA knockdown approach to constrain the expression 
of pol ζ and REV1 . I established that both these polymerases are vital for AP-site bypass. 
However, neither polymerase was indispensable, suggesting roles of additional DNA 
polymerases in AP-site bypass in human cells. Therefore, it will be interesting in the future to 
investigate the effect of other TLS polymerase as well as the effect of replicative polymerase in 
AP-site bypass. The latter could be achieved by replicating the lesion-containing vectors in TLS 
polymerase deficient mammalian cells and also in replicative polymerase inhibited (by 
aphidicolin) cells. These studies will provide important mechanistic details about AP-site bypass 
and mutagenesis. Furthermore, it will strengthen the understanding of different mechanisms for 




In the second chapter I have investigated the translesion synthesis of 8,5’-Cyclopurines in 
the E. coli and in HEK293T cells. Reports have been published on the synthesis of 8,5’-
cyclodeoxyadenosine triphosphates and its effects on DNA replication. Due to highly cytotoxic 
and mutagenic nature of these cyclopurines in E. coli, it will be interesting to evaluate the role of 
8,5’-Cyclopurine-2’-deoxynucleoside triphosphates as potential antibacterial agents. This could 
be achieved by using these triphosphates as incoming nucleotides for in vitro replication assays. 
If as anticipated, the DNA synthesis is inhibited by these analogues, they can be used as viable 
candidates for development of new anti-bacterial drugs. 
 Similar to E. coli, both S-cdA and S-cdG exhibited significant mutagenicity in HEK293T 
cells and I found that multiple TLS polymerase are involved in the mutagenesis of cyclopurines 
in human cells. However, the specific role of individual polymerases in the mutagenesis of the 
8,5’-cyclopurines did not immerge from the current study. Furthermore, the involvement of 
replicative enzymes in the mutagenesis of these lesions is yet to be investigated. Therefore, in the 
future it will be interesting to study the effect of replicative enzymes in the mutagenicity of these 
lesions. Moreover, in vitro replication assays with individual polymerases in the presence of all 
four nucleotides will give important mechanistic information on TLS of these lesions. This work 
would pave the way towards better understanding of the roles cyclopurines in the etiology of 
human diseases.     
In the third chapter I investigated the translesion synthesis across tobacco specific 
nitrosamine derived O2-alkylthymidine lesions. Tobacco specific nitrosamine, 4-
(Methylnitrosamino)-1-(3-pyridyl)-1-butanone (NNK) is one of the most important human 
carcinogens present in tobacco smoke and tobacco products. I established that O2-POB-dT is 




mammalian cells inducing mainly T→ A substitutions. siRNA knockdown of TLS polymerases 
showed that pol eta, pol zeta, and REV1 have a role in lesion bypass as well as in the 
mutagenesis of these lesions. Therefore it will be interesting to perform in vitro kinetic assays to 
investigate the fidelity of TLS polymerase in the incorporation and the extension past these 
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